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ABSTRACT 
The subcellular space is a dense, complex environment that viral pathogens must efficiently 
navigate for their survival and dissemination. The prototypal poxvirus member, vaccinia virus 
(VACV) has been shown to subvert both host microtubule-based and actin-based transport 
mechanisms to this end. The utilisation of fluorescent protein technology has been at the crux of 
many of these discoveries, but addressing remaining questions is made difficult by the various 
morphological forms of VACV and the sheer number of viruses being transported at any one time 
in a single infected cell.  
We have used the development of photoswitchable fluorescent protein Dendra2 to create a cutting 
edge imaging system that allows us to gain insight into the dynamics of subcellular virus 
dissemination. We have constructed recombinant viruses expressing core protein A3 and envelope 
proteins B5 and F13 fused to Dendra2 in both parental and deletion strains of the Western Reserve 
strain and have examined the envelopment at and egress from the trans-Golgi network. 
Egress of wrapped virus to the cell periphery following vaccinia virus (VACV) replication is 
dependent on interactions with the microtubule motor complex kinesin-1 and is mediated by the 
viral envelope proteins A36 and F12. We have utilised a mouse-based infection model to validate 
the important role these transport events have during an in vivo, endemic infection.  
Ectromelia virus, an orthopoxvirus and the causative agent of mousepox, encodes an A36 
homologue (ECTV-Mos-142) that is highly conserved despite a large truncation at the C terminus. 
Deleting the ECTV A36R gene leads to a reduction in the number of extracellular viruses formed 
and to a reduced plaque size, consistent with a role in microtubule transport. We also observed a 
complete loss of virus-associated actin tails, another phenotype dependent on A36 expression 
during VACV infection.  
ECTV ΔA36R was severely attenuated when used to infect the normally susceptible BALB/c 
mouse strain. ECTV ΔA36R replication and spread from the draining lymph nodes to the liver and 
spleen were significantly reduced in BALB/c mice and in Rag-1-deficient mice, which lack T and 
B lymphocytes. The dramatic reduction in ECTV ΔA36R titers early during the course of infection 
was not associated with an augmented immune response. Taken together, these findings 
demonstrate the critical role that subcellular transport pathways play not only in orthopoxvirus 
infection in an in vitro context but also during orthopoxvirus pathogenesis in a natural host.  
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CHAPTER 1: Introduction 
 2 
1.1 CELLULAR TRANSPORT 
1.1.1 Introduction 
Pathogen subversion of essential host-cell functions is fundamental to survival and dissemination 
inside the host. Outside the cell, pathogens may spread by diffusion through extracellular fluids 
such as blood and lymph, although pathogenic mechanisms such as flagella [1] and type IV pili [2] 
are able to enhance this process. Inside the cell, pathogens must access specific host compartments 
to replicate and evade host innate and adaptive immune functions. Entry into and navigation of the 
intracellular space is critically important for viral pathogens, which are unable to complete their 
replicative cycles without host cell machinery.  
The complexity and density of the subcellular environment present substantial barriers to pathogen 
motility. Host cells face the same cytoplasmic hurdles when transporting and organising cytosolic 
components and their own biological processes and have therefore evolved complex transport 
systems that pathogens themselves have evolved to exploit.  
1.1.2 Transport through the cytoplasm 
Eukaryotic cells are differentiated from their prokaryotic ancestors primarily by their highly 
compartmentalised organisation, such as the nucleus and other organelles. Organelles are 
membrane-delineated compartments where specific biochemical processes such as Adenosine 
triphosphate (ATP) generation (mitochondria, [3]), protein folding and lipid metabolism 
(endoplasmic reticulum, [4]), protein packaging and transport (the Golgi apparatus, [5]) and 
hydrolytic degradation (lysosomes, [6]) occur. Although organelles are present in some prokarya 
[7], they are definitive features of all eukaryotic cells that are believed to contribute to eukaryotic 
evolvability [8].  
Movement of large macromolecular complexes and membrane traffic between organelles through 
the cytoplasm cannot be achieved efficiently through passive transport. High concentrations of 
dissolved macromolecules such as nucleic acids and proteins lead to an environment that impedes 
the diffusion of even relatively small objects to a degree that would disrupt effective metabolic 
functioning. For example, 80 nm synthetic microspheres have been shown to diffuse at a rate of 
approximately 0.5 µm/min, a diffusion coefficient 500 to 1000-fold lower than water [9]. With 
mammalian cells ranging from 8 to 130 µm in diameter, transport from the nucleus to the plasma 
membrane would take between 8 min and over 2 h [10]. 
The increased spatial complexity and size of eukaryotic cells, as well as the density of the 
cytoplasm necessitates sophisticated transport mechanisms to target cellular components to 
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locations in the cell determined by need and independent of concentration. These cargos can be 
directed to different cellular compartments by signalling sequences that are hydrophobic 
membrane insertable peptides translated at the N-terminus of completed proteins [11]. In 
eukaryotic cells, two structures fulfil the bulk of the requirements to transport directed cargos: the 
microtubule cytoskeleton, and the actin cytoskeleton, which are jointly responsible for long-range 
and short-range transport respectively.  
A third network of cytoskeletal filaments in eukaryotic cells is composed of intermediate 
filaments, although unlike the actin and microtubule cytoskeletons, intermediate filaments are only 
present in metazoans and insects [12]. Intermediate filaments are composed of a large and diverse 
group of proteins that differ depending on cell type. Over 50 members have been identified and 
include keratins, vimentin and lamins. Functionally, intermediate filaments have roles in cell shape 
determination, structural support against mechanical stressors, motility and signal transduction 
[13, 14]. Filaments composed of these proteins lack directionality (are not polar) and are therefore 
unsuited to fulfilling subcellular transport requirements; as such they are beyond the scope of this 
thesis.  
1.1.3 The microtubule cytoskeleton 
Beyond its function as a subcellular transport system, the microtubule cytoskeleton also plays key 
roles in cellular movement; maintenance of internal organisation; mitotic and meiotic cell division; 
signalling and sensing the extracellular environment; and the formation of flagellum and primary 
cilia [15, 16]. The microtubule cytoskeleton in non-dividing metazoan cells consists of a network 
of polar filaments predomininantly arranged radiating from the centre to the periphery of the cell. 
At this point of radiation, adjacent to the Golgi network, is a microtubule organising centre 
(MTOC) called the centrosome.  
The centrosome consists of two centrioles surrounded by pericentriolar material (PCM) and it is 
proteins contained in the PCM, such as γ-tubulin, pericentrin and ninein that possess microtubule 
nucleation and anchoring activity [17]. γ-tubulin is present in a complex called the γ-tubulin-
containing ring complex (γ-TuRC), a template upon which microtubules can form [15, 18, 19]. 
Microtubules also nucleate from secondary MTOCs to form non-centrosomal microtubule arrays 
such as those in epithelial cells, although γ-tubulin is essential in all cases [20]. 
The microtubule filaments comprise two proteins: α-tubulin and β-tubulin, that heterodimerise. 
These then generate a polarised protofilament through the successive binding of α-tubulin in each 
αβ dimer to the previous β-tubulin on the end of the protofilament. The end of more rapid growth 
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is referred to as the positive or plus -end and the more static end being referred to as the negative 
or minus-end. Both tubulins are bound to a molecule of GTP, at a non-exchangable (N) site in α-
tubulin and an exchangeable (E) site in β-tubulin [21]. The addition of a new heterodimer to the 
protofilament initiates the hydrolysis of the previous β-tubulin-bound GTP to GDP that can be 
exchanged for another GTP upon depolymerisation [22] [Figure 1.1]. A GTP cap forms when the 
rate of hydrolysis to GDP is slower than the addition of new heterodimers [23]. A number of these 
protofilaments, with 13 being typical in many cell types, will associate laterally to form a curved 
sheet that will then close into the metastable tubular structure of a single microtubule [Figure 1.1] 
[24]. This structure is a hollow tube with a diameter of 25 nm [25]. 
The growth of microtubules in the cell is not a static event, microtubules will cycle through phases 
of growth and rapid depolymerisation or collapse with resultant shrinking. This non-equilibrium 
process is called dynamic instability and allows for the rapid rearrangement of the microtubule 
cytoskeleton to cellular requirements [26]. This process is believed to occur stochastically, with 
the loss of the stabilising GTP-bound tubulin cap at the end of microtubules [Figure 1.1] [23, 27]. 
Dynamic instability may act to probe the subcellular environment and through the stabilisation of 
particular microtubules, can lead to a functional conformation of the microtubule network that 
connects important cellular structures/organelles and is responsive to changing cellular 
requirements [28].  
A diverse group of unrelated proteins, collectively known as Microtubule-Associated Proteins 
(MAPs) have key roles in regulating microtubule dynamics. Activities include the binding and 
severing of microtubules (katanin [29]), influencing the rate of catastrophe (transitions from slow 
growth to rapid depolymerisation) (Op18/stathmin [30]), rescue (the reversal of catastrophe) 
(pVHL [31]) or stabilisation of microtubules (Tau [32]). A subset of MAPs are plus-end tracking 
proteins (+TIPs) that form complexes at the growing end of microtubules. EB1 is believed to play 
a key role in the formation and dynamics of these end complexes including promoting catastrophes 
and rescues, as well as nucleation, growth and closure of microtubule sheets into microtubules [33, 
34]. 
Additionally, microtubules undergo a variety of post-translational modifications at either α- or β-
tubulin that include the addition or removal of tyrosine, glycine, glutamate, acetate, phosphate and 
palmitoyl groups [35]. These have complex and wide ranging effects, many of which are mediated 
through recruitment of the aforementioned MAPs that in turn modulate microtubule dynamics. For 
example, the C-terminal tyrosine of α-tubulin is required for recruitment of CLIP170, a +TIP 
interaction partner of EB1 and mediator of microtubule dynamics [36, 37]. The function of another 
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group of MAPs, the molecular motor complexes such as kinesins and dyneins, is also regulated by 
post-translational modifications and can affect their processivity (the distance a motor travels 
along a path before falling off) [38, 39], recruitment [39, 40] and subcellular targeting [41].  
Microtubule motor complexes mediate the subcellular transport capabilities of microtubules by 
moving along their surface. These motors have specific directionalities that are made possible by 
the polarity of microtubules. Transport of cargoes can occur in an anterograde direction, from the 
minus to the plus end of microtubules, or in the opposite retrograde direction from the plus-end to 
the minus-end. In many cell types, the majority of filaments are oriented such that anterograde 
transport moves cargos from the MTOC to the cell periphery and retrograde transport the reverse, 
although this is not always the case in specialised cells such as neurons [42]. 
Families of molecular motors generally specialise in unidirectional transport, for example, the bulk 
of kinesin motor complexes carry out anterograde transport while dyneins carry out retrograde 
transport. It is the regulated packaging, binding and release of cargoes to and from specific motors 
that allow the cell to coordinate many of its complex transport needs. 
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Figure 1.1:  Microtubule subunits and dynamics 
Dimers of α- and β- tubulin form into protofilaments, with sheets of 13 protofilaments associating laterally 
to form microtubules (a closing lattice seam is represented in the growing microtubule). Newly added 
dimers are bound to GTP that are hydrolysed to GDP over time; the tips of growing microtubules therefore 
have a GTP cap which is not present in the metastable intermediate microtubule. This lack of a stabilising 
GTP cap can result in catastrophe leading to the rapid dissociation and depolymerisation of the 
microtubule. Depolymerised tubulin dimers undergo GDP exchange for GTP ready for addition to 
protofilaments. From [43]. 
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1.1.3.2 Kinesin 
Kinesins represent a superfamily of molecular motors comprising 15 kinesin families from 
kinesin-1 to kinesin-14B and can be classified based on the relative position of the motor 
domain, which in turn has functional implications. N-terminal kinesins mediate plus-end 
directed (anterograde) movement (motor domain at the N-terminus), C-terminal kinesins 
mediate minus-end directed (retrograde) movement (motor domain at the C-terminus), and 
M-kinesins regulate the depolymerisation of microtubules [44] (motor domain at the middle 
of the protein). 
Kinesins play specialised transport roles in axons and dendrites that are beyond the scope of 
this thesis but comprehensively reviewed in Hirokawa (2005) [45]. In non-neuronal cells, 
they are involved in bi-directional trafficking of cargos from the cis-Golgi network to the 
endoplasmic reticulum and anterograde transport from the trans-Golgi network to the cell 
periphery [46]. The correct positioning of the Golgi apparatus in the cytoplasm is itself 
dependent on the transport functionalities of motors of opposing directionalities; an 
anterograde kinesin 6 family member, KIF20A, retrograde kinesin 14B family member, 
KIFC3 and cytoplasmic dynein [47-49]. 
Conventional kinesin (kinesin-1) is the most abundant kinesin and has been shown to 
transport tubulin dimers [50], mitochondria [51], lysosomes containing LAMP2 [52] and 
synaptic vesicle and membrane precursors [53, 54]. It is an anterograde microtubule motor 
typically consisting of two kinesin heavy chains (KHCs) and two kinesin light chains 
(KLCs). There are 4 known KLC isoforms, and multiple splice forms for each isoform; 
KLC1 is ubiquitous, KLC2 is widely expressed and enriched in neuronal cells, KLC3 is 
testis-specific and the distribution of KLC4 has yet been characterised [55, 56]. However, 
KLCs are not essential to kinesin-1 function and various transport processes involving 
kinesin-1 do not have any association or involvement of KLCs, with recent estimates 
indicating that 14% of kinesin-1 complexes in tissue extracts lack KLC [44, 57, 58]. 
Together, the KHCs and KLCs form a structure with a N-terminal motor domain, a long 
stalk and a C-terminal cargo-binding domain [Figure 1.2.].  
The motor domain of kinesin-1 is formed by the N-terminal of the KHCs and possesses both 
a microtubule binding site and an adenosine tri-phosphate (ATP) binding site on each chain. 
As the phosphatase activity of the motor domain converts ATP to adenosine di-phosphate 
(ADP), a conformational change occurs in the KHC that releases binding to the microtubule 
filament. When a new ATP is bound, the KHC undergoes a further conformational change 
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and attaches once more to a filament. Each KHC of the kinesin will cycle through this 
ATPase activity, resulting in a step-wise progression [Figure 1.2]. 
Kinesin-1 can be composed of three KHC isoforms, KIF5A, KIF5B and KIF5C. KIF5B is 
the most significant of these isoforms and is expressed ubiquitously in tissues. The cargo-
binding domain of these KHCs may act alone or in conjunction with KLCs and/or other 
adaptor proteins to bind cargo. A variety of C-terminal domains can be formed through 
alternative splicing of KIF transcripts and combined with the diversity of complexes formed 
with various KLCs/adaptor proteins, allows for a high degree of specificity in cargo 
recruitment [44, 59]. The best-characterised molecular features implicated in mediating 
interactions between kinesin-1 complex with respective cargos reside in KLC (although 
KHC complexes alone can also mediate cargo binding). KLC possesses a tetratricopeptide 
repeat (TPR) domain that interacts with tryptophan-aspartic acid or tryptophan-glutamic acid 
(WE or WD) motifs on cargos through a series of electrostatic interactions and sequence 
specific elements [60]. 
Kinesin-mediated transport requires tight regulation of the temporal-spatial dynamics for the 
delivery of cargoes to their intended destination (reviewed in [46]). This can be achieved 
through autoinhibition of kinesins by intramolecular association when cargoes are not 
bound, thereby preventing motor complexes from binding to microtubules [Figure 1.2] [61]. 
The binding of cargo and/or other adaptor proteins may relieve autoinhibition; for example, 
the binding of cargo Jun N-terminal Kinase (JNK) Interacting Protein (JIP1) and 
Fasciculation and Elongation Protein ζ1 (FEZ1) is necessary for complex formation between 
kinesin-1 and microtubules and subsequent activity [62].  
Binding cargo and/or accessory proteins alone is insufficient in many cases to activate 
processive movement of a kinesin motor complex. Phosphorylation of kinesins and adaptor 
proteins by kinases plays varied roles in regulating kinesin motor activity, in addition to 
governing the association/dissociation of cargos [63, 64] as well as the strength of binding to 
microtubules [65, 66]. Binding of kinesins to adaptor proteins and cargos has also been 
shown to be modulated by Ca2+ signalling through Ca2+ responsive motifs in adaptor 
proteins [67] and by the GTP/GDP bound state of Rab GTPases that play intrinsic roles in 
organelle localisation [68, 69]. 
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Figure 1.2:  Kinesin-1 and transport along microtubules 
(A) A diagrammatic representation of KIF5. Two kinesin-1 heavy chains form a heterotetramer with two 
KLC in their cargo binding tail regions, represented on the right. The motor domain is represented on the 
left. Black bars in the domain representations of KIF5 and KLC indicate regions of binding. From [45]. (B) 
Transport is initiated when cargos bind to autoinhibited kinesin motor complexes, which then associate 
with microtubules for processive movement from the minus end near the centre of the cell toward the plus 
end near the cell periphery. Upon reaching transport destinations, cargo binding is released, with the 
motor re-entering its autoinhibited state. Adapted from [61]. 
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1.1.3.3 Dynein 
Although dyneins represent a large family of proteins, a single member, cytoplasmic dynein 
is responsible for almost all retrograde microtubule transport in non-neuronal cells, with 
reported biological functions ranging from vesicular transport to maintaining the 
cytoplasmic localisation of organelles, such as the Golgi apparatus. Intraflagellar transport 
(IFT) dynein is the only other member in the family involved in cytoplasmic transport, with 
all others functioning in the axonemes that power cilia and flagella [70].  
Cytoplasmic dynein consists of 9 polypeptides: two heavy chains (DYNC1H), two 
intermediate chains (DYNC1I), two light intermediate chains (DYNC1LI) and three light 
chains (TxTex1/DYNLT1, LC8/ DYNLL1, roadblock/LC7/DYNLRB1) [71] [Figure 1.3]. 
The dynein heavy chain houses the catalytic subunit of the cytoplasmic dynein complex; it is 
an AAA+ (ATPases Associated with cellular Activities) that at its C-terminus possesses a 
microtubule-binding domain and a motor domain. The motor domain is composed of six 
AAA+ modules that hydrolyse ATP eliciting processive movement along microtubules in a 
manner similar to kinesin [72]. The N-terminus of dynein is required for self-dimerisation 
and the docking of non-catalytic subunits to the complex, in addition to the mediation of 
cargo and dynein adaptor binding [72]. 
The functions of cytoplasmic dynein are governed by dynein adaptors such as dynactin, 
lissencephaly 1 (LIS1), nuclear distribution protein E (NUDE), NUDE-like (NUDEL), RZZ 
and Bicaudal D. Some of these adaptors mediate cargo binding, while others have dramatic 
effects on the mechanics of the motor domain [70]. Arguably the best characterised of these 
adaptors is dynactin, which is itself a large, multi-subunit protein complex consisting of 
p150Glued, p62, dynamitin (p50), Arp1, Arp11, β-actin, CapZ α/β, p24, p27 and p25 [73]. 
One of the key effects of dynactin on cytoplasmic dynein is to enhance processivity, which 
allows for the transport of cargos over long distances within the cytoplasm [74-76]. In many 
eukaryotic systems dynactin modulates localisation of dynein to the plus-end of 
microtubules, where dynein complexes are recruited to bind to cargo for retrograde transport 
[70]. The requirement of dynactin for many aspects of dynein function is apparent by the 
functional abrogation of dynein from loss-of-function alleles of dynactin subunits, for 
example p150Glued [77, 78]. 
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Figure 1.3:  Dynein composition and binding of accessory proteins 
The C-terminal domain of the dynein heavy chain (HC) is responsible for microtubule binding and 
ATPase activity for processive movement along microtubules. The N-terminal region mediates 
dimerisation, as well as binding to the intermediate (IC), light intermediate (LIC) and light chains (LC), 
with LC binding indirectly through the IC. Dynein adaptors Dynactin, RZZ, Bicaudal D (through interaction 
partner Egalitarian), NUDE, NUDEL and LIS1 then interact with dynein through various components of 
the complex or through direct interaction with HC. From [70]. 
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1.1.4 The actin cytoskeleton 
A primary role of the actin cytoskeleton in eukaryotic cells is a structural one, maintaining their 
three dimensional shape. Beyond this, it is involved in essentially all cellular processes, 
significantly cellular motility, the formation of cellular extensions, endocytosis, cytokinesis and 
intracellular transport [79]. The role of actin in intracellular transport is two-fold, as a propulsive 
force through polymerisation and the utilisation of actin filaments as tracts for mysosin motors 
[80]. Cellular actin is highly conserved between different species and is the most abundant protein 
in many cell types, making up as much of 5% of total cell protein, signifying its essentiality to cell 
function [81].  
There are six actin isoforms in vertebrates, four of which form contractile tissues in muscle cells; 
α-skeletal and α-cardiac in striated muscle and α- and γ-isoforms in smooth muscle [82, 83]. The 
remaining two isoforms, β- and γ- cytoplasmic actin, are ubiquitous and together form the actin 
cytoskeleton in many cell types [84]. Although β- and γ- cytoplasmic isoforms are identical 
barring four conservative amino acid differences at their N-terminus, they have distinct but 
overlapping cellular localisations with discrete functional roles being the emerging paradigm from 
recent research [85]. The preferential localisation of β-actin to stress fibres, circular bundles and 
cell-cell contacts suggests a role in cell attachment and contraction, while the concentration of γ-
actin at cortical and lamellipodial structures in moving cells is consistant with a role in cell 
motility [85]. 
The monomeric, G (globular)-actin form of β- and γ-isoforms polymerise to form F (filamentous)-
actin. Actin filaments are polar and have a plus-ends and minus-ends (more commonly referred to 
as the “barbed” and “pointed” ends, respectively, owing to their appearance when decorated with 
myosin S1 fragments) [86]. Although G-actin monomers can be added on both ends, addition to 
the barbed end occurs at a much faster rate than at the pointed end [87]. 
Actin is also an ATPase; monomers bound to ATP are preferentially added to the filament and are 
subsequently hydrolysed to ADP.Pi over time [88]. As this process occurs at a slower rate than 
addition of monomers to the barbed end, a cap of ATP-bound actin forms at the barbed end, while 
ADP-bound actin dominates at the pointed end. The slight change in the structure of actin when 
bound to ATP or ADP results in the barbed and pointed end of the actin filament having different 
critical concentrations (the lowest concentration of monomers in the surrounding region required 
for their addition to the filament), which is 0.06 µM for the barbed end and 0.6 µM for the pointed 
end [89]. 
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At steady state, when the overall length of filaments is stable, a process called treadmilling may 
occur. This is when elongation at the barbed end occurs at the same rate as depolymerisation at the 
pointed end, so that the filament appears to move forward while maintaining the same length [89]. 
The concentration of G-actin in the cell cytoplasm ranges between 20-100 µM, far above the 
critical concentrations (of both barbed and pointed ends) for native actin filaments; it is therefore 
necessary to sequester G-actin so that filament formation can be regulated. Sequestering of G-actin 
is achieved through the binding of accessory proteins such as thymosin β4 [90] or profilin [91] 
[Figure 1.4: (11)]. 
Polymerisation of F-actin from G-actin monomers and the subsequent controlled depolymerisation 
back to G-actin underlies the dynamic functionality of the actin cytoskeleton [92]. Although 
filaments may nucleate from single actin monomers, small actin oligomers are unstable and it is 
therefore the formation of new filaments that is the rate-limiting step in regulating the dynamics 
and function of the actin cytoskeleton [88]. Nucleation requires de novo synthesis of F-actin 
through actin nucleators such as the Arp2/3 complex, formins, Spire, cordon-bleu and leiomodin 
[93] [Figure 1.5].  
Actin nucleators coordinate and orientate G-actin to the nascent F-actin filament to stimulate 
polymerisation in three main ways. Firstly, the Arp2/3 complex binds to the side of an existing 
actin filament and initiates the assembly of a new filament generating 70° branches [Figure 1.4: 
(4)]. The Arp2/3 complex forms a cap at the nascent filament’s pointed end, while addition of 
actin monomers may continue at the barbed end [Figure 1.4: (5)] [94]. On its own, the Arp2/3 
complex does not nucleate actin filaments efficiently and rates of nucleation are dramatically 
increased by the presence and binding of Nucleation Promoting Factors (NPFs) such as the 
Wiskott-Aldrich Syndrome Protein family proteins. Important members of this family are WASP 
(Wiskott-Aldritch Syndrome Protein) and N-WASP (Neural WASP) [95]. NPFs increase the 
nucleation efficiency of the Arp2/3 complex via their WH2 (WASP Homology 2) domains 
recruiting and orienting G-actin to the nascent F-actin seed [96]. 
Unlike the Arp2/3 complex, all other known actin nucleators generate unbranched filaments. 
Formins possess conserved formin homology (FH) domains that bind to the barbed ends of actin 
and act as a processive cap on the elongating filament. Similarly to formins, all other nucleators 
that have been identified contain G-actin-binding motifs that function in a similar manner as FH 
domains; these include WH2 domains in Spire that may introduce three or more actin monomers 
to the nascent actin filament simultaneously [93] [Figure 1.5].  
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Accessory proteins are critical to the regulation of actin polymerisation and dynamics [84]. These 
include the aforementioned proteins that sequester G-actin as well as proteins that prevent the 
further addition of G-actin to filaments (CapZ, [97]) [Figure 1.4: (7)]. Other accessory proteins  
stabilise (tropomodulins, [98]), depolymerise (actin depolymerising factor/cofilin, [99]) [Figure 
1.4: (9)], sever (gelsolin, [100]) and bundle actin filaments (fascin-1, [101]). Many of these actin 
binding proteins are pleiotropic; profilin, for example, beyond its role in ADP:ATP exchange 
[Figure 1.4: (10)] and sequestering actin, can also inhibit nucleation while allowing filament 
extension [102]. 
The signalling cascades that regulate the dynamic remodelling of cellular actin are primarily 
through Rho GTPases, of which there are approximately 20 in humans, including Rho, Rac and 
Cdc42 [103]. Guanine nucleotide exchange factors (GEFs) or GTPase-activating proteins (GAPs) 
activate Rho GTPases that then bind to downstream effectors such as protein kinases, actin 
nucleators and NPFs, which can stimulate assembly and disassembly of F-actin [Figure 1.4: (2)-
(3)] [104]. 
The polymerisation of G-actin into F-actin is not the only mechanism for actin-based motility in 
the cell cytoplasm. Like the microtubule network with kinesins and dyneins, ATP-driven 
molecular motors in the myosin family can traverse actin filaments to effect intracellular transport 
of cargoes. 
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Figure 1.4:  F-actin formation by Arp2/3 and interaction of adaptor proteins 
Filaments are nucleated with Arp2/3; generating F-actin by addition of ATP-actin at the barbed end near 
the plasma membrane. This nucleation may occur in the cytoplasm or on already formed filaments, 
generating 70o branch points. Filaments can be capped by capping proteins or bundled by adaptors. At 
the pointed end (-) of the filament, depolymerisation of F-actin occurs, often with the aid of severing 
adaptors such as ADF/Cofilin. Monomers can then be sequestered, or bound to profilin for exchange of 
ADP to ATP. From [105]. 
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Figure 1.5:  Different actin nucleators 
While actin alone (a) is capable of nucleating and forming filaments, this is kinetically unfavourable and 
actin nucleators dramatically improve the efficiency of filament formation. Actin nucleators may form 
branched arrays such is the case with Arp2/3 (with the aid of NPFs) by binding along previously formed 
actin filaments and mimicking an actin dimer (b). Other nucleators form unbranched filaments, either with 
tandem WH2 domains forming a scaffold for addition of actin monomers such as the case of Spire (c) or 
with FH2 domains in formins stabilising actin dimers and extending along a growing filament to promote 
nucleation as a processive cap (d). From [106]. 
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1.1.4.2 Myosin 
Myosins represent a superfamily of F-actin motor proteins with more than 35 classes 
discovered. All classes characterised thus far, with the exception of class VI, are plus-end 
directed motors. The best understood member is muscle Myosin II that together with actin 
filaments forms the sarcomere that generates the force required for muscle contraction. 
Other myosins are involved in a broad range of biological processes, from cytokinesis to 
vesicle and organelle transport, as well as being implicated in the transport of RNA 
polymerases in the nucleus [107, 108]. 
Similar to kinesins, myosins have a N-terminal motor “head” domain, a variable “neck” 
domain and a C-terminal cargo-binding “tail” domain. The motor domain has an actin and 
ATP binding site. The motor generates movement through a swinging lever arm mechanism, 
in which the swinging lever arm is the distal part of the head not bound to the actin filament 
[109] [Figure 1.6]. The movement is driven by the innate ATPase activity of the myosin that 
hydrolyses ATP to ADP.Pi, which is subsequently released and exchanged for ATP. This 
reaction elicits the conformational changes in the head domain resulting in movement along 
the actin filament [110] [Figure 1.6]. 
Although myosins are able to function as monomers and oligomers (as in the sarcomere of 
muscles), the majority of those involved in cytoplasmic transport such as Myosin V are 
dimers with two motor domains complexed with multiple myosin light chains to form 
functional motor complexes [107]. These motors undergo step-wise processive movement 
along actin filaments, resembling the action of kinesin-1 along microtubules [111].  
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Figure 1.6:  The swinging lever arm cross-bridge mechanism of myosin force 
generation 
When actin and myosin are bound in their rigor state, the distal part of the myosin head is bent. Binding 
of ATP to myosin releases binding to the actin filament, with ATP hydrolysis to ADP.Pi allowing the 
binding to the actin filament again. This stimulates the release of ADP.Pi, which causes a conformational 
change in the distal part of the head, generating a pulling force along the filament. In myosin-based 
transport of cargo, each release allows binding further along the filament, with the other chain of the 
myosin dimer retaining an association to the filament and allowing processive movement. Adapted from 
[109]. 
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1.2 PATHOGEN SUBVERSION OF HOST-CELL TRANSPORT MECHANISMS 
1.2.1 Introduction 
Pathogens encode a diverse range of factors that interact with the preexisting regulatory pathways 
of the host cell machinery to manipulate transport mechanisms including those based on the 
microtubule and actin cytoskeletons. Such pathogen-encoded factors are varied in their mode of 
action but all contribute to the intracellular motility and/or intercellular spread of the pathogen. In 
many cases, they are critical virulence factors that when absent, severely attenuate spread of the 
microbe. 
1.2.2 Microtubule-based transport of intracellular pathogens 
Pathogen utilisation of the microtubule network for subcellular transport is the major mechanism 
used by viruses for subcellular motility as they rely on host cell machinery for their often 
extremely complex replicative cycles. Viruses require well-regulated trafficking not only to enter 
the cell but also to transport viral components to their appropriate subcellular locations for virus 
assembly, organise viral replication organelles and additionally in the dispersal of mature progeny 
virus.  
Many viruses display a reliance on microtubules for their replicative cycles; these range from 
relatively small retroviruses like human immunodeficiency virus-1 (HIV-1, ~100 nm) to large 
double stranded DNA viruses such as herpes simplex virus-1 (HSV-1, ~300 nm) and vaccinia 
virus (VACV, ~400 nm) [Table 1.1]. For most of these viruses, the utilisation of microtubules 
following cell entry has been well described [see Table 1.1, for references]. Although they are also 
likely to utilise microtubules for subsequent egress, this has been less widely characterised, being 
restricted to a few members of Adenoviridae, Asfaviridae, Retroviridae. Herpesviridae and 
Orthopoxviridae. 
In most cases, the subversion of the microtubule network is dependent on molecular motors 
transporting viral cargos as it would transport cellular cargos. However, microtubules are often 
also manipulated in motor-independent ways, for example, human T cell leukaemia virus orientate 
the MTOC to cell-to-cell contacts where a virological synapse can form to promote dissemination 
[112, 113]. Both VACV and African swine fever virus (ASFV) disrupt centrosomes interfering 
with the nucleation of microtubules [114, 115]. VACV additionally affects microtubule dynamics 
through viral protein F11-mediated modulation of Ras family gene homology member A (RhoA) 
[116]. RhoA has diverse physiological roles in regulating microtubules, these include outgrowth 
 20 
for motility as well as intitial polarisation of the microtubule cytoskeleton [117]. How this aspect 
of viral-mediated microtubule remodelling aids in infection has yet to be elucidated. 
The reliance of viruses on motor-dependent microtubule-based transport is not generally reflected 
in bacterial pathogens. A few species including Citrobacter freundii, Serratia marcescens, 
Escherischia coli, Listeria and Salmonella utilise the microtubule cytoskeleton to infect host-cells 
[118, 119] and while the mechanisms behind these processes are not well understood, they likely 
involve microtubule remodelling to permit invasion. There are however a few notable examples, 
namely Wolbachia, Salmonella, Chlamydia trachomatis, Campylobacter jejuni and Orientia 
tsutsugamushi that utilise motor-dependent microtubule-based subcellular transport in their 
replicative cycles [see Table 1.1]. 
For many of the aforementioned viral and bacterial pathogens, the motors involved in the 
particular motor-dependent transport processes have been elucidated, these are listed in Table 1.1 
and key examples will be discussed below. 
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Table 1.1. Microtubule-based motor-dependent transport of intracellular pathogens 
FAMILY PATHOGEN MOTORS 
INVOLVED 
REFERENCES 
Viruses 
Adenoviridae Adenovirus (AdV) Dynein, kinesin-1 [120-123] 
Parvoviridae Adeno-associated virus 
(AAV) 
? [124] 
 Canine parvovirus Dynein [125] 
Asfarviridae African swine fever virus 
(ASFV) 
Dynein, kinesin-1 [126-128] 
Herpesviridae HSV-1 Dynein, kinesin-1, 
kinesin-3 
[129-134] 
 Pseudorabies virus (PrV) Dynein, kinesin-3 [135-137] 
 Human cytomegalovirus 
(HCMV) 
? [138] 
 Karposi’s Sarcoma-
associated herpesvirus 
(KSHV) 
Kinesin-2 [139] 
 Rhesus rhadinovirus Dynein [140] 
 Equine herpesvirus type 1 Dynein [141] 
Rhabdoviridae Rabies virus 1 Dynein [142] 
 Mokola virus 3 Dynein [142] 
Retroviridae Human foamy virus ? [143] 
 HIV-1 Dynein, kinesin-2, 
kinesin-4 
[144-148] 
 Bovine immunodeficiency 
virus 
Dynein [149] 
Hepadnaviridae Hepatitis B (HBV) ? [150] 
 Hepatitis C (HCV) Dynein [151] 
Papillomaviridae Human papillomavirus 
(HPV) 
Dynein [152, 153] 
Polyomaviridae Simian virus 40 (SV40) Dynein [154, 155] 
 Murine polyomavirus 
(MPYV) 
?  [156] 
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Reoviridae Mammalian orthoreovirus Dynein [153, 157] 
Paramyxoviridae Sendai Virus (SeV) ?  [158] 
Orthomyxoviridae Influenza virus Dynein [159] 
Picornaviridae Poliovirus Dynein [160] 
Arenaviridae Lassa virus (LASV) Kinesin-3 [161] 
Filoviridae Ebola virus (EBOV) Dynein [162] 
Orthopoxviridae VACV Dynein, kinesin-1 [114, 163] 
Flaviviridae Dengue virus Dynein [164] 
 West Nile virus Dynein [164] 
Bacteria 
 Wolbachia Dynein, kinesin-1 [165, 166] 
 Salmonella Dynein, kinesin-1 [167, 168] 
 Chlamydia trachomatis Dynein [169] 
 Campylobacter jejuni Dynein [170] 
 Orientia tsutsugamushi Dynein [171] 
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1.2.2.1 Dynein 
As obligate parasites, viral pathogens replicate within susceptible, living host cells. Many 
DNA viruses establish replication centres within the nucleus where host cell DNA 
replication machinery resides [172]. Viruses that replicate in the cytoplasm, including DNA 
viruses that encode their own replication machinery (such as members of Poxviridae) and 
many RNA viruses that utilise host cell machinery, form replication centres in peri-nuclear 
locations proximal to the centrosome [173] [Figure 1.7].  
Upon entry into the cell, which may occur via fusogenic or endocytotic pathways, viruses 
commonly undergo retrograde transport along microtubules to establish sites of replication. 
For a number of viruses, an interaction with a molecular motor has yet to be characterised 
(Adeno-associated virus [AAV], Pseudorabies virus [PrV], Human cytomegalovirus 
[HCMV], Murine polyomavirus [MPYV] and Sendai virus [SeV]) and in these instances, 
microtubule dependent retrograde transport has been verified in three main ways [124, 135, 
138, 156, 158]. Firstly, immunofluorescence assays (IFA) have demonstrated viral particle 
colocalisation with microtubules. Secondly, live cell microscopy revealed directional 
saltatory transport with speeds consistent with microtubule-based motility. Finally, treatment 
with the microtubule destabilising agent nocodazole has been demonstrated to inhibit viral 
replication or movement into the perinuclear region.  
For many viruses that undergo retrograde transport, the specific involvement of dynein has 
been validated [Table 1.1], either through direct protein interaction studies, IFA 
colocalisation with dynein or the abrogration of retrograde transport following treatment of 
cells with anti-dynein antibodies or dominant negative expression of dynein and dynein 
adaptor subunits [Table 1.1]. Furthermore, the specific viral proteins that mediate 
interactions with dynein have been eludicated in several cases. In adenovirus, the capsid 
hexon subunit interacts directly with dynein intermediate chains and light intermediate 
chains in a pH-dependent manner (requiring a pH <5.5 for activation of the interaction). This 
reflects the pathophysiology of adenovirus, which enters the cell via an endocytotic vesicle 
with a final pH estimated to be ≤5.5 before being transported to the nucleus [122] [Figure 
1.7].  
In many cases the identification of viral protein/s involved in dynein recruitment has proved 
more elusive. HSV-1 is a prime example where multiple protein interactions between dynein 
components and viral proteins have been elucidated through biochemical assays, yet remain 
to be functionally validated [136]. Currently, the leading candidates include inner tegument 
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proteins UL36 (VP1/2) and UL37 [174]. Inner tegument has been shown to bind to dynein 
and dynactin components in cytosolic cell extracts and capsids deficient of inner tegument 
are unable to be transported through the cytoplasm [174]. Conversely, deletions of UL37 in 
closely related PrV has demonstrated a delay in retrograde transport rather than complete 
abrogation, perhaps indicating a degree of functional redundancy between proteins 
mediating dynein interaction [175, 176]. 
 
Figure 1.7:  Viral entry and transport to the centrosome 
Diverse families of viruses undergo dynein-mediated retrograde transport along microtubules to 
perinuclear locations. Herpesvirus enters the cell through membrane fusion and nucleocapsids are 
transported to the centrosome before entering the nucleus. Adenovirus and parvovirus enter via 
endosomes before being transported. HIV also enters via an endosome, but fuses with the endosomal 
membrane for uncoating, so only its preintergration complex (PIC) is trafficked to the perinuclear region. 
From http://viralzone.expasy.org/all_by_protein/983.html, accessed 30/09/2013. 
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1.2.2.2 Kinesin 
Viral particles that egress to the cell periphery following replication and morphogenesis face 
similar challenges as incoming viruses, but in reverse. While in some instances, anterograde 
microtubule transport has been reported without an elucidated motor (Hepatitus B [HBV], 
[177]), in better-characterised viruses kinesin-1, kinesin-2, kinesin-3 and kinesin-4 have all 
been implicated in viral transport. 
For Adenovirus [AdV] (kinesin-1, [123]), ASFV (kinesin-1, [128]), VACV (kinesin-1, 
[163]), Karposi’s Sarcoma-associated herpesvirus [KSHV] (kinesin-2, [139]), Pseudorabies 
virus [PrV] (kinesin-3, [137]) and Lassa virus [LASV] (kinesin-3, [161]), a single kinesin 
motor has been reported as essential for efficient virus dissemination. With the exception of 
AdV, a simple transport paradigm exists where viral proteins such as ORF45 (KSHV) 
interact with kinesin subunits such as KIF3A for anterograde transport to the cell periphery 
[139]. Conversely, in the case of AdV, kinesin-1 is involved in viral entry into the nucleus 
through the nuclear pore complex (NPC); this process involves the simultaneous binding of 
NPC proteins and kinesin-1 subunits to the capsid, which leads to increased nuclear 
envelope permeability and viral uncoating resulting in entry of the viral genome to the 
nucleus [123].  
For HSV-1, three (kinesin-1, kinesin-2, kinesin-3) kinesin motors are implicated in virus 
transport [132-134]. The kinesin-1 interaction follows the egress transport paradigm outlined 
previously, with US11 interacting with the heptad repeat binding region of KIF5B to 
transport non-enveloped HSV-1 nucleocapsids through the cytoplasm [132]. The kinesin-2 
interaction on the other hand mediates anterograde transport of envelope glycoproteins for 
virion assembly, rather than the transport of virus particles themselves [133].   
For HIV-1, two (kinesin-2, kinesin 4) kinesin motors are implicated in virus transport [146, 
147]. The kinesin-2 interaction in HIV-1 follows the classical egress transport paradigm like 
HSV-1 and KIF5B, with KIF3A transporting HIV-1 containing compartments in 
macrophages for viral release [147]. The remaining kinesin interaction with kinesin-4 motor 
KIF4 mediates anterograde transport of viral component Gag for virion assembly [146]. 
Salmonella replicates in a compartment called the Salmonella-containing vacuole (SCV) that 
displays a perinuclear localisation for most of the infectious cycle, but subsequently 
relocates to the cell periphery to aid bacterial dissemination. This movement is microtubule 
and kinesin-1 dependent. PipB2 and SifA localise to the surface of SCV and Salmonella-
induced filaments [Sifs]) and recruit inactive kinesin-1 and SKIP (SifA and kinesin-
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interacting protein) respectively [178, 179]. SKIP then interacts with the TPR domain of 
KLC and activates kinesin-1 to mediate anterograde transport [168].  
1.2.2.3 Bidirectional transport 
Cytoplasmic transport of viral cargos is not as simple as retrograde transport occurring 
during entry and anterograde transport during egress. In fact, HSV-1 and PrV undergo 
bidirectional transport during their entry and egress, AdV during its entry and VACV during 
its egress [120, 180, 181]. Bidirectional saltatory transport of endosomes, vesicles and 
mitochondria is typical in cellular contexts and although the purpose of this movement is 
unclear, it may facilitate roaming over larger regions of the cell, effective distribution, 
circumventing of obstacles and erroneous transport correction, all of which are qualities that 
would also be pertinent in a viral context [131, 182]. In HSV-1, the simultaneous binding of 
both retrograde (dynein) and anterograde (kinesin-1) motors has been demonstrated, 
although how directionality is determined and regulated remains to be clarified [134]. 
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1.2.3 Actin-based motility 
Pathogens manipulate the actin cytoskeleton in a variety of ways to aid their replicative cycles and 
infection of neighbouring cells. These include restructuring or bypassing the dense actin cortex to 
infect cells (for example, the internalisation of SV40 into caveolae, [183]), activating cell 
signalling pathways that remodel actin and induce cell motility (for example, Human T-
lymphotrophic virus-1 [HTLV-1], [184]), myosin-based mechanisms that induce so-called 
‘surfing’ along filopodia towards the cell body prior for infection (MLV, [185]), myosin-based 
exocytotic release of infectious progeny (HSV-1, [186]), virus-tipped filopodial formation (HIV-1, 
[187]) and Arp2/3 complex-based actin nucleation. 
Of these, Arp2/3 complex-based actin nucleation is one of the best-understood mechanisms of 
actin-based motility. Many pathogens that have been found to utilise this actin based motility are 
intracellular bacterial species. They include Listeria monocytogenes, Shigella flexineri, Rickettsia 
coronii, Rickettsia rickettsii, Mycobacterium marinum and Burkholderia psuedomallei [see Table 
1.2 for references]. All these bacterial species utilise varying yet overlapping set of regulatory 
components to manipulate host pathways for their motility, ultimately leading to modulation of the 
activity of the Arp2/3 complex. Poxviruses and baculovirus are the only known viral pathogens 
demonstrated to use actin-based motility.  
Enterohaemorrhagic and enteropathogenic Escherichia coli (EHEC and EPEC) do not grow 
intracellularly but are nonetheless able to mediate cellular actin polymerisation [188, 189]. This 
manifests as the formation of actin ‘pedestals’ directly under the cell surface where extracellular 
bacteria come into contact with the cell. While pathogen-mediated actin polymerisation generally 
aids in intracellular spread, in EHEC and EPEC it promotes adherence of bacteria to the gut 
epithelium. 
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Table 1.2. Actin-based transport of intracellular pathogens 
FAMILY PATHOGEN NUCLEATOR/MOTOR 
INVOLVED 
(MICROBIAL FACTOR) 
REFERENCES 
Viruses 
Poxviridae VACV Arp2/3 complex 
(A36) 
[190, 191] 
 Variola virus (VARV) Arp2/3 complex [192] 
 Monkeypox virus (MPXV) Arp2/3 complex [192] 
Baculoviridae Autographa californica 
multiple 
nucleopolyhedrovirus 
(AcMNPV) 
Arp2/3 complex 
(P78/83) 
[193] 
Flaviviridae HCV Myosin 18A – 
endocytotic pathways 
[194] 
Herpesviridae HSV-1 Myosin Va [186] 
 KSHV c-Cbl-myosin IIA [195, 196] 
Lentiviridae HIV-1 Myosin II [197] 
 HIV-1 Diaphanous 2 [187] 
Bacteria 
 Listeria monocytogenes Arp2/3 complex 
(ActA) 
[198-201] 
 Shigella flexineri Arp2/3 complex 
(IcsA) 
[202] 
 Rickettsia coronii Arp2/3 complex 
(RickA) 
[81] 
 Rickettsia rickettsii Arp2/3 complex 
(RickA) 
[203] 
 Mycobacterium marinum Arp2/3 complex 
(unknown) 
[204, 205] 
 Burkholderia pseudomallei ? (BimA) [206, 207] 
 Enteropathogenic or 
Enterohaemorraghic 
Escherichia coli (EPEC) 
Arp2/3 complex (Tir) [188, 189] 
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1.2.3.1 Nucleation 
Almost all actin-nucleating pathogens identified thus far utilise the Arp2/3 complex for their 
motility (with the exception of B. pseudomallei). As previously mentioned, the Arp2/3 
complex is an actin nucleator that generates branching arrays due to the formation of new 
actin filments attached at 70o angle branch points from previously formed actin filaments 
[94] [Figure 1.4]. The Arp2/3 complex is composed of seven polypeptides; two of these, 
Arp2 and Arp3, are actin-related proteins (ARPs) that share structural similarities and amino 
acid identity to cellular actin isoforms. Upon activation, they provide a template upon which 
G-actin can be oriented [92]. De novo filament formation increases total levels of actin 
polymerisation and is able to provide a propulsive force to facilitate cellular processes such 
as rocketing vesicles and migration of the leading edge during cellular motility. 
The NPFs such as WASP and N-WASP are able to dramatically increase rates of Arp2/3 
complex-based nucleation. These NPFs possess a VCA domain at their C-terminus 
containing two verprolin homology (V) domains, also known as WASP homology 2 (WH2) 
domains, a cofilin homology (C) domain and an acidic (A) domain, which together provides 
a binding site for monomeric actin and the Arp2/3 complex [208]. NPFs increase nucleation 
efficiency of the Arp2/3 complex via their WH2 domains recruiting and orienting G-actin to 
the nascent F-actin seed [96], while the CA domains are thought to bind and induce 
conformational changes within the complex [209].  
The inactive form of N-WASP has its Arp2/3 complex binding site occluded by 
autoregulatory elements at the amino terminal end of the protein [81]. Upon activation by 
the Rho GTPase Cdc42, a conformational change is induced in the N-WASP and the 
autoinhibition relieved [210]. 
Pathogens that nucleate actin can be grouped into two categories, those that encode NPF 
mimics (L. monocytogenes, R. rickettsii/coronni, B. pseudomallei) and those that recruit 
cellular NPFs (S. flexineri, M. marinarum, EPEC/EHEC and poxviruses) [211]. Each 
pathogen is able to generate F-actin structures with characteristic morphologies (ranging 
from short, highly cross-linked filaments to long, parallel bundled filaments) and associated 
characteristic rates of actin polymerisation [207]. These structures are generally referred to 
as actin comets or tails, with the bacterial cell or virus particle localising to the polymerising 
face of the structure. Through enhancing intracellular spread, potentially while avoiding 
immune detection, actin polymerisation has been demonstrated to play an important role in 
virulence for many of these pathogens [199, 212-215]. 
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L. monocytogenes encodes a WASP family mimic ActA that is essential for motility. ActA 
possesses a VCA domain for G-actin and Arp2/3 complex binding [199, 201] [Figure 1.8]. 
The central region of ActA has an Enabled-vasodilator stimulated phosphoprotein (Ena-
VASP) binding site that recruits profilin to the growing end of actin filaments, enhancing the 
rate of actin polymerisation [216]. This effect is responsible for increasing rates of 
dissociation between ActA and the Arp2/3 complex, effectively allowing the bacteria be 
pushed rapidly from Arp2/3 complex branch points by growing actin filaments [217]. Unlike 
the cellular homologue WASP, ActA lacks autoinhibitory domains and constitutively 
enhances actin nucleation [81].  
The importance of ActA to L. monocytogenes virulence goes further than the stimulation of 
actin-based motility for cell-to-cell spread protected from host immune defenses [92], with 
recruitment of ActA to the bacterial cell surface having been found to prevent 
ubiquitinylation-mediated autophagic destruction of the bacterium [218]. It has also been 
found to be critical for bacterial aggregation and biofilm formation, which improves 
persistence of the bacteria in the intestines of mice, as well leading to increased shedding of 
bacteria in faeces, aiding transmission to other hosts [219]. 
S. flexineri induces Arp2/3 complex-dependent actin nucleation but recruits host NPFs rather 
than encoding functional NPF mimics. S. flexineri encodes IcsA, a protein that localises to 
the bacterial cell surface and is essential for actin-based propulsion and recruits N-WASP 
through a region of glycine rich repeats [Figure 1.8]. IcsA is thought to act as a functional 
mimic of Rho GTPase Cdc42 by disrupting the autoinhibited state of N-WASP [202, 207, 
220]. Similarly to L. monocytogenes, growing actin filaments push against the surface of 
intracellular bacteria and propelling them through the cytoplasm and subsequently into 
neighbouring cells.  
All of the pathogens described so far that utilise actin polymerisation utilise the Arp2/3 
complex with the exception of B. pseudomallei, which encodes the protein BimA. While, the 
Arp2/3 complex has been shown to colocalise with B. pseudomallei induced F-actin 
strcutures [221], dominant negative experiments that sequester Arp2/3 complex components 
have no effect on B. pseudomallei tails [222]. BimA appears to be a NPF mimic with similar 
biochemical characteristics to WASP (including 2 WH2 domains) [Figure 1.8], yet evidence 
suggests that the Arp2/3 complex may be unnecessary for polymerisation, with BimA itself 
serving directly as a nucleator [222]. 
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Interestingly, the nucleocapsids of Autographa californica multiple nucleopolyhedrovirus 
(AcMNPV), a baculovirus that stimulates actin-based motility, undergo motility during two 
stages of its replicative cycle. First, during the early stage of infection when virus transits to 
the nucleus and translocates through the nuclear pore complex; and second, for transport and 
accumulation of nucleocapsids at the cell periphery following the onset of viral gene 
expression. Both stages of movement require the ability of nucleocapsid protein P78/83 to 
stimulate actin nucleation with the host Arp2/3 complex. The exact mechanism of this 
stimulation, whether the Arp2/3 complex is directly or indirectly recruited through an NPF 
has yet to be determined [193]. The accelerated passage of virus through infected insect 
tissues that is enabled by actin polymerisation is vital to evasion of host defense 
mechanisms. 
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Figure 1.8:  Intracellular bacterial actin polymerisation 
The membrane of the bacteria L. monocytogenes, S. flexineri, R. cornorii and B. pseuodomallei are shown 
in green. Each encodes a transmembrane protein essential for actin-based motility, ActA, IcsA, RickA and 
BimA respectively. Two of these, ActA, and RickA, are NPF mimics with WH2 domains for actin monomer 
binding and CA domains that directly recruit and activate Arp2/3. Conversely, IcsA recruits host cell N-
WASP that in turn recruits Arp2/3 for polymerisation. The pathway of BimA directed actin polymerisation is 
unclear, with Arp2/3 potentially not required for nucleation. From [207]. 
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1.3 POXVIRUSES 
Poxviridae are a family of large, double stranded DNA viruses that includes many important 
human, animal and insect pathogens. The family is divided into two subfamilies, 
Chordopoxvirinae and Entomopoxvidinae that infect vertebrates and insects respectively. These 
two subfamilies are further divided into 11 recognised genera [Table 1.3] with additional species 
such as yoka virus and cotia virus currently unclassified and potentially representing new genera 
[223, 224]. 
Structurally, poxviruses are unlike many other viruses in that they do not display any helical or 
icosohedral symmetry, instead virions measuring approximately 320 x 250 x 130 nm are brick-
shaped or ovoid, with a “dumbbell”-shaped core containing the viral genome [225-228]. Poxvirus 
genomes are as large as 360kb and encode hundreds of genes, of which 49 are conserved across all 
poxviruses [229] [230]. This core set of genes includes genes functioning in morphogenesis 
(H3L/intracellular mature virus morphogenesis viral protein/VP55), transcription (A5R/RNA 
polymerase subunit 19) and replication (E9L/DNA polymerase) [229]. It is these genes that allow 
poxviruses to replicate in the host cell cytoplasm, an uncommon feature of DNA viruses, shared 
by certain members of the nucleocytoplasmic large DNA virus clade (NCLDV) that also includes 
iridoviruses, asfarviruses and mimiviruses [231]. 
 
Table 1.3. Members of Poxviridae 
SUBFAMILY GENUS EXAMPLE VIRUSES  
Chordopoxvirinae Avipoxvirus Fowlpox virus 
 Capripoxvirus Sheeppox virus 
 Leporipoxvirus Myxoma virus 
 Molluscipoxvirus Molluscum contagiosum virus 
 Orthopoxvirus Variola virus, cowpox virus, vaccinia virus 
 Parapoxvirus Orf virus 
 Suipoxvirus Swinepox virus 
 Yatapoxvirus Yaba monkey tumour virus 
Entomopoxvirinae Alphaentomopoxvirus Melolontha melolontha virus 
 Betaentomopoxvirus Amsacta moorei virus 
 Gammaentomopoxvirus Chironomus luridus virus 
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The most well-known member of poxviridae is variola virus (VARV), the causative agent of 
smallpox, one of the most devastating human diseases in history. It is an ancient disease, with 
evidence of its characteristic pus-filled lesions present on the preserved remains of ancient 
Egyptian mummies dating to approximately 1200 BC [232]. In the 20th century alone, smallpox is 
believed to have caused in the realm of 300-500 million deaths, with an overall mortality rate of 
30%. A global vaccination program led by the World Health Organisation (WHO) eradicated the 
disease in 1979, with the last recorded natural case in Somalia in 1977 [232]. 
Smallpox was the first disease documented for which preventative innoculation was attempted. A 
practice developed in India before 1000 AD where dried scabs from smallpox victims were ground 
and administered to healthy individuals in an attempt to introduce small amounts of live virus to 
stimulate an immune response but not fatal disease [233]. This process, called variolation, existed 
throughout the world in various forms, with variable success in producing protective immunity 
due to the uncontrolled dosage and virulence of virus administered (variolation could also produce 
fatal disease). 
In 1796, Edward Jenner, a British physician, observed that people infected with cowpox were 
subsequently protected from smallpox. He inoculated virus from cowpox lesions into the skin of 
healthy individuals and demonstrated protective immunity against smallpox, effectively practising 
the first vaccination [234]. Cowpox virus (CPXV) was subsequently used globally against 
smallpox. In the 1960s, in an attempt to obtain a purified vaccine strain for use in the WHO’s 
global eradication attempt, it was discovered that the virus being used for vaccination was not 
CPXV, but a closely related virus that was subsequently named vaccinia virus (VACV) [235].  
Various aspects of VACV biology have since been widely studied, including its replication, 
interactions with the host cell and the immunological response to infection. VACV is the 
prototypal poxvirus, with research able to be broadly extrapolated to other viruses in the family 
due to substantial similarities existing in the pathogenesis and replication between members of this 
group [228]. 
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1.3.1 Vaccinia virus 
Some of the reviewed information below was published in an earlier form: TP 
Newsome, AJ Marty, H Lynn, & DJ Procter [2009]. Navigating the subcellular 
space: Lessons from vaccinia virus in Viral Transport, Assembly and Egress, edited 
by RJ Diefenbach & AL Cunningham (Research Signpost, Kerala, India, 2011) 
VACV is a member of the orthopoxviridae genus of the poxviridae family. It infects a wide range 
of vertebrates, including cows, rodents and humans, although none of these are the natural 
reservoir host [236]. The origins of VACV remain controversial; while there is the possibility that 
the natural host is extinct, it has also been speculated that the natural host are cows or horses, 
although the virus may no longer exist in these hosts in the wild [235, 237, 238]. 
To date, there are 35 VACV strain genome sequences collated at The Viral Bioinformatics 
Resource Centre (http://athena.bioc.uvic.ca/), of which Western Reserve (WR) and Copenhagen 
(Cop) are the most widely utilised laboratory strains. Both possess genomes of approximately 
200kb and contain greater than 200 open reading frames ([239], http://www.poxvirus.org/). These 
numbers are typical of most VACV strains, with Modified Vaccinia Ankara (MVA), a severely 
attenuated vaccine strain generated through over 500 passages through chicken embryo fibroblasts 
being a notable exception with only 163 intact open reading frames [240]. 
VACV genes are annotated with a capital letter, a number, and then either L or R. The first capital 
letter corresponds to the fragment of the VACV-Cop genome digested with HindIII restriction 
nuclease that the gene is located in, with the fragments designated alphabetically from the largest 
fragment A to the smallest, P [239, 241]. The number represents the gene’s sequential position 
within that fragment from the 5’ to the 3’ end of the genome. The L or R indicates the transcription 
direction of the open reading frame (left or right) and as such, is omitted from protein names (for 
example, the E9L locus encodes for the E9 protein) [242]. 
The VACV replicative cycle is complex and involves the production of distinct morphological 
forms with characteristic transport steps [Figure 1.9]. The replicative cycle can be divided into 
three main phases; entry, morphogenesis and egress. Entry involves the viral membrane fusing 
with the host cell plasma membrane or an endosomal membrane and release of the core into the 
cytoplasm [243-245]. This process is mediated by a complex of up to 12 viral proteins called the 
entry fusion complex (EFC) [246, 247] 
The released viral core is transported along microtubules to a perinuclear location while early 
mRNA and protein synthesis is initiated, with DNA replication following soon after [248-250]. 
The viral enzymes necessary for transcription of early genes are present in infecting particles [251] 
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and early mRNAs can therefore be detected 20 min after infection of HeLa cells [252]. 
Intermediate and late genes are regulated by the products of earlier gene transcription and protein 
synthesis, so are not detected until 100 and 140 min post infection respectively [252]. The cascade 
of early gene products regulating intermediate gene transcription and intermediate gene products 
regulating late gene transcription is dependent on specific promoter sequences that coordinates the 
tight temporal regulation of gene expression [253-257]. 
At 2 hpi (hours post infection), sites of DNA replication begin to be surrounded by membranes of 
the endoplasmic reticulum (ER) that coalesce to form a viral replication and morphogenesis 
compartment called the virus factory (VF) [250, 258]. Replicated viral DNA is packaged into 
membrane crescents containing lipid and virally-encoded proteins to form immature virus (IV). 
These then undergo proteolytic cleavage of several core proteins to generate the characteristic 
brick-shaped intracellular mature virus (IMV) [259]. IMV are infectious and their formation is 
thought to be the end-point of morphogenesis for the majority of virus particles, which are then 
released upon cell lysis.  
However, a small subset (5-20%) of IMVs are transported along microtubules to the trans-Golgi 
network (TGN) where they are wrapped by an additional two lipid membranes to become 
intracellular enveloped virus (IEV) [260], a process regulated by viral gene A27L [163] (which is 
discussed further below) [Figure 1.10]. While there is dispute in the field about the number and 
origin of the IMV membrane(s), which may be derived from the membranes of the intermediate 
compartment or otherwise synthesised de novo [261], the IEV membranes that wrap IMV are 
known to be derived from endosomal or trans-Golgi cisterna [260, 262]. 
After being wrapped, IEV will undergo egress with a final microtubule-based transport step to 
move virus from the TGN to the cell periphery [263]. At the cell periphery, the outermost 
membrane fuses with the plasma membrane to generate cell-associated enveloped virus (CEV). 
CEV may stimulate actin-based motility that generates a propulsive force to push CEV into the 
extracellular space, where they become extracellular enveloped virus (EEV). As virus particles are 
large, actin-based motility of CEV can be directly visualised by fluorescent light microscopy 
revealing movement in association with thick actin bundles at speeds of approximately 0.2 µm/sec 
[264]. The formation of EEV is believed to play roles in mediating long-range spread of virus 
within a host [265, 266] as the additional membrane has been demonstrated to aid evasion of host 
defense mechanisms such as complement [267]. 
Although there are substantial structural differences between IV and IMV, the key difference 
between all other morphological forms is the number of membranes present (alternate 
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nomenclature which differentiates IMV, called mature virus [MV] from all the enveloped forms of 
the virus known collectively as wrapped virus [WV] acknowledges this), which in turn alters the 
protein composition of virions [Figure 1.10]. The IMV form contains all proteins necessary for 
replication, including structural proteins, the proteins of the aforementioned EFC and enzymes 
such as DNA polymerases and endonucleases [268].  
Eight proteins; A33, A34, A56, B5, F13, A36, F12 and E2 are integral to or associated with the 
IEV membranes and absent from IMV, with A36, F12 and E2 specifically associated exclusively 
with outer of the two membranes, and are therefore are absent from EEV [Figure 1.10] [266]. 
These proteins have a range of functions associated with viral egress or infectivity, including 
efficient wrapping of IEV, formation and release of EEV and microtubule-based transport of IEV 
[269-273]. Those proteins responsible for microtubule-based transport of IEV, A36, E2 and F12 
are of particular interest and are discussed further below. 
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Figure 1.9:  The VACV replicative cycle 
Upon fusing with the plasma membrane of the host cell, the viral core is released into the cytoplasm to 
be transported along microtubules to a perinuclear location where it generates a viral replication centre 
called the virus factory (VF). DNA is packaged into immature virus (IV) that undergo cleavage to become 
intracellular mature virus (IMV). A subset of IMVs are transported along microtubules to the trans-Golgi 
network (TGN) where they are wrapped by two lipid membranes to become intracellular enveloped virus 
(IEV). A final microtubule-based transport step occurs to transport IEV to the cell periphery, where the 
outer most membrane fuses with the plasma membrane to generate cell-associated enveloped virus 
(CEV). These may stimulate actin-based motility that generates a propulsive force to push CEV into the 
extracellular space, where they are referred to as extracellular enveloped virus (EEV). 
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Figure 1.10:  Localisation of envelope proteins 
Schematics of IMV, IEV, CEV and EEV are shown indicating the different localisation of various intergral 
membrane and membrane-associated proteins. A36 and F12 (and E2, which is associated with F12 but 
not represented) are located on the outer IEV membrane only, but are not present in CEV and EEV as 
formation of CEV leads to dissociation of F12 and redistribution of A36 beneath the CEV particle on the 
plasma membrane. A33, A34, A56 (only in two thirds of EEV particles), and B5 are on the outer surface 
of CEV/EEV and F13 is present between the IMV surface and IEV membranes. From [266]. 
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1.3.1.2 A27L 
A27L encodes a 14kDa protein referred to as A27 that is resides on the surface of IMV (or MV, 
when released from the cell) [274]. Acting in concert with H3, D8 and A26, A27 mediates 
attachment of MV to the host cell through binding to glycosaminoglycans and laminin on the cell 
surface [275]. Both A25 and A26 are involved in the endocytotic entry pathway of VACV into the 
cell and require A27 to mediate their association with the MV [276, 277]. A27 itself is bereft of 
transmembrane domains and is anchored to IMV though its interaction with A17 [274]. In addition 
to facilitating the association of A25 and A26, A27 also plays a direct role in membrane fusion 
during entry [278, 279], although the exact nature of this role has been contentious [247]. A27 is 
not one of the 12 proteins identified as a component of the EFC that mediates membrane fusion 
[247]. 
A27 plays diverse roles in the VACV replicative cycle and has also been found to be essential in 
the microtubule-based viral egress of progeny virus particles. Deletion of A27 leads to a greatly 
reduced-size plaque phenotype, with minimal effects on virus production in a one-step growth 
curve. This indicates that deletion of A27 does not disrupt IMV production while nonetheless 
abrogating EEV production [280]. The underlying mechanism that manifests this phenotype is 
unclear; it has been reported that disruption of A27 leads to inhibition of microtubule-based 
movement of IMV to the TGN for wrapping in addition to defects in wrapping [163]. Conversely, 
imaging of a fluorescently tagged ΔA27L virus reveal IMV undergoing bidirectional microtubule-
based motility to and from the VF, with reductions in EEV production being attributed solely to 
aberrant wrapping [280].  
1.3.1.3 A36R 
A36 is a type Ib transmembrane protein that contains a ∼190 residue surface in contact with the 
cytoplasm [191, 281]. It is localised to the trans-Golgi network and acquired by virus particles 
during the wrapping of IMV to form IEV at this compartment. As previously mentioned, it is 
integral to the outer of two IEV membranes that fuses to the plasma membrane upon formation of 
CEV and is therefore absent from EEV particles. Viruses deleted for A36R display a reduction in 
transport of IEV to the cell surface, a phenotype reminiscent of cells treated with the microtubule 
destabilising drug nocodazole [282-286] [Figure 4.1]. In immunofluorescence assays, this 
presents phenotypically as a loss of formation of CEV/EEV, except in regions where the TGN lies 
in proximity to the cell membrane [Figure 1.11]. 
A key role for A36 is to direct the recruitment of the kinesin-1 anterograde motor complex. 
Expressing dominant negative constructs that interfere with kinesin-1 function also inhibit IEV 
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egress from the trans-Golgi network [282, 287]. This interaction appears to be via a direct 
interaction with kinesin-1 light chain (KLC), with yeast-2-hybrid assays and fluorescence 
resonance energy transfer approaches confirming an interaction between A36 and the TPRs of 
KLC2 [181] [288]. 
This interaction between A36 and kinesin-1 has been mapped to a bipartite tryptophan motif in 
A36 at residues 64/65 (A36W64E65) and 97/98 (A36W97D98) [181, 282, 286]. When both these sites 
are mutated to AA, egress of virus to the cell periphery is retarded to the same extent as in 
complete loss of A36, and recruitment of kinesin-1 is abolished. The A36W97D98 site plays the 
dominant role in this interaction and A36W64E65 an ancilliary role; with a A36WDAA mutant (both 
residues of the A36W97D98 tryptophan motif mutated to AA) generating plaques approximately 33% 
the size of parental plaques, compared to approximately 95% of a A36WEAA mutant [286].  
A simple paradigm that emerges from these findings suggests that A36 on the surface of IEV 
presents an interaction site for kinesin-1 resulting in transport to the cell periphery. Confounding 
this paradigm is the viral protein F12 that is also been implicated in the microtubule transport of 
IEV, but the exact function of this protein and its mechanism of action remains to be resolved 
[285, 289-291] [Section 1.3.1.4].  
A36 also directs a second transport event following delivery of IEV to the cell periphery. Upon 
fusion of the outer IEV membrane to the plasma membrane, A36 localises directly beneath CEV 
[281]. Two tyrosine residues, A36Y112 and A36Y132 are phosphorylated by Src and Abl family 
kinases leading to the initiation of signalling cascades involving Nck (recruited by A36Y112), Grb2 
(recruited A36Y132), WIP, N-WASP and finally the Arp2/3 complex [292-298]. This leads to the 
rapid nucleation of actin filaments that propel CEV across the surface of the cell thereby 
facilitating cell-to-cell spread [299, 300] [Figure 1.11]. 
Mutation of these two critical tyrosine residues to phenylalanine (A36Y112F and A36Y112F, together 
referred to as A36YdF) prevents tyrosine phosphorylation and completely abolishes viral actin-
based motility [300, 301] [Figure 1.11]. It is the A36Y112 that is the critical tyrosine, with the 
A36Y112F mutant leading to an approximately 10-fold reduction in actin tail formation [301]. In the 
absence of A36Y132 phosphorylation, the effects on motility are more subtle; there is a modest 
reduction in the initiation efficiency of actin-based motility (the chance that an infected cell will 
have actin tails), although infected cells have on average fewer numbers of CEV-associated actin 
tails [293]. 
This nucleation of actin by A36 has also been recently demonstrated to aid in EEV release. Cells 
infected with the A36YdF virus deficient in localised actin nucleation, displayed a 10-fold reduction 
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in virus release with transmission electron microscopy and 3D-SIM super-resolution microscopy 
demonstrating CEV trapped in small invaginations/pits at the plasma membrane [302]. These 
results indicate that the propulsive force generated by actin polymerisation promoted the 
disengagement of CEV attachment sites with the plasma membrane and facilitating the release of 
EEV into the extracellular space [302].  
The early expression of VACV A36 is believed to be important in repulsion of super-infecting 
virions, a process that allows viral spread to occur at a rate beyond the speed of its replicative 
cycle. Through cell surface signalling involving B5 on the virus surface and A36 and A33 on the 
host membrane, viral entry into early-stage infected cells yet to manufacture infectious virus is 
blocked. Super-infecting virions are directed toward uninfected cells, allowing plaques to expand 
at a rate that outpaces the rate of replication [299]. 
1.3.1.4 F12L 
F12 is a 65-kDa protein that lacks transmembrane domains [303]. It is recruited to the virus upon 
membrane wrapping at the trans-Golgi network and is therefore present on IEV particles but 
absent from IV and IMV [289]. It is also absent from CEV and EEV, indicating that like A36, it is 
lost from the virus upon fusion with the plasma membrane. While A36 is present in the cell 
membrane beneath CEV however, F12 is not detectable. This transient recruitment to IEV during 
egress to the cell periphery strongly indicates involvement of F12 in microtubule-based transport 
[285]. 
A VACV deletion mutant of F12L produces a small plaque phenotype [Figure 1.11]. While the 
effect of the deletion on IMV production is fairly minor, production of CEV and EEV production 
was affected dramatically, with a seven-fold reduction in infectious EEV released from infected 
cells [303]. Immunofluorescence and electron microscopy (EM) revealed large numbers of IEV 
clustered in the centre of the cell, indicating deficient dispersal of virions [283, 289]. With reduced 
transport to the cell periphery, there is a concurrent reduction in actin-tail formation (by 99.5%), 
unlike ∆A36R however, actin tails can still be formed [303]. 
The transient nature of the F12 interaction suggests protein–protein interactions may be involved 
in recruiting the protein to IEV. Yeast 2-hybrid screens between F12 and IEV proteins A33, A34, 
A36 and B5 demonstrated interaction between F12351-458 and A3691-111 [291, 304]. Deletion of the 
A36 interaction site in a recombinant virus (B5R-GFP/F12LΔ351–458) abrogates association with 
IEV and subsequent viral egress, effectively reproducing the ΔF12L phenotype [291, 304]. A 
caveat to this study was that there was no evidence that F12LΔ351–458 retained any functionality or 
indeed was correctly folded. 
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The precise role of F12 in IEV transport is yet to be definitively determined. Kinesin-1 is not 
recruited to IEV in the absence of F12, with A36 alone being insufficient for the recruitment of 
kinesin-1 [290]. This suggests that F12 may potentially stabilise interactions between A36 and 
kinesin-1 or that F12 could fulfil a regulatory role. If, however, F12 acts through A36, an apparent 
paradox is how loss of F12 leads to a stronger phenotype than loss of A36. Fewer IEV reach the 
cell surface in the absence of F12L than A36, and plaque growth is more dramatically retarded 
[283, 303] [Figure 1.11]. This paradox and observations of IMV accumulation in the virus factory 
in the ∆F12L strain [291] has led to conflict in the field regarding the existence of additional non-
transport roles of F12 such as in IEV wrapping, as well as exploration of additional F12 interaction 
partners that may be disrupted by deletion of F12L.  
Using a recombinant virus in which F12 was fused to affinity tag Glutathione S-Transferase 
(GST), the viral protein E2 was identified as a co-purifying protein [285]. Like F12, E2 colocalises 
with IEV in transit along microtubules and deletion of E2L results in a reduction in IEV egress and 
a small plaque phenotype, effectively mimicking loss of F12L [285, 305]. There is 
interdependence between these two proteins in recruitment to IEV, with loss of either leading to 
abrogation of IEV localisation of the other partner [285]. Wrapping defects are also apparent with 
loss of either E2 and F12, with examination of EM images revealing excess layers of membrane 
and other forms of aberrant wrapping [285, 305]. Quantitative measurements in a later study 
utilising serial section and tilt series analyses of EM images contradicted previous findings by 
showing both F12 and E2 deletion viruses wrap normally, with no difference in the number of 
IMV or partially wrapped IEV relative to wild type [290]. 
Complicating the elucidation of F12 function, it has been proposed that F12 may be a KLC mimic, 
possessing 14 TPR-like sequences that make up 80% of the protein. Structural modeling of TPR-
like repeats 1-6 and 7-12 of F12 demonstrates substantial similarity to the TPR domain of KLC2 
[290]. TPR domains mediate protein-protein interactions, including those between KLC and 
WD/WE motifs in cargo proteins [Section 1.1.3.2]. The structural similarity to TPR domains has 
subsequently been contested in a report suggesting that F12 is an inactivated DNA polymerase 
[306]. 
Additionally, F12 possesses a critical WD motif, that when mutated blocks the recruitment of F12 
and KHC to IEV and preventing egress to the cell periphery [290]. Together, these results imply a 
role for F12 as a mediator of binding of kinesin-1 to IEV, however, while protein-protein 
interactions have been found between F12 and IEV protein A36, there is so far no evidence of 
direct interaction with either KHC or KLC [181, 290, 291]. 
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Figure 1.11:  Effect of gene mutations and deletions on phenotype 
The plaque phenotype of WR, A36RYdF, ∆A36R and ∆F12L are represented in the upper panels and 
immunofluorescence images with cell-associated virus (CEV) in green (anti-B5R, non-permeabilised cells) 
and F-actin in red are displayed in the lower panels. While all enveloped form of virus are B5-positive, 
CEV are differentiated from IEV in IFA by applying α-B5 antibodies to cells that have not been 
permeabilised. As antibodies are too large to diffuse through intact cell membranes, only IEV that have 
reached the cell periphery and fused with the cell membrane to become CEV will be detected. Disruption 
of A36 tyrosine phosphorylation (A36RYdF strain) completely abrogates actin-based motility, but does not 
inhibit the appearance of CEV in the cell periphery indicating intact microtubule-based motility. 
Correspondingly, there is a limited reduction in plaque size relative to WR. Disruption of 
microtubule-based transport (ΔA36R, ΔF12L) on the other hand strongly attenuates both plaque size and 
CEV dispersal. Unlike ∆A36R, ΔF12L has intact actin-based motility, and the reduced numbers of 
enveloped viruses that reach the cell surface are capable of forming actin tails. Scale bar is 100 µm in the 
upper panels and 10 µm in the lower panels. From [307]. 
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1.4 PROJECT AIMS AND HYPOTHESES 
A speculative model of regulation [Figure 1.12] of VACV motility generated from current 
research in the field suggests that during motility, a small stretch of residues on the cytoplasmic 
surface of A36 is able to interact with multiple partners thereby enabling motility. Egress of IEV 
to the cell periphery occurs when a complex of kinesin-1, F12 and E2 binds to A36, mediated by a 
bipartite tryptophan motif in A36 at residues 64/65 (WE) and 97/98 (WD). Upon reaching the cell 
periphery, the outer IEV membrane fuses with the plasma membrane and phosphorylation of 
A36Y112 and A36Y132 promotes kinesin-1 release and the recruitment of the actin nucleation 
machinery. Stimulation of actin-polymerisation propels EEV into the extracellular space by 
breaking cellular–viral membrane contacts. 
This speculative model highlights A36 as the critical mediator of all virus motility, with F12/E2 
playing an ancillary role, possibly in stabilising kinesin-1 recruitment. The suggested role of F12 
is however inconsistent with mutant plaque phenotypes which demonstrate stronger attenuation in 
the absence of F12 than A36 (which may or may not be due to a role in IEV morphogenesis). This 
project therefore broadly aims to elucidate and clarify the contributions of proteins A36 and F12 to 
microtubule-based egress of IEV. To achieve this, this we aimed to generate a novel viral imaging 
system utilising photoactivatable fluorescent proteins to track the trajectories of viruses in different 
mutant backgrounds. While appearing to play important roles in microtubule-based egress of 
VACV, the contentious role of A27 was not dissected in this thesis. 
Lastly, we aimed to investigate the contribution of cytoskeletal-based motility to virulence in an 
animal model of smallpox. To do this, we aimed to characterise microtubule- and actin-based 
motility in ECTV, the causative agent of mousepox, which is a smallpox-like disease in mice. Due 
to the substantial genomic similarities between the two viruses, we hypothesised they would share 
similar characteristics in their microtubule- and actin-based motility and we aimed to generate a 
deletion mutant of an A36R homolog to test virulence in mice. 
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Figure 1.12:  Speculative model of IEV regulation 
While IEV are formed at the TGN, A33 potentially occlude kinesin-1 access to A36 and inhibits 
premature transport. A complex of kinesin-1, F12 and E2 is then recruited to A36 and transports virions 
to the cell periphery. Phosphorylation of Y112 and Y132 residues in A36 by tyrosine kinase promotes 
kinesin-1 release and initiates recruitment of the actin polymerisation machinery. From [307]. 
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CHAPTER 2: Materials and Methods 
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2.1 MOLECULAR BIOLOGY AND BIOCHEMISTRY 
2.1.1 Chemicals and reagents 
Chemicals, reagents and commercial kits used and mentioned in this thesis are listed below, along 
with their suppliers and catalogue number in brackets. 
• 30% Acrylamide/Bis Solution, 37.5:1 (2.6% C) (Bio-Rad Laboraroties) (Cat: # 161-0158) 
• 35mm Glass Bottom Dishes (MatTek) (Cat: #P35G-0-10-C) 
• µ-Dishes 3cm No. 1.5 glass (Ibidi) (Cat: #81151) 
• Agarose (Bioline) (Cat: # Bio41025) 
• Alexa Fluor® 568 Phalloidin (Invitrogen) (Cat: # A12380) 
• Amersham ECL Westertn Blotting Detection Reagent (GE Health)(Cat: # RPN3243) 
• Amersham Hyperfilm ECL (GE Health)(Cat: # 28-9068-37) 
• Ammonium Persulphate for electrophoresis (APS) (Sigma-Aldrich) (Cat: # A3678) 
• Ampicillin (Astral Scientific) (Cat: # AM0339) 
• 3',3",5',5"-tetrabromophenolsulfonphthalein (bromophenol blue) (Sigma-Aldrich) (Cat: # B8026) 
• Boric Acid (Astral Scientific) (Cat: # AM0588) 
• Bovine Serum Albumin, Nuclease free (Fisher Biotec) (Cat: # BSA-50) 
• Carboxymethylcellulose sodium salts, medium viscosity (Sigma-Aldrich) (Cat: # C9481) 
• Chloramphenicol Crystalline (Sigma-Aldrich) (Cat: # C0378) 
• 4', 6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich) (Cat: # D9542) 
• D-Glucose (Astral Scientific) (Cat: # AM0188) 
• Dimethylsulfoxide (DMSO) (Sigma-Aldrich) (Cat: # D2650) 
• Disodium hydrogen Orthophosphate (Merck) (Cat: # 10248) 
• dNTP Set (Bioline) (Cat: # Bio39026) 
• Dulbecco's Modified Eagle Medium (D-MEM) (1X), liquid (High Glucose) (Invitrogen) (Cat: #11995073) 
• ECL Western Blotting Reagent (GE Health) (Cat: # RPN2106) 
• Ethidium Bromide (Amresco) (Cat: # X328) 
• Ethylenediaminetetraacetic Acid (EDTA) Disodium Salt Dihydrate (Astral Scientific) (Cat: # AM0105) 
• Fetal Bovine Serum (FBS) (Diethelm Keller Siber Hegner, DKSH) (Cat: # SFBS) 
• Fibronectin from bovine plasma (Sigma-Aldrich) (Cat: #F1141-1MG) 
• Frosted l End 1 Side, 1.0-1.2mm (Livingstone) (Cat: # 7105-1A) 
• GelRedTM Nucleic Acid Gel Stain (Biotium) (Cat: # 41003) 
• Glycerol, minimum 99% GC (Sigma-Aldrich) (Cat: # G5150) 
• Glycine (Astral Scientific) (Cat: # AM0167) 
• GPT Selection Reagent, 500X Mycophenolic Acid; 100X Aminopterin (Millipore) (Cat: # TR-1001) 
• Hybond-C Extra (Amersham Biosciences, GE) (Cat: # RPN203E) 
• Hyperladder I (Bioline) (Cat: # Bio33026) 
• Hypoxanthine Cell Culture Tested (Sigma-Aldrich) (Cat: # H9636) 
• Immersion Oil (Olympus) (Cat: # AV239000) 
• Immersion Oil (Olympus) (Cat: # AV9602) 
• Lens Paper (Olympus) (Cat: # AX6476) 
• Lipofectin Reagent (Invitrogen) (Cat: # 18292-001) 
• Lipofectamine 2000 Transfection Reagent (Invitrogen) (Cat: # 11668027) 
• Magnesium Acetate Tetrahydrate (Sigma-Aldrich) (Cat: # M5661) 
• Magnesium Chloride (APS Chemical) (Cat: # 296) 
• β-Mercaptoethanol (Sigma-Aldrich) (Cat: # M3148) 
• 2-(N-Morpholino)ethanesulfonic acid hydrate (MES) (Sigma-Aldrich) (Cat: # M8250) 
• Microscope Coverslips No.1 Thickness Circular, 12mm (Livingstone) (Cat: # CS12RD) 
• Minimum Essential Medium Eagle, with EAR (MEM) (Sigma-Aldrich) (Cat: # M2279) 
• Modified Eagle Medium (MEM) (2X), liquid (Invitrogen) (Cat: # 11935046) 
• Mycophenolic Acid (Sigma-Aldrich) (Cat: # M5255) 
• Paraformaldehyde (PFA) (Sigma-Aldrich) (Cat: # P6148) 
• Penicillin-Streptomycin-Glutamine (100X) (Cat: # 10378-016) 
• Phenol Buffer Saturated (pH 6.7/8.0) (Astral Scientific) (Cat: # 0945) 
• Phenol:Chloroform (pH6.7/8.0) premixed with isoamyl (25:24:1) (Astral Scientific) (Cat: # 0883) 
• Phosphate Buffered Saline Tablet (Astral Scientific) (Cat: # AME404) 
• Polyvinyl Alcohol 4-88 (Mowial) (Sigma-Aldrich) (Cat: # 81381) 
• Polyoxyethylene Sorbitan Monolaurate (Tween-20) (Sigma-Aldrich) (Cat: # p2287) 
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• P-Phenylenediamine Free Base (Sigma-Aldrich) (Cat: # P6001) 
• QiaexII Gel Extraction Kit (Qiagen) (Cat: # P20021) 
• Qiaprep Spin Minikit (Qiagen) (Cat: # P27106) 
• 0.25% Trypsin-EDTA 1X (Invitrogen) (Cat: # 25200114) 
• Rubidium Chloride (Sigma-Aldrich) (Cat: # 215260) 
• 5mL Serological Pipets (Beckon Dickinson) (Cat: # 357543) 
• 10mL Serological Pipets (Beckon Dickinson) (Cat: # 357551) 
• 25mL Serological Pipets (Beckon Dickinson) (Cat: # 357525) 
• Skim Milk Powder (Oxoid) (Cat: # LP0031) 
• Snap Strip II PCR tubes 8-Strip Standard Tube & with Individual Attached Flat Caps (Astral 
Scientific) (Cat: # I324500) 
• Sodium Chloride (Astral Scientific) (Cat: # AMX190) 
• Sodium Dihydrogen Orthophosphate (APS Chemicals) (Cat: # 471) 
• Sodium Dodecyl Sulfate (SDS) (Astral Scientific) (Cat: # AM0227) 
• Sodium Orthovanadate (Sigma-Aldrich) (Cat: # S6508) 
• 60X15mm Standard Dishes (Beckon Dickinson) (Cat: # 353002) 
• 100X20mm Standard Dishes (Beckon Dickinson) (Cat: # 353003) 
• STrEP-Tactin Superflow resin suspension (Qiagen) (Cat: # 30001) 
• Syringe Filter (Diethelm Keller Siber Hegner, DKSH) (Cat: # 431227) 
• Tetracycline Hydrochloride Crystalline (Sigma-Aldrich) (Cat: # T3383) 
• Tris-hydroxymethyl-aminomethane (Tris Base) (Astral Scientific) (Cat: # AM0479) 
• 6-Well Flat-Bottom with Lid (Beckon Dickinson) (Cat: # 353046) 
• Wizard® SV Gel and PCR Clean-Up System (250 preps) (Promega) (Cat: # A9282) 
• Wizard® Plus SV Miniprep DNA Purification System + Vaccum Adaptors (250 preps) (Promega) 
(Cat: # A1470) 
• Xanthine (Sigma-Aldrich) (Cat: # X4002) 
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2.1.2 Polymerase Chain Reaction (PCR) and Cloning 
PCR was carried out according to standard methods using primers listed in Table 2.1 below. PCR 
product cleaned with Wizard SV PCR Clean-Up Kit (Promega) and vectors (1µg) were digested 
with suitable restriction enzymes (5U) (all restriction enzymes from NEB) in corresponding buffer 
provided by manufacturer for 5min at 37ºC. DNA loading dye (2.5% Ficoll 400, 11mM EDTA, 
3.3mM Tris-HCl, 0.017% SDS and 0.015% bromophenol blue) was mixed with digested sample 
and separated on 1% agarose gel in TBE buffer (10.781g/L Tris-base, 0.744g/L EDTA and 5.5g/L 
Boric acid). PCR products and gel slices containing digested vector backbone or insert were 
purified with Wizard SV Gel Extraction Kit (Promega) or QiaexII Gel Extraction Kit (Qiagen). 
Purified products were used for DNA ligation. DNA ligations were set up according to 
manufacturer’s instructions (T4 DNA ligase, NEB) and performed either overnight at 4 ºC or 2 
hours at room temperature.  
Ligations were transformed into XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, 
USA, Cat: # 200314) and plated onto Luria Broth (LB) agar plates (10g/L NaCl, 10g/L Tryptone, 
5g/L Yeast Extract, 15g/L Bacteriological Agar) supplemented with ampicillin (50µg/mL). 
Successful ligations colonies were amplified and prepared with Qiaprep Spin Minikit (Qiagen) 
before being subjected to diagnostic digests and sequencing. All successfully cloned PCR products 
were sequenced at Australian Genome Research Facility Ltd. The vectors constructed and used in 
this study are detailed in Table 2.2. 
2.1.2.1 Construction of vectors for VACV 
All vectors used and constructed for this thesis are detailed in Table 2.2, including primers 
and restriction sites used. All primers used are listed in Table 2.1. All viral DNA was 
originally amplified from VACV WR (ATCC VR-1354) genomic extraction [Section 2.3.4]. 
Vectors constructed and used in VACV experiments were either for transient expression of 
fusion proteins or for homologous recombination to generate recombinant viruses [Section 
2.4], with constructs used for homologous recombination bolded in Table 2.2. 
With the exception of commercial vectors purchased or received as gifts, three main types of 
vectors were used, the first were CB6 vectors with protein expression, either fluorescent 
proteins or fusions between viral proteins and fluorescent proteins, under the control of a 
constitutive CMV promoter [Figure 2.1]. The second were pE/L vectors with protein 
expression, again of fluorescent or fluorescent fusion proteins under the control of a 
synthetic viral early/late promoter (pE/L) [282, 308] [Figure 2.1]. The third type were GPT 
selection vectors which contained an Escherichia coli gpt gene that encodes guanine-
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hypoxanthine phosphribosyltransferase (GPT, [309]) and screenable marker gene 
monomeric Red Fluorescent Protein (mRFP, [310]). GPT acts as a selection marker by 
allowing growth of VACV in the presence of mycophenolic acid (MPA; an inhibitor of 
purine metabolism), xanthine and hypoxanthine [311]. 
To generate pE/L LA-PSCFP2-A3L(500) and pE/L LA-Dendra2-A3L(500)GPT, 
homologous recombination cassettes for generation of viruses with fusions between viral 
proteins and PSCFP2 and Dendra2 [312] [see Section 2.4.1.2 and 3.1.2.4], a two step fusion 
PCR was carried out to create the LA-PSCFP2 and LA-Dendra2 fragment to then be cloned 
into vectors [see Table 2.2]. For pE/L LA-PSCFP2-A3L(500), primers 
A3L.LA.CFPsew1/A3L.LA.CFPsew2 were used to amplify the region 500 bp upstream of 
A3L (the left arm; LA) from VACV genomic DNA and primers A3L.LA.CFPsew3/PSCFP2 
were used to amplify the PSCFP2 gene without a stop codon from the PSCFP2-N vector. 
These PCR products from the first two reactions were cleaned with Wizard SV PCR Clean-
Up Kit (Promega), then diluted and combined in the PCR reaction to be used as template for 
a second step of amplification with A3L.LA.CFPsew1/PSCFP2 resulting in a full-length 
fusion product incorporating the two first-step fragments. 
The same process with differering primers and template was used for generation of pE/L 
LA-Dendra2-A3L(500)GPT. The LA of A3L was amplified from VACV genomic DNA 
with A3L.LA.Dendrasew1/A3L.LA.Dendrasew2 and the Dendra2 gene was amplified from 
the Dendra2-N vector with A3L.LA.Dendrasew3/Dendra2 primers. The second step of the 
fusion PCR utilised these two first step products as the template with 
A3L.LA.Dendrasew1/Dendra2 to generate a full-length product. 
A slightly different modular approach was used for construction of F13L-Dendra2 and 
F13L-GFP viruses [313] to enable transient dominant selection of recombinant viruses 
[Section 2.4]. A 300 bp fragment spanning 150 bp of the end of the F13L ORF (LA) and 
150 bp of the sequence immediately downstream of the ORF (RA) were synthesised with 
NotI and BamHI sites between them and flanked by HindIII/SalI restriction sites. This 
fragment was cloned HindIII/SalI into a variation of the GPT Selection Vector [314] which 
has mCherry in place of mRFP, and lacks the represented BglII/NotI/BamHI MCS [Figure 
2.1D]. Fluorescent protein gene inserts Dendra2 and GFP were then shuttled from other 
vectors between the LA and RA in the construct with NotI/BamHI. 
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2.1.2.2 Construction of vectors for ECTV 
Vectors used for ECTV experiments were similar to those used for VACV and are detailed 
in Table 2.2. One construct, pE/L ECTV 137.5 Y112F, required a two-step fusion PCR to 
introduce a point mutation into the A36R gene, as opposed to fusing a viral sequence and 
fluorescent protein sequence together, as described for VACV constructs above. The first 
step involved amplification of ECTV genomic DNA with primer pairs a36r.for/a36r.mutrev 
and a36r.mutfor/a36r.rev which each amplified half of A36R. These PCR products from the 
first two reactions were diluted and combined to be used as template for a second step of 
amplification with a36r.for/a36r.rev, resulting in a full-length A36R gene product 
incorporating a Tyr to Phe mutation at site 112.  
A vector which encoded Lifeact (pE/L Lifeact-GFP), a 17 amino acid peptide that binds to 
filamentous actin [315], fused to the 5’ end of GFP under the control of pE/L was 
constructed with PCR-based methods. However, as Lifeact was so short, the sequence of 
Lifeact was able to be directly added to the synthesised primer LifeactGFP.for, which was 
used with the GFPrev primer on a vector template of GFP to generate a PCR product 
spanning all of the GFP sequence. This PCR product was digested with BglII and NotI 
purified with and ligated in to a pE/L GFP vector. 
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Figure 2.1:  CB6 and pE/L GFP fusion protein vector restriction maps 
Restriction maps of CB6 GFP, pE/L GFP-N and pE/L GFP-C vector maps used to generate the majority of 
expression constructs used in this project. MCS is the multiple cloning site, all vectors have neomycin 
(Neo) and ampicillin (Amp) resistance genes.  
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Table 2.1. Primers used for amplification of DNA 
GENE NAME SEQUENCE (RESTRICTION SITE IN BLUE, KOZAC SEQUENCE IN 
ORANGE, BASE INSERTION TO MAINTAIN CORRECT READING 
FRAME IN RED, STOP CODON IN GREEN) 
For VACV, Chapter 3 and Chapter 4 
PSCFP2 PSCFP1 AAAGATCTACCATGAGCAAGGGCGCCGAGC 
PSCFP2 PSCFP2 TTGCGGCCGCCCTTGTACAGCTCATCCATGC 
PSCFP2 PSCFP3 AAGCGGCCGCCAGCAAGGGCGCCGAGCTG 
PSCFP2 PSCFP4 TTGGATCCTTACTTGTACAGCTCATCCATGC 
A3L A3L1 AAGGCGGCCGCGAAGCCGTGGTCAATAGCG 
A3L A3L2 TTGGATCCCGAGAATGAATAAGTACTAAAGG 
A3L A3L.LA.CFPsew1 AAAGATCTCGTTGACGCCGAGCAATGC 
A3L A3L.LA.CFPsew2 GGCGCCCTTGCTCATTATTTATATTCGTAG 
A3L A3L.LA.CFPsew3 CTACGAATATAAATAATGAGCAAGGGCGCC 
A3L A3L.TDSfor.LA AAGTCGACCGTTGACGCCGAGCAATGC 
A3L A3L.TDSrev.A3L500  TTAAGCTTCGAGAATGAATAAGTACTAAAGG 
Dendra2 Dendra1 AAAGATCTACCATGAACACCCCGGGAATTAAC 
Dendra2 Dendra2 TTGCGGCCGCCCCACACCTGGCTGGGCAGGGG 
Dendra2 Dendra3 AAGCGGCCGCCAACACCCCGGGAATTAACCTG 
Dendra2 Dendra4 TTGGATCCTTACCACACCTGGCTGGGCAG 
A3L A3L.LA.Dendrasew1  AAAGATCTGTCGACCGTTGACGCCGAGCAATGC 
A3L A3L.LA.Dendrasew2 GTTAATTCCCGGGGTGTTCATTATTTATATTCGTAGTT
TTTAC 
A3L A3L.LA.Dendrasew3  GTAAAAACTACGAATATAAATAATGAACACCCCGGG
AATTAAC 
B5R B5R(end).for GTTCCATAAATTGCTACCG 
B5R B5R.RA.rev AAAGGATCCTATACCATTAAGTGTATCCATCACC 
F13L F13L.for AAAGATCTACCATGTGGCCATTTGCATCG 
F13L F13L.rev TTGCGGCCGCCAATTTTTAACGATTTACTGTG 
For ECTV, Chapter 5 and Chapter 6 
A36R-RA a36r.rafor ACCGCGGCCGCCAGATAATGCAGTTTATCAGTGTCG 
A36R-RA a36r.rarev ACAGGATCCGCTCAATATACGTACTACTAGTTC 
A36R-LA a36r.lafor AAAAAGCTTCTGTTGAAGTACTTAATGAAGATACC 
A36R-LA a36r.larev AAAGTCGACCGGATGCTCGAGGTTACAAACATGG 
A36R a36r.for GGGAGATCTACCATGATGCTGGTACCACTTATCACG 
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A36R a36r.rev TTTGCGGCCGCCGAAAGGATTGGATGAAAGTTAGG 
A36RY112F a36r.mutfor AGCACGGAACATATTTTCGATAGTGTTGCCGGA 
A36RY112F a36r.mutrev TCCGGCAACACTATCGAAAATATGTTCCGTGCT 
Lifeact LifeactGFP.for AAAGATCTACCATGGGTGTCGCAGATTTGATCAAGAA
ATTCGAAAGCATCTCAAAGGAAGAAGCGGCCGCCAG
CAAGGGC 
Lifeact GFPrev TTTGGATCCAACTCCAGCAGGACCATGTGA 
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Table 2.2. Vector constructs made and used 
VECTOR DESCRIPTION CREATED BY 
For VACV, Chapter 3 and Chapter 4 
CB6 GFP-N For constitutive expression of GFP, Figure 2.1 T. P. Newsome 
pE/L GFP-N For expression of GFP [316] under a viral promoter 
and generation of N-terminal GFP fusion proteins by 
cloning viral genes in, Figure 2.1 
T. P. Newsome 
pE/L GFP-C For generation of C-terminal fusion proteins by 
cloning viral genes in, Figure 2.1 
T. P. Newsome 
pE/L LA-B5R-YFP-
RA 
Used as a source of LA and RA for construction of  
pE/L LA-B5R-PSCFP2-RA  and pE/L LA-B5R-
Dendra2-RA rescue constructs [see below] 
 
T. P. Newsome, 
[285] 
GPT Selection Vector Used as vector for GPT selection, Figure 2.1 T. P. Newsome 
PSCFP2-N Used as template to amplify PSCFP2 Evrogen (FP802) 
PSCFP2-C Used as template to amplify PSCFP2 Evrogen (FP801) 
pE/L PSCFP2-N Primers PSCFP1/PSCFP2 used to amplify PSCFP2 
gene from PSCFP2-N vector and cloned into pE/L 
GFP-N with BglII/Not1 in place of GFP 
H. Lynn 
pE/L PSCFP2-C Primers PSCFP3/PSCFP4 used to amplify PSCFP2 
gene from PSCFP2-C vector and cloned into pE/L 
GFP-C Not1/BamH1 in place of GFP 
H. Lynn 
CB6 PSCFP2-N PSCFP2 was cloned in the place of GFP in the CB6 
GFP-N vector with BglII/Not1 to use for constitutive 
expression of PSCFP2 
H. Lynn 
pE/L B5R-PSCFP2 B5R from pE/L B5R-GFP cloned BglII/Not1 into 
pE/L PSCFP2-C, for transient expression of B5R-
PSCFP2 to check localisation 
H. Lynn 
pE/L PSCFP2-
RA(B5R) 
The region downstream of B5R (the right arm [RA]) 
was cloned from pE/L LA-B5R-YFP-RA into pE/L 
PSCFP2-C with BamH1 in the first step in 
construction of a recombination cassette to generate a 
B5R-PSCFP2 virus 
H. Lynn 
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pE/L LA-B5R-
PSCFP2-RA 
A fragment spanning the region upsteam of B5R (the 
left arm [LA]) and B5R were cloned from pE/L LA-
B5R-YFP-RA into pE/L PSCFP2-RA(B5R) as the 
second step in the contruction of a recombination 
cassette to generate a B5R-PSCFP2 virus [see 2.4.1.2] 
H. Lynn 
pE/L PSCFP2-
A3L(500) 
Primers A3L1/A3L2 were used to amplify an 
approximately 500 bp fragment of A3L from the 
VACV WR genome and cloned into pE/L PSCFP2-N 
with Not1/BamH1 in the first step in construction of a 
recombination cassette to generate a PSCFP2-A3L 
virus 
H. Lynn 
pE/L LA-PSCFP2-
A3L(500) 
A fusion PCR was performed to generate a fragment 
spanning a 500 bp LA of A3L and PSCFP2 [see 
2.1.2.1 for more details] which was cloned BglII/Not1 
into pE/L PSCFP2-A3L(500) in the second step in 
construction of a recombination cassette to generate a 
PSCFP2-A3L virus 
H. Lynn 
pE/L LA-PSCFP2-
A3L(500)GPT 
A PCR was performed using primers 
A3L.TDSfor.LA/A3L.TDSrev.A3L500 with the LA-
PSCFP2-A3L(500) vector to introduce SalI/HindIII 
restriction sites and cloned SalI/HindIII into the GPT 
selection vector as a recombination cassette to 
generate a PSCFP2-A3L virus [see 2.4.1.2] 
H. Lynn 
Dendra2-N Used as template to amplify Dendra2 Evrogen (FP822), 
Gift from K. 
Lukyanov 
Dendra2-C Used as template to amplify Dendra2 Evrogen (FP821), 
Gift from K. 
Lukyanov 
pE/L Dendra2-N Primers Dendra1/Dendra2 used to amplify Dendra2 
gene from Dendra2-N vector and cloned into pE/L 
GFP-N with BglII/Not1 in place of GFP 
H. Lynn 
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pE/L Dendra2-C Primers Dendra3/Dendra4 used to amplify Dendra2 
gene from Dendra2-C vector and cloned into pE/L 
GFP-C Not1/BamH1 in place of GFP 
H. Lynn 
pE/L Dendra2-
RA(B5R) 
The RA of B5R was cloned from pE/L LA-B5R-YFP-
RA into pE/L Dendra2-C with BamH1 in the first step 
in construction of a recombination cassette to generate 
B5R-Dendra2 virus 
H. Lynn 
pE/L LA-B5R-
Dendra2-RA 
A fragment spanning the LA of B5R and B5R were 
cloned from pE/L LA-B5R-YFP-RA into pE/L 
Dendra2-RA(B5R) as the second step in the 
contruction of a recombination cassette to generate 
B5R-Dendra2 virus [see 2.4.1.2] 
H. Lynn 
CB6 GFP-A3L(500) A3L(500) was cloned Not1/HindIII from pE/L LA-
Dendra2-A3L(500)GPT vector into the CB6 GFP 
vector in the first step in construction of a 
recombination cassette to generate Dendra2-A3L 
virus 
H. Lynn 
pE/L LA-Dendra2-
A3L(500)GPT 
A fusion PCR was performed to generate a fragment 
spanning a 500 bp LA of A3L and Dendra2 [see 
2.1.2.1 for more details] which was cloned 
SalI/HindIII into the GPT selection vector as a 
recombination cassette to generate a PSCFP2-A3L 
virus [see 2.4.1.2] 
H. Lynn 
pE/L LA-RA (F13L-
fluorion) 
Generated as the first step in the construction of a 
homologous recombination cassette to generate both 
both F13L-Dendra2 and F13L-GFP viruses [see 
2.1.2.1 for more details] 
J. Horsington 
pE/L LA-Dendra2-
RA (F13L-fluorion) 
Recombination cassette used to generate F13L-
Dendra2 virus [see 2.1.2.1 for more details] 
H. Lynn 
pE/L LA-GFP-RA 
(F13L-fluorion) 
Recombination cassette used to generate F13L-GFP 
virus [see 2.1.2.1 for more details] 
H. Lynn 
For ECTV, Chapter 5 and Chapter 6 
pE/L VACV LA-
A36R-GFP 
Used for transient expression of VACV A36R T. P. Newsome, 
[317] 
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pE/L VACV A36R-
YdF- 
Used for transient expression of VACV A36RYdF T. P. Newsome, 
[317] 
pE/L ECTV 137.5-GFP  Used for transient expression of ECTV A36R (137.5), 
the A36R gene was amplified from ECTV Mos 
genomic DNA with primer pair a36r.for/a36r.rev and 
cloned BglII/NotI into pE/L GFP-C 
S. Y. Han 
pE/L ECTV 137.5 
Y112F 
Used for transient expression of ECTV A36RY112F 
[see 2.1.2.2 for more details] 
S. Y. Han 
pE/L ECTV 137.5 
Knockout construct Regions of approximately 900 bp of ECTV Mos 
genomic DNA flanking the gene locus A36R were 
amplified with primer pairs a36r.ra.for/a36r.ra.rev for 
RA and a36r.la.for/a36r.la.rev for the LA and cloned 
into the GPT selection vector HindIII/SalI and 
NotI/BamH1 respectively 
C. O’Sullivan 
pE/L Lifeact-GFP Used for the transient expression of Lifeact-GFP [see 
2.1.2.2 for more details]. 
H. Lynn 
 60 
2.1.3 SDS-PAGE 
SDS sample buffer 
62.5mM Tris-HCl 
0.25M glycerol 
2% (w/v) SDS 
0.01% (w/v) bromophenol blue 
12.5% (v/v) β-mercaptoethanol 
Resolving gel 
10% Acrylamide/Bis Solution, 37.5:1 
0.375M Tris-HCl, pH 8.8 
0.1% (w/v) SDS 
0.1% APS 
0.1% TEMED 
Stacking gel 
4% Acrylamide/Bis Solution, 37.5:1 
0.375M Tris-HCl, pH 6.8 
0.1% (w/v) SDS 
0.1% APS 
0.1% TEMED 
Mammalian cells, generally BSC-1 [Section 2.2] which were either uninfected controls, or had 
been infected with the appropriate virus [Section 2.3.2] were harvested in sodium dodecyl 
sulphate (SDS)-reducing sample buffer. Samples were then heated at 95°C for 3 min and cooled 
for 3 min on ice. This cycle was repeated three times to degrade genetic material, then protein 
samples were loaded into 10% SDS-polyacrylamide gels and were separated by gel electrophoresis 
(SDS-PAGE) in a Mini-Protean Tetra Cell (BioRad). 
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2.1.4 Immunoblot 
Resolved proteins from SDS-PAGE were transferred to nitrocellulose membranes (Amersham 
Hybond-C Extra, GE Health) with a Mini Trans-Blot (BioRad) using buffers compatible with 
equipment (manufacturers instructions). Membranes were then probed with primary antibodies 
[Table 2.3] diluted in PBST-milk (5% [w/v] skim milk in PBS with 0.1% Tween 20) for 30 min. 
The membrane was washed three times in PBST-milk and probed with secondary antibodies 
conjugated with horseradish peroxidase (HRP) [Table 2.4] for 30 min. Immunoreactive protein 
bands were visualised by applying Amersham enhanced chemiluminescence (ECL) Western 
blotting reagent (GE Health) on top of PBS washed membranes and exposing Amersham 
Hyperfilm ECL photographic film (GE Health) before development with a CP1000 photographic 
film developer.  
 
Table 2.3. Primary antibodies used for immunoblot 
ANTIBODY SPECIES DILUTION ORIGIN 
α-A36 Rabbit 1 in 1000 [191] 
α-B5 Rat 1 in 2000 [264] 
α-β-actin (AC-74) Mouse 1 in 2000 Sigma-Aldrich 
α-β-tubulin (236-10501) Mouse 1 in 2000 Invitrogen 
α-mRFP (Ab-2) Rabbit 1 in 2000 Chemicon 
α-GFP (4E12) Mouse 1 in 2000 Cancer Research UK 
α-Dendra2 (1G6) Mouse 1 in 1000 Origene  
 
Table 2.4. Secondary antibodies used for immunoblot 
ANTIGEN LABEL SPECIES DILUTION ORIGIN 
α-mouse HRP Goat 1 in 1000 Pierce 
α-rat HRP Goat 1 in 1000 Pierce 
α-rabbit HRP Goat 1 in 1000 Pierce 
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2.2 TISSUE CULTURE 
2.2.1 Cell lines 
Cells lines, unless otherwise noted, were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM, Invitrogen) supplemented with 5% fetal bovine serum (FBS, DKSH), 292 µg/mL L-
Glutamine, 100 Units/mL penicillin and 100 µg/mL streptomycin (Invitrogen) and incubated at 
37ºC with 5% CO2 atmosphere in a Heraeus BB 15 Function Line cell culture incubator (Thermo-
Scientific). Details of all the cell lines used in this thesis are listed in Table 2.5. Cells were 
obtained from collaborators or the American Type Culture Collection (ATCC). 
 
Table 2.5. Cell lines and media 
CELL LINE SPECIES MEDIA SOURCE 
HeLa Human DMEM M. Way (ATCC, CCL-2) 
BSC-1 Monkey DMEM M. Way (ATCC, CCL-26) 
NIH3T3 Mouse DMEM M. Way (ATCC, CRL-1658) 
MEFs Mouse DMEM [318] 
N-WASP null 
MEFs 
Mouse DMEM [318] 
P-815 Mouse RPMI ATCC, H-2d 
YAC-1 Mouse RPMI ATCC, TIB-160 
 
2.2.2 Transfection 
Two different transfection protocols were used over the course of this thesis to transfect cells, 
generally HeLa. Lipofectin (Invitrogen) was used first, and then Lipofectamine 2000 (Invitrogen) 
when it was demonstrated to lead to higher transfection efficiencies. Both types of transfections 
were carried out according to manufacturer’s instructions.  
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2.3 VIRUS CULTURE TECHNIQUES 
2.3.1 Viruses 
The VACV WR strain (ATCC VR-1354) was a gift from Michael Way, Cancer Research UK, and 
was used as the parental strain for all VACV lines used in or generated in this study. These strains 
and their origin are listed in Table 2.6 and the process used for generation of recombinant viruses 
are detailed in Section 2.4 below. ECTV-Moscow strain (ECTV-Mos; ATCC VR1374) was a gift 
from Professor RM Buller, St. Louis University School of Medicine. 
Table 2.6. Virus strains generated or used in this study 
VIRUS STRAIN VIRUS GENERATED BY 
WR VACV ATCC VR-1354 
∆A36R VACV [215] 
∆F12L VACV [303] 
∆B5R VACV [272] 
B5R-CFP VACV T. Newsome 
B5R-PSCFP2 VACV H. Lynn 
PSCFP2-A3L VACV H. Lynn 
B5R-Dendra2 VACV H. Lynn 
B5R-Dendra2/∆F12L VACV H. Lynn 
F13L-GFP VACV H. Lynn 
F13L-Dendra2 VACV H. Lynn 
F13L-Dendra2/∆A36R VACV H. Lynn 
Dendra2-A3L VACV H. Lynn 
Dendra2-A3L/B5R-CFP VACV H. Lynn 
Mos ECTV ATCC VR1374 
∆A36R ECTV S. Han 
 
2.3.2 Infection 
For all infections, growth medium was removed from cells and the cells washed once in PBS. 
Virus at a specified MOI was diluted in DMEM not supplemented with FBS (serum free medium; 
SFM) and applied to washed cells. Cells were incubated at 37ºC with 5% CO2 atmosphere for 1 
hour before SFM with virus was aspirated and the cells recovered with fresh growth medium 
appropriate for the cell line.  
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2.3.3 Plaque assays 
For plaque assays, confluent BSC-1 monolayers were infected as described, but instead of 
recovery with fresh growth medium, were overlaid with GIBCO Modified Eagle Medium (MEM; 
Invitrogen) supplemented with 292 µg/mL L-Glutamine, 100 Units/mL penicillin, 100 µg/mL 
streptomycin and 0.45% Ultra Pure Agarose (Invitrogen) for purification or 1.5% carboxy-methyl 
cellulose (CMC) for purification or plaque visualisation/staining. Plaques were allowed to form for 
3-5 days before examination as specified.  
If plaque assays were for purification, plaques were picked by using a P1000 pipette tip to collect 
an agarose plug and the infected cells immediately beneath the plug. These were resuspended in 
SFM, frozen and thawed for three cycles before being placed onto a confluent monolayer of BSC-
1 in a well of a 24-well plate for amplification. One hour post infection (hpi), an equal volume of 
DMEM with 10% FBS was added to the well for a final FBS concentration of 5%. 
For plaque assays to visualise plaque morphologies, the MEM/CMC overlay was aspirated and 
cells were washed three times with PBS before the plaques were imaged individually on an 
Olympus BX51 Microscope [see Section 2.5.5] or the cell monolayer was stained with crystal 
violet (0.5% (w/v) in 20% methanol solution) for 10 min and then washed again three times with 
PBS. Individual plaques are formed by the lysis or cytopathic effects caused by viral infection and 
generate visible clearings in the stained cell monolayer. Stained monolayers were scanned with a 
high-resolution gel scanner (BioRad GS-800). 
2.3.3.1 Measuring plaque size 
Plaque size was measured in pixels using ImageJ (ver. 1.4.4, a public domain imaging 
processing program developed by the National Instutes of Health [NIH]) to draw a line 
across the diameter of the plaque (always horizontally) and then converted to mm with a 
ruler placed for scale.  
2.3.4 Preparation of viral genomic DNA 
PCR-based methods were used to check or confirm virus genotypes. This required the extraction 
of genomic DNA (gDNA) from virus-infected cells. Virus-infected cells were scraped into 1ml of 
SFM and centrifuged for 10 min (16100 rcf, 4˚C) in a refrigerated centrifuge (Eppendorf 
Microcentrifuge 5415R) to pellet cells. The cell pellet was resuspended in 500 µl TE, 0.1% SDS 
and the microcentrifuge tube vortexed to lyse cells. 500 µl of phenol-chloroform-isoamylacohol 
(25:24:1, Astral Scientific) was added to the lysed cells and inverted to mix. This mixture was 
centrifuged for 4 min (16100 rcf, 4˚C) and the top (aqueous) layer was transferred to a new 
microcentrifuge tube. This step was repeated a second time before 1 ml 100% chilled ethanol and 
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50 µl 3M NaAcetate was added to the aqueous layer and inverted to mix. This was cooled to -20˚C 
overnight or -80˚C for 1 hr to precipitate gDNA before a final centrifuge for 30 min (16100 
rcf, 4˚C). The supernatant was removed and the gDNA pellet was allowed to dry (on bench or 
50˚C for 10 min).  
The pellet was resuspended in Milli-Q H2O or 10 mM Tris 1 mM EDTA (pH 8.0) solution 
(TE). DNA was then used (1 µl per 50 µl PCR) as a template for PCR using appropriate primers to 
confirm or identify the genotype based on the generation of a specific amplicon. Furthermore, in 
certain instances these successful PCR amplicons were used for DNA sequencing (all sequencing 
performed by the Australian Genome Research Facility Ltd.). 
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2.4 MAKING RECOMBINANT VIRUSES 
2.4.1 Fluorescent recombinant VACV 
Three conceptual methods were used to generate fluorescent recombinant VACV (used throughout 
Chapters 3 and 4), the first is homologous recombination and involved the introduction of DNA 
into the virus through a double crossover event between homologous regions of viral genomic 
DNA and vector DNA [319, 320]. The second method, called transient dominant selection (TDS), 
instead introduced genetic material into the virus through a single crossover event between 
homologous regions of viral and vector DNA [321]. This generates an unstable intermediate that 
integrates the entirety of the vector into the viral genome, which possesses both screenable and 
selectable markers as well as the gene fusion of interest. Upon removal of a selective pressure, a 
second recombination event occurs through regions of homology within the newly recombinant 
viral genomic DNA, removing the screenable and selectable markers, but leaving the gene fusion 
of interest [Figure 2.2]. TDS can therefore be used to generate virus strains with gene 
insertion/deletion but which do not encode selection genes [313]. The third method involves the 
coinfection of cells with two different recombinant viruses and allowing intergenomic 
recombination to occur by a single strand-annealing model involving viral DNA polymerase [322-
324]. Resulting progeny viruses that contain both genes of interest are then selected and purified. 
2.4.1.1 Homologous recombination 
Non-TDS recombination was used to generate B5R (VACV-WR-187, Genbank accession: 
YP_233069) and A3L (VACV-WR-122, Genbank accession: YP_233004) fusions. For 
B5R, regions of homology flanking B5R (the left arm and right arm) were cloned into a 
vector, along with a genetic fusion between B5R and the fluorescent marker, PSCFP2 or 
Dendra2 [see Section 2.1.2.1 and Table 2.2]. These vectors (pE/L LA-B5R-PSCFP2-RA 
and pE/L LA-B5R-Dendra2-RA) were then introduced into cells infected with ∆B5R 
through Lipofectin (Invitrogen) or Lipofectamine 2000 (Invitrogen) transfection according 
to manufacturer’s instructions. Homologous recombination was allowed to occur between 
genomic DNA and vector for 24 hpi before the cells were scraped into SFM and virus was 
released from cells by freeze-thawing 3 times in liquid nitrogen.  
Plaque assays were performed to select for successful recombinants that displayed both 
fluorescent markers and restored plaque size (the ∆B5R mutant has an attenuated small 
plaque phenotype [325]) on an Olympus BX51 Microscope [Section 2.5.5]. PSCFP2 
displayed blue fluorescence and was imaged with a DAPI filter, while Dendra2 displayed 
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green fluorescene and was imaged with a FITC filter [Section 3.1.2.4]. Three rounds of 
plaque assays were performed to purify the recombinant virus. 
2.4.1.2 Transient Dominant Selection 
The process for generating A3L fusions was similar to B5R fusions [Section 2.4.1.1], but as 
∆A3L is unviable, the construction of the recombination cassette and the homologous 
recombination differs (as we cannot select for restored plaque size). Instead of regions of 
interest flanking the gene of interest being cloned into the recombination cassette, the 
fluorescent protein gene (PSCFP2 or Dendra2) was fused with overlap extension PCR to the 
first 500bp of A3L (to form an N-terminal fluorescent fusion protein) and 500bp upstream of 
A3L (left arm) were cloned into a GPT selection vector for TDS (pE/L LA-Dendra2-
A3L(500)GPT) [see Section 2.1.2.1, Table 2.2].  
Recombinations were carried out in the same way as non-TDS homologous recombination, 
then plaque assays were carried out with the addition of GPT selection medium 
(25 µg/ml mycophenolic acid [MPA], 250 µg/ml xanthine, 15 µg/ml hypoxanthine) in the 
overlay [Section 2.1.2.1]. Plaques able to grow under GPT selection that displayed red 
fluorescence imaged with the TxRed filter of an Olympus BX51 Microscope [Section 2.5.5] 
were picked and purified three times by plaque assay with GPT selection throughout. These 
intermediate viruses [Figure 2.2] were then allowed to intra-genomically recombine in a 
GPT selection negative infection, 24 hpi virus was collected and a plaque assay was 
performed to isolate the desired fluorescent recombinant which displayed green fluorescence 
imaged with a FITC filter [Section 3.1.2.4]. Two additional rounds of plaque purification 
was performed without GPT selection before the integrity of viruses was checked with PCR 
and immunoblot [Section 2.1.2, 2.1.3]. 
TDS was also used to generate F13L-Dendra2 and F13L-GFP as described above, utilising 
vectors pE/L LA-Dendra2-RA (F13L-fluorion) and pE/L LA-GFP-RA (F13L-fluorion) [see 
Section 2.1.2.1, Table 2.2]. As regions of homology were shorter than in pE/L LA-Dendra2-
A3L(500)GPT, recombination occurred at a lower efficiency, but still high enough for 
recombinant viruses to be isolated [313, 326].  
2.4.1.3 Recombinations between viruses 
Recombinant viruses were generated in a third way, which unlike the aforementioned 
methods involves the recombination between two strands of viral genomic DNA rather than 
between genomic DNA and a transfected vector. This method was used to generate viruses 
with two observable phenotypes/screenable markers, such as two fluorescent proteins 
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(Dendra2-A3L/B5R-CFP), or otherwise a fluorescent protein and a mutation that created a 
small plaque phenotype (B5R-Dendra2/∆F12L and F13L-Dendra2/∆A36R).  
Two viruses, each encoding one of the two observable phenotypes were used to coinfect 
cells. 24hpi, cells were lysed and the first of three plaque assays was conducted to select 
both phenotypes/markers in single plaques. For Dendra2-A3L/B5R-CFP, these were plaques 
that displayed green fluorescence as imaged with a FITC filter and blue fluorescence as 
imaged with a CFP filter [Section 3.1.2.4]. For both B5R-Dendra2/∆F12L and F13L-
Dendra2/∆A36R, small plaques compared to a B5R-Dendra2 or F13L-Dendra2 control that 
also displayed green fluorescence as imaged with a FITC filter were picked.  
2.4.2 ECTV deletion virus construction 
To construct an ECTV ∆A36R mutant, non-TDS homologous recombination was carried out with 
both selectable (GPT) and screenable (mRFP) markers [Section 2.1.2]. HeLa cells grown to 70% 
confluency were infected with ECTV Mos at an MOI of 1 and transfected with the recombination 
cassette (pE/L ECTV 137.5 Knockout construct, Figure 2.2, Table 2.2) using Lipofectamine 2000 
(Invitrogen), according to manufacturers instructions. Cells were scraped 24 hpi and lysed by 
freeze thawing. Plaque assays were performed with GPT selection medium in the overlay. Plaques 
formed in the presence of GPT selection that also displayed mRFP fluorescence were purified and 
verified as ∆A36R with sequencing. 
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Figure 2.2:  Transient dominant selection overview 
For Knock out (A) upstream (LA) and downstream (RA) DNA of the gene of interest are cloned or 
synthesised side-by-side into a vector containing pE/L GPT and pE/L mRFP. For Knock-in (B), upstream 
(LA) and downstream (RA) DNA of the location for the intended gene insertion are cloned/synthesised 
either side of the intended insert/gene fusion along with pE/L GPT and pE/L mCherry. After an initial 
crossover event, the entire construct is introduced into the genome. This insert is unstable, and is only 
retained under selection. Once selection is removed, internal homologous recombination will occur, 
leading to progeny that have either the parental genome or the intended genetic alteration (KO or knock-
in). 
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2.5 IMMUNOFLUORESENCE 
2.5.1 General buffers and solutions 
Cytoskeletal buffer (CB), pH 6.1 
10 mM 2-(N-morpholino) ethanesulfonic acid (MES) buffer 
0.15 M NaCl 
5 mM ethylene glycol tetraacetic acid (EGTA) 
5 mM MgCl2 
50 mM glucose 
Mowiol mounting media 
10% (w/v) Polyvinyl Alcohol 4-88 (Sigma-Aldrich) 
25% (w/v) glycerol 
0.1M Tris, pH 8.5 
Blocking buffer 
1% BSA 
2% FBS 
Made up in CB 
2.5.2 Fixation methods 
Cells were grown on glass coverslips, infected with appropriate viruses and fixed with 3% 
paraformaldehyde (PFA) in cytoskeletal buffer (CB) for 10 min at room temperature before being 
washed 3 times in PBS and stored at 4oC. 
2.5.3 Antibodies and fluorescent chemicals 
Antibodies and fluorescent chemicals were mostly commercial, unless otherwise noted according 
to Tables 2.7-2.9. One antibody, α-A36-Y112, was not commercial or previously published, and 
was generated by Niki Scapelhorn at Cancer Research UK. It was raised against the 
phosphorylated peptide corresponding to residues 105-119 of VACV A36 
(APSTEHIpYDSVAGST) and purified as described previously [296], but affinity is not 
influenced by phosphorylation of tyrosine 112 of A36.  
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Table 2.7. Primary antibodies used for IFA 
ANTIBODY SPECIES DILUTION ORIGIN 
α-A36 Rabbit 1 in 250 [191] 
α-A36-Y112 Rabbit 1 in 250 N. Scapelhorn 
α-A27 Mouse 1 in 2000 [327] 
α-B5 Rat 1 in 300 [264] 
α-β-actin (AC-74) Mouse 1 in 300 Sigma-Aldrich 
α-cortactin (4F11) Mouse 1 in 300 Merck-Millipore 
α-GFP (3E1) Mouse 1 in 300 Cancer Research UK 
α-KHC (H-50) Rabbit 1 in 200 Santa Cruz Biotechnology 
α-phosphotyrosine (4G10) Mouse 1 in 1000 Chemicon 
 
Table 2.8. Secondary antibodies used for IFA 
ANTIGEN LABEL SPECIES DILUTION ORIGIN 
α-mouse Alexa Fluor 350 Goat 1 in 200 Invitrogen 
α-mouse Alexa Fluor 488 Goat 1 in 200 Invitrogen 
α-mouse Alexa Fluor 568 Goat 1 in 200 Invitrogen 
α-rat Alexa Fluor 350 Goat 1 in 200 Invitrogen 
α-rat Alexa Fluor 488 Goat 1 in 200 Invitrogen 
α-rat Alexa Fluor 568 Goat 1 in 200 Invitrogen 
α-rabbit Alexa Fluor 488 Goat 1 in 200 Invitrogen 
α-rabbit Alexa Fluor 568 Goat 1 in 200 Invitrogen 
 
Table 2.9. Fluorescent chemicals  
CHEMICAL LABEL STRUCTURE 
SPECIFICITY 
DILUTION ORIGIN 
Phalloidin Alexa Fluor 488 Actin 1 in 300 Invitrogen 
Phalloidin Alexa Fluor 568 Actin 1 in 300 Invitrogen 
DAPI N/A dsDNA 1 µg/mL Sigma-Aldrich 
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2.5.4 Staining and mounting 
Before staining, cells were either permeabilised with 0.1% Triton X-100 in CB for 5 min or not 
permeabilised, as specified. After washing three times in PBS, cells were blocked in blocking 
buffer for 20 min then incubated for 40 min with suitable primary antibodies, unless stated 
otherwise, diluted in blocking buffer. After an additional three washes with PBS, secondary 
antibodies diluted in blocking buffer were applied to cells for 20 min. When appropriate, Alexa 
Phalloidin conjugates were also added to blocking buffer to incubate with secondary antibodies. If 
dsDNA staining was required, coverslips were again washed three times in PBS and incubated 
with 1µg/mL 4',6-diamidino-2-phenylindole (DAPI) for 3 min. Coverslips were then washed in 
MQ and excess water drained before being mounted on a glass slide with 0.3-1% (w/v) P-
phenylenediamine (Sigma-Aldrich) in mowiol mounting media [Section 2.5.1]. Slides were 
incubated at 37oC for 30 min until the mowiol mounting media solidified prior to imaging. 
2.5.5 Wide field microscopy 
For imaging of IFAs, slides were analysed by phase-contrast and fluorescent microscopy using 
Olympus BX51 Microscope with Reflection Fluorescence System, Mercury Burner (U-RFL-T), F-
view monochrome fluorescence camera and DAPI (347 nm/442 nm [#31013v2]), eCFP (436 
nm/480 nm [#49001]), FITC (495 nm/515 nm [#31001]) and TxRed (584 nm/610 nm [#31004]) 
Chroma filters. Micrographs were captured using AnalySIS LS Starter (Olympus Soft Imaging 
Systems, ver. 2.8), and edited using Photoshop CS5.1 (Adobe, ver. 12.1) and ImageJ (NIH, ver. 
1.4.4).  
2.5.5.1 Measuring actin tails 
As actin tails are not straight, to measure the length of tails, a freehand line was drawn with 
the line tool on an overlay of the micrograph in ImageJ (NIH, ver. 1.4.4). This length of line 
was then measured in pixels with the Measure function. This was converted to metric 
measurements with the scale bar. 
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2.6 CONFOCAL MICROSCOPY 
2.6.1 Fibronectin coating 
Fibronectin from bovine plasma (Sigma-Aldrich) was diluted in 1.5ml of PBS to 5 µg/cm2 and 
rocked in a 3cm No. 1.5 glass µ-Dishes (Ibidi) for 1h. Remaining liquid was aspirated and the 
dishes were allowed to dry in a sterile environment. Dry plates were stored at 4oC ready for cell 
seeding. 
2.6.2 Photoactivation and tracking 
HeLa seeded onto fibronectin coated No. 1.5 glass µ-Dishes (Ibidi) were infected with the 
appropriate virus and then imaged on an Olympus FV1000 confocal microscope at the Australian 
Centre for Microscopy and Microanalysis (ACMM, Sydney). Laser lines on the microscope that 
were utilised in this study are listed below [Table 2.10].  
Infected cells were imaged sequentially with a UPLSAPO 60X oil objective lens with 405 nm 
diode laser and 488 nm multi-line argon laser (PSCFP2) or 488 nm multi-line argon laser and 559 
nm diode laser (Dendra2) with 4.0 pixel/sec scan speed to obtain pre-activation images. In viruses 
with a CFP tag, a 458 nm multi-line argon laser was also used. A 40 x 40 pixel region of interest 
(ROI), the region of the cell with the brightest 405 nm (PSCFP2) or 488 nm (Dendra2) emission, 
was selected for photoconversion. The ROI was activated with 3% of the 405 nm SIM laser under 
“Tornado” setting for 100ms at a scan speed of 100µs/pixel. After activation, either a time course 
or Z-stack from the basal to apical surface was collected (step size was detemined by automated 
optimisation). See Chapter 3 Results for more details.  
Table 2.10. Laser lines used 
WAVELENGTH LASER TYPE POWER 
405 nm Diode 50 mW 
458 nm Multi-line argon (458, 488, 515 nm) Total 30 mW 
488 nm Multi-line argon (458, 488, 515 nm) Total 30 mW 
559 nm Diode 15 mW 
 
2.6.3 Imaging live actin tails 
35 mm glass bottom dishes (MatTek) were coated in 5 µg/cm2 fibronectin (Sigma-Aldrich) for 2 h 
before HeLa cells were seeded and grown to 70% confluency. Cells were infected and recovered 
with fresh growth medium 1hpi before being transfected with pE/L Lifeact-GFP 6 h prior to 
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imaging (standard protocol, Lipofectamine 2000, Invitrogen). Either 8-10 hpi (VACV) or 24-26 
hpi (ECTV), images of cells were acquired with Olympus Fluoview (Ver. 3.1) on an Olympus 
FV1000 confocal microscope using with a 488nm laser line. Resulting movies were processed 
with a Manual Tracking plugin in Image J (Ver. 1.44o). See Chapter 5 Results for more details. 
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2.7 MOUSE WORK AND IMMUNOLOGY 
2.7.1 Ethics Statement 
This study was performed in strict accordance with the recommendations in the Australian code of 
practice for the care and use of animals for scientific purposes and the Australian National Health 
and Medical Research Council Guidelines and Policies on Animal Ethics. The protocol was 
approved by the Animal Ethics and Experimentation Committee of the Australian National 
University (Permit Number: J.IG.75.09). 
2.7.2 Mouse experiments 
Inbred, specific-pathogen-free female BALB/cAnNCrl (BALB/c), C57BL/6J wild-type mice and 
Rag-1-deficient B6.129S7-Rag1tm1Mom/J (B6.Rag-1-/-) [328] mice on a C57BL/6J background at 6-
8 weeks of age were obtained from the Australian National University Bioscience Services 
(Canberra ACT, Australia). Groups of female BALB/c mice were infected subcutaneously in the 
left hind leg with 102, 103, or 104 pfu ECTV or ECTV ∆A36R and monitored for survival and 
clinical signs of disease for 33 days. Separate groups of infected mice were euthanized at 5 and 8 
dpi. Rag-1-/- mice were inoculated with 103 PFU virus and also sacrificed at days 5 and 8 dpi for 
determination of viral titers in organs. Viral load in livers, spleens and lymph nodes were 
quantified by viral plaque assay on BSC-1 cell monolayers as described previously [329] and are 
expressed as log10 PFU/gram tissue or per lymph node. On day 28 p.i., all surviving BALB/c mice 
infected with ECTV ∆A36R from the first group were bled and then challenged with a lethal dose 
by a subcutaneous route of 104 PFU ECTV on day 33. Eight days later, mice were sacrificed and 
anti-ECTV antibody in serum and virus in spleen, liver and lymph nodes were measured. 
2.7.3 Enzyme-linked immunosorbent assay (ELISA) 
Serum samples were assayed by ELISA for total ECTV-specific IgG as described earlier [330]. 
Briefly, U-bottom 96-well plates (Immulon 2, Dynatech Lab Inc., Alexandria, VA, USA) were 
coated with purified ECTV. Sera were assayed at 1:200 dilution and ECTV-specific antibody 
detected using horseradish peroxidase-conjugated goat anti-mouse IgG (Southern Biotechnology 
Associates, Birmingham, AL, USA) and color developed with TMB One-Step substrate (Dako 
Cytomation, Carpinteria, CA, USA).  
2.7.4 Plaque reduction neutralisation test 
The plaque reduction neutralisation test, used to determine the neutralising activity of the antibody 
present in serum samples to ECTV-WT has been described [330]. Serial dilutions of sera, starting 
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at a 1: 50 dilution were used. The neutralization titer was taken as the reciprocal of the dilution of 
sera that caused a 50% reduction in the number of virus plaques.  
2.7.5 Cytotoxic T lymphocyte (CTL) and natural killer (NK) cell assays 
CTL and NK cell assays were performed as described elsewhere [329, 331]. To measure ex vivo 
CTL responses, spleen cells from infected animals were assessed for the ability to kill 51Cr-
labelled virus-infected or uninfected syngeneic P815 target cells over a 6 h culture period. To 
assess NK cell activity ex vivo, spleen cells from infected or uninfected BALB/c and C57BL/6 
mice were cultured with 51Cr-labelled YAC-1 target cells for 4 h and the radioactivity in the 
supernatant measured in a TopCount NXT™ scintillation counter. 
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CHAPTER 3: Optimising 
Phototracking of Vaccinia Virus 
Transport 
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3.1 INTRODUCTION 
Some of the work detailed in this chapter (the method of generation of F13L-
Dendra2 and F13L-GFP viruses) has been published: NB Marzook*, DJ Procter*, 
H Lynn, Y Yamamoto, J Horsington, TP Newsome [2013]. Methodology for the 
efficient generation of fluorescently tagged vaccinia virus proteins. Journal of 
Visualised Experiments. 17(83), e51151. All viruses utilised in this chapter were 
constructed and purified by H. Lynn with the exception of previously published 
viruses as noted in Table 2.6. All of the represented data was generated and analysed 
by H. Lynn. 
3.1.1 Imaging viral subcellular transport 
Fluorescent protein technology has been instrumental in gaining insights into the subcellular 
transport mechanisms of VACV. However, the various morphological forms of VACV and the 
sheer number of viruses being transported at any one time in a single infected cell presents a 
considerable challenge to addressing many aspects of the replication cycle. We propose that 
utilising recent advances in fluorescent protein technology, specifically the development of 
photoswitchable fluorescent proteins, may allow us to probe further into the characterisation and 
regulation of virus dissemination. 
3.1.2 Fluorescent proteins 
Fluorescent proteins contain chromophores that absorb light of certain wavelengths and emit 
longer, less energetic wavelengths of light. They are described by the predominant colour of the 
wavelength of light they emit, for example, green fluorescent protein (GFP) emits green light 
(~500 nm) [332]. Each of these visible emissions or fluorescence consists of a wide spectrum of 
wavelengths at different intensities that can be described by an emission spectrum [Figure 3.2C]. 
Likewise, a range of wavelengths can excite/be absorbed by the chromophore and this can be 
represented by an excitation spectrum [Figure 3.2C]. The peak in the excitation spectrum is where 
the most efficient stimulation of the chromophore occurs.  
Fluorescent proteins can be excited by different light sources, either incoherent lightsources such 
as short-arc lamps commonly used on both widefield and confocal microscopy systems that emit a 
wide spectrum of light (which can then narrowed by use of interference filters) or otherwise high 
intensity monochromatic lightsources; for example laser lines that are a single wavelength and are 
more often associated with confocal microscopy systems [333]. Laser lines closer to the excitation 
peak of the fluorophore will cause brighter emission, although excitation of the fluorophore 
anywhere along the excitation spectrum will cause a signal to be generated.  
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A large toolbox of fluorescent proteins covering the visual light spectrum from near ultraviolet 
blues to near infrared reds have been created, optimised and characterised [Figure 3.1] [310, 334-
337]. These engineered and enhanced proteins allow for the coupling of two to three fluorescent 
tags in the same sample, enabling the simultaneous imaging of multiple proteins (without 
requiring optical demixing). 
 
Figure 3.1:  Range of non-oligomerising fluorescent proteins available 
Representatives of fluorescent proteins derived from Aequorea GFP or Discosoma RFP through 
directed mutagenesis or by somatic hypermutation (SHM) that cover the entire visible light spectrum, 
expressed in bacteria and purified. E represents enhanced versions of GFP-derived fluorescent 
proteins all of which are monomeric (although some will dimerise at high concentrations), m represents 
other monomeric proteins, and tdTomato is a head-to-tail dimer. From [336]. 
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3.1.2.2 Green Fluorescent Protein (GFP) and other traditional protein tags for 
fluorescent imaging 
GFP from the jellyfish Aequorea victoria was the first fluorescent protein to be adopted widely as 
a genetically encoded in situ fluorescent tag. The particular utility of GFP is that all functions for 
chromophore formation and maturation are present within its coding sequence and no additional 
substrates or coenzymes are required for fluorescence [338, 339]. This enabled it to be readily 
cloned and expressed in multiple organisms with fluorescence functionality intact [340].  
Wild-type GFP (wt-GFP) has an excitation spectrum that peaks at 395 nm, with a secondary peak 
at 470 nm and an emission spectrum that peaks at 508 nm [Figure 3.2C] [341]. This fluorescence 
is emitted from an 4-(p-hydroxybenzylidene)imidazolidin-5-one structure that is that is formed by 
the autocatalytic covalent modification of three adjacent amino acids (Ser65-Tyr66-Gly67) in a 
process called chromophore maturation [338, 340, 342, 343] [Figure 3.2A]. This chromophore is 
situated in the middle of a α-helix bridge that runs through the centre of a β-barrel formed from 11 
β-sheets in the folded GFP structure [343, 344] [Figure 3.2B]. 
The hydrogen bonding and other electrostatic interactions between the chromophore and 
sidechains on the inside of the β-barrel influence the maturation, colour, brightness and 
photostability of the chromophore [345]. They have therefore been subject to multiple mutagenesis 
studies to improve GFP in all these aspects. Additionally, mutagenesis studies have aimed to 
increase the utility of GFP in standard in vitro contexts (carried out in mammalian animal or cell 
culture models at 37oC).  
The expression of wt-GFP was improved by optimising codons to mammalian expression while 
several additional mutations were found to facilitate folding at 37°C and prevent GFP dimerisation 
[340, 346, 347]. The speed of chromophore maturation was improved by almost four fold (to 
approximately 27 min) with the substitution of Thr65 for Ser65 (S65T) [332]. Finally, the 395 nm 
and secondary 470 nm excitation/absorbance peaks were converted into a single peak at 489 nm, 
leading to brighter fluorescence upon imaging while retaining a very similar emission profile 
[Figure 3.2C] [348, 349]. A GFP variant known as enhanced GFP (EGFP) includes all of these 
improvements [350].  
Other mutants from GFP have resulted in a series of fluorescent proteins with shifted 
excitation/emission spectra, either towards shorter wavelengths like blue fluorescent protein (BFP) 
and cyan fluorescent protein (CFP) or towards longer wavelengths like yellow fluorescent protein 
(YFP) [Figure 3.1] [351, 352]. Further longer wavelength shifted fluorescent proteins are also 
available, including those with red or infrared emission profiles, although these do not originate 
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from A. victoria GFP mutants. Instead, they are mostly derived from a monomeric red fluorescent 
protein (mRFP), which originates from modification of multimeric DsRed protein from 
Discosoma coral [Figure 3.1] [310, 353].  
The obligate tetramerisation of wild type DsRed severely limits the study of subcellular 
localisation, with fusion proteins forming intracellular aggregates, thus impeding its widespread 
utility and use. A total of 33 mutations were required to create a monomeric protein (mRFP) with 
comparable brightness to DsRed in living cells [310].  
The brightness of a fluorescent protein is a combination of factors including the molar extinction 
coefficient (the amount of light absorbed by the fluorescent protein), the fluorescence quantum 
yield (the efficiency of light emitted per photon of light absorbed), amount of protein expression, 
rate of maturation and the photostability of the protein (the rate of bleaching/decrease in emission 
over time excited) [354]. As such, improvements in certain values can compensate for decreases in 
others. This is true for mRFP, which compensates for a lower extinction coefficient, quantum yield 
and photostability than DsRed with fast chromophore maturation (~1 h compared to 10 h for 
DsRed) [310, 334]. Many of the later generation excitation/emission shifted mRFP derivatives 
improved on these various characteristics, creating a spectrum of fluorescent proteins with 
comparable experimental utility as EGFP, a benchmark for fluorescent protein technology [335]. 
 
Figure 3.2:  The structure and spectral properties of GFP 
(A) A schematic of the wtGFP chromophore which forms from the autocatalytic cyclisation of Ser65, Tyr66, 
and Gly67 into 4-(p-hydroxybenzylidene)imidazolidin-5-one. (B) The protein structure of wtGFP with a α-
helix bridge (blue) holding the chromophore (yellow) in the centre of an 11-sheet β-barrel (green). (C) The 
excitation (blue) and emission (green) spectra of wtGFP (open circles) and EGFP (closed squares). In 
generating EGFP, the two absorbance peaks of wtGFP were converted into a single peak without substatial 
alteration of the fluorescence emission peak. From [350]. 
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3.1.2.3 Photoactivatable FPs 
Even though the suite of traditional fluorescent proteins makes it possible to carry out 
sophisticated imaging of multiple targets or structures with high resolution spatially and 
temporally, there are still many questions that cannot be answered. For instance, as encoded 
fluorescent protein fusions are continuously being synthesised and degraded in cells, proteins of all 
ages are imaged simultaneously. Analysis of protein and protein complex turnover and temporal 
expression patterns is therefore extremely difficult [350]. The complexity of cellular processes, 
where many objects are constantly moving and interacting with others further clouds analyses of 
biological processes with traditional fluorescent tags. 
One solution to this problem is distinguishing a specific subset of the fluorescent population from 
the bulk of the fluorescence signal. This can be achieved by purposefully photobleaching the 
fluorescence in selected areas of the cell and monitoring recovery of fluorescence in a process 
called fluorescence recovery after photobleaching (FRAP) [355]. FRAP can be performed with 
traditional fluorescent protein tags and can reveal information on protein turnover and diffusion 
kinetics. A complementary method called fluorescence loss in photobleaching (FLIP) can also be 
performed with traditional protein tags and involves the bleaching of a region of interest while 
monitoring the decline in fluorescence in a surrounding region or selected compartment to reveal 
information on protein mobility [355]. 
Alternatively, a selected area of the cell can be highlighted by region selective increase in 
fluorescence brightness (photoactivation) or alteration of excitation/emission spectra 
characteristics (photoswitching, although this process is also referred to as photoactivation) 
[Figure 3.3]. As photoconverted molecules display a distinguishably different fluorescence, their 
behaviour can be studied independently to subpopulations/areas that are not of interest [350]. This 
process cannot be performed with traditional fluorescent protein tags but requires newer 
generation photoconvertible fluorescent proteins [Figure 3.3]. These include photoactivatable 
green fluorescent protein (PA-GFP), Kaede, Eos, Dendra and photoswitchable cyan fluorescent 
protein (PS-CFP) [356-359]. 
PA-GFP was developed through the improvement of the native photoconversion of the wtGFP 
chromophore from a neutral/protonated state to an anionic species. The neutral state has a major 
absorption peak (at 395 nm), while the anionic species predominantly absorbs at the minor 
absorption peak (at 475 nm) [Figure 3.2C]. Intense irradiation with UV or near 400 nm light shifts 
the equilibrium towards the anionic state, thereby shifting the absorbance profile [360]. The 
T203H mutation in PA-GFP leads to the almost total absence of a minor absorption peak prior to 
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photoconversion, providing maximum contrast between pre- and post- activated chromophores 
(with a 100-fold difference) [356]. 
A second photoactivatable fluorescent protein type includes Anthozoa-derived green- to-red 
convertible proteins and their enhanced variants. In the dark, these proteins mature (fold and form 
their chromophore) to the green fluorescent state, while irradiation with UV-violet light results in 
their irreversible transition into a red fluorescent state. The first member of this group was named 
Kaede [357], then EosFP and mEosFP [358] and KikGR [361]. The mechanism of photoactivation 
of these proteins involves intense irradiation by near-400 nm light causing the cleavage of a 
carboxyamide group containing peptide from the chromophore, which changes the absorbance and 
emission of the aromatic rings to a red fluorescence profile [358, 362]. 
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Figure 3.3:  Photoconvertible fluorescent proteins 
Schematic representation of traditional fluorescent protein tags compared to photoconvertible 
fluorescent proteins. (A) When a standard fluorophore is excited with light of the appropriate 
wavelength (blue), it emits light of a longer wavelength (green), the process of exciting the fluorophore 
will bleach it, causing a non-fluorescent state. (B) Photoactivatable fluorophores will be non-fluorescent 
at first and are not able to be excited. Upon the stimulation of the fluorophore with an activating 
wavelength of light (purple), the fluorphore will become fluorescent and act similarly to standard 
fluorophores. (C) A similar process occurs with photoswitchable fluorophores, but rather than being 
non-fluorescent at first, they have an “A” fluorescent state (blue absorbing and green emitting), and 
upon the stimulation by activating light, will convert to longer wavelength shifted “B” state (green 
absorbing and red emitting). Figure from [363]. 
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3.1.2.4 Photoswitchable Cyan Fluorescent Protein 2 (PSCFP2) and Dendra2 
Two of the newest available photoactivatable fluorescent proteins are PSCFP2 and Dendra2. As 
well as having some of highest reported contrast between pre- and post-activated fluorescence 
states (over 2000-fold for PSCFP2 and 4000-fold for Dendra2), they are bright in both states 
(relative to other photoactivatable fluorescent proteins), monomeric and mature at 37oC [312]. 
PSCFP2 is derived from mutagenesis of acEGFP (which is itself a mutant from a colourless 
Aequorea coerulescens protein) [364]. It has a preactivation cyan profile with an excitation 
maximum of 400 nm and emission maximum of 468 nm [Figure 3.4A]. The mechanism for 
photoconversion is similar to that of PA-GFP, with irradiation of high intensity near 400 nm light 
causing PSCFP2 to undergo an irreversible chromophore deprotonation that leads to a longer 
wavelength shift of the emission profile. After activation, PSCFP2 has a green profile with an 
excitation maximum of 490 nm and emission maximum of 511 nm [Figure 3.4B] [312]. The cyan 
to green shift of PSCFP2 is a unique characteristic among photoactivatable proteins and may have 
utility in multichannel imaging in various contexts. 
Dendra2 is derived from the mutagenesis of a fluorescent protein present in the coral 
Dendranephthya spp. (in the class Anthozoa) [365]. It has a pre-activation green profile with 
excitation maximum of 490 nm and emission maximum of 507 nm [Figure 3.4C]. The mode of 
photoactivation is similar to other Anthozoa-derived photoactivatable fluorescent proteins with 
intense ~400 nm light causing the irreversible cleavage of a peptide from the chromophore and 
shift into a red emission profile [312]. The post-activation excitation and emission maximum is 
553 nm and 573 nm, respectively [Figure 3.4D]. A characteristic unique to Dendra2 is that as blue 
excitation light (such as 488 nm lasers) can be used for photoactivation, this may provide 
advantages over near 400 nm light exposure, as intense ultra violet light is damaging to cells and 
can induce an apoptotic response [312, 366]. 
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Figure 3.4:  Spectral properties of PS-CFP2 and Dendra2 
The excitation spectra (dashed lines) and emission spectra (solid lines) of PSCFP2 and Dendra2 are 
represented. PSCFP2 before (A) and after (B) photoconversion, with cyan and green profiles 
respectively. Dendra2 before (C) and after (D) photoconversion, with green and red profile respectively. 
Dotted black lines represent the emission spectrum of standard mercury lamp filters for widefield 
imaging and laser lines are represented with vertical lines. From [312]. 
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3.1.3 Viral fusion proteins for effective imaging 
Vaccinia virus has a complex replicative cycle [Introduction 1.3.1] and involves a series of 
distinct morphological forms with multiple transport steps [307]. The various morphological forms 
are composed of overlapping but different viral protein profiles. Selective tagging of viral proteins 
with fluorescent proteins, either alone or in combination, affords us a degree of discernment 
between the various morphological forms [Figure 3.5]. Three such viral proteins are A3 encoded 
by A3L, B5 encoded by B5R and F13 encoded by F13L. In this chapter, we aimed to develop a 
system of imaging and tracking specific subsets of viruses in the complex morphological cycle of 
VACV by generating recombinant viruses with fusions of the following proteins with the 
photoconvertible fluorescent proteins PSCFP2 and Dendra2. 
3.1.3.1 A3L 
A3 is a 62kDA viral core protein with a high degree of conservation across the poxvirus 
family [367]. It is processed from a 74kDa precursor protein and effective processing is 
linked to virion assembly and maturation; when proteolytic processing is inhibited, IMV do 
not form [368-370]. A3 is highly expressed in mature virions, constituting 11% of the virion 
by mass [370, 371]. The essentiality of the protein to the formation of the viral core 
precludes the analysis of ∆A3L recombinant viruses as they are unviable. A3 is however 
amenable to tagging and fluorescent protein fusions exhibit high levels of fluorescence 
without significant 	  attenuation [295, 313]. As A3 is a core protein, particles positive for A3 
represent both IMV and wrapped morphological forms of the virus (IEV, CEV and EEV).  
3.1.3.2 B5R 
B5 is a 42kDa integral membrane protein that is recruited to virus particles upon IEV 
morphogenesis at the TGN [372, 373]. It is one of 5 integral membrane proteins that are 
present in both the inner and outer membrane (along with A56, F13, A33 and A34) [163]. 
B5 functions in various processes during virus replication, most importantly in IEV 
morphogenesis and ∆B5R mutants display highly attenuated small plaque phenotypes [272, 
273, 325]. Although expressed in far lower levels than A3, B5 is nonetheless a highly 
expressed, virus particle localised viral protein and is amenable to tagging. Recombinant 
viruses expressing B5 fluorescent fusion proteins exhibit bright fluorescence without 
significant attenuation [374]. As B5 is an integral membrane protein, virus particles positive 
for B5 represent only wrapped morphological forms of the virus (IEV, CEV and EEV) and 
not IMV. When combined with an A3 tagged with a second, complementary fluorescent 
protein tag, IMV can be distinguished from the wrapped morphological forms in live cells.  
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3.1.3.3 F13L 
F13 is a 37kDa protein that associates with both the inner and outer membrane of IEV 
through palmitylated cysteines [375-377]. It localises to the TGN and is the most abundant 
protein in EEV [260]. It has similar functions as B5, with ∆F13L producing a small plaque 
phenotype with defects in membrane wrapping and IEV morphogenesis [378-380]. F13, like 
B5, is amenable to tagging and fusions with fluorescent proteins yield bright particles for 
imaging that represent the wrapped morphological forms of VACV [313, 377]. Direct 
comparisons between F13 and B5 indicate that F13 may be a superior tag for monitoring 
wrapped morphological forms of the virus with B5 fusions displaying an additional diffuse 
localisation not seen in untagged B5 [284]. This additional diffuse localisation was not 
detected in the F13L-GFP virus infections. 
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Figure 3.5:  Discerning viral morphological forms with multiple fluorescent tags 
The fluorescence profile of a doubly labelled virus (in this instance where an IMV protein such as A3 
has been labelled with a red fluorescent protein and an IEV protein such as B5 or F13 has been 
labelled with a green fluorescent protein) allows for the differentiation of viral compartments and 
morphological forms. IMV particles, and the virus factory where there is a high density of IMV particles, 
will have a red fluorescent profile. IEV particles and other enveloped forms of the virus will be postitive 
for both IMV and IEV fusion proteins and the resultant colocalisation of red and green signals will lead 
to a yellow fluorescent profile. The membranes of the TGN will have a strong green signal due to the 
presence of the IEV fusion protein, but will also have a strong red signal due to the accumulation of 
IMV in the compartment undergoing the wrapping process. This differentiation of morphological forms 
can still be achieved in viruses with only a single fluorescent protein fusion by using an antibody raised 
against the complementary viral protein (such as α-B5). The viral proteins involved in the microtubule 
transport steps are shown in brackets underneath the microtubule transport stages.  
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3.2 RESULTS 
3.2.1 B5R-PSCFP2 and PSCFP2-A3L both display unperturbed subcellular localisation and 
functional microtubule-based egress 
To study IEV and IMV dynamics in VACV, we generated recombinant viruses expressing the IEV 
protein B5 and core protein A3 fused to PSCFP2 [Section 2.4.1.2]. For B5R-PSCFP2, a plasmid 
construct containing regions upstream and downstream of B5R flanking a genetic fusion of B5R 
with PSCFP2 was cloned. PSCFP2 was fused C-terminally to B5R as it has been previously 
demonstrated that C-terminus fusions of fluorescent proteins to B5 do not effect subcellular 
targeting of B5 and yield recombinant viruses with similar plaque phenotypes to parental strain 
WR [374, 381]. We then recombined this construct to rescue VACV ∆B5R that produces a small 
plaque phenotype and selected for recombinant viruses with restored WR-like large plaque sizes 
and exhibited faint blue fluorescence. Three rounds of purification were carried out to clonal, 
purified virus [Section 2.3.3]. 
As functional N-terminal fusions of fluorescent proteins to A3L have previous been published 
[317], we generated a plasmid construct with the sequence upstream of A3L cloned as a left arm to 
a genetic fusion of PSCFP2 to the first 500 bp of the A3L sequence [Section 2.1.2.1]. As deletion 
strains for A3L cannot be generated, selection of recombinant viruses by restoration of plaque size 
was not possible for the PSCFP2-A3L virus. Instead, the recombination sequence was shuttled into 
a vector containing both selectable marker gpt, an E. coli gene that encodes xanthine-guanine 
phosphoribosyltransferase to allow growth on GPT selection media, and screenable marker 
monomeric red fluorescent protein (mRFP) expressed from an artificial synthetic early/late 
promoter [Section 2.1.2.1]. We recombined this construct with WR and using TDS [Section 
2.4.1.3], selected for recombinant virus able to replicate in the presence of GPT selection media 
with visible red fluorescent plaques. Following three rounds of purification, selection was removed 
to allow intragenomic recombination and removal of gpt and mRFP. Successful secondary 
recombinants were selected by picking plaques with faint blue fluorescence for an additional three 
rounds of purification.  
We tested the integrity of B5R-PSCFP2 and PSCFP2-A3L with PCR analysis from genomic 
DNA. For B5R-PSCFP2, a primer pair consisting of a forward and reverse primer complementary 
to the end of the B5R ORF and 300 bp downstream of the stop codon of the ORF respectively was 
used (B5R(end).for/B5R.RA.rev [Table 2.1]). While an amplicon of approximately 300 bp was 
produced from the WR control, the B5R-PSCFP2 amplicon was 1000 bp; encompassing to 
PSCFP2 (717 bp) and the RA of B5R [Figure 3.6A]. When a second PCR was carried out with the 
same forward primer and a reverse primer complementary to the last 20 bp of PSCFP2 
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(B5R(end).for/PSCFP4), the WR virus genomic DNA did not produce a visible band, while B5R-
PSCFP2 produced an amplicon of approximately 700 bp [Figure 3.6A], further validating the 
successful insertion of a B5R-PSCFP2 genomic fusion. 
To validate PSCFP2-A3L, a primer pair consisting of a forward primer complementary to a region 
approximately 500 bp upstream of the start codon and a reverse primer complementary to a region 
500 bp into the A3L ORF was used (A3L.LA.CFPsew1/A3L2). A product of approximately 1700 
bp, encompassing the left arm (500 bp) and PSCFP2 (717 bp) fused to the beginning of A3L (500 
bp) was amplified from the PSCFP2-A3L genome, compared to a 1000 bp amplicon from WR 
[Figure 3.6B]. When a second PCR was carried out with a forward primer complementary to the 
first 20 bp of PSCFP2 with the same reverse primer (PSCFP1/A3L2), the WR genomic DNA did 
not produce a visible band compared to the 1200 bp amplicon from PSCFP2-A3L [Figure 3.6B]. 
We confirmed the expression of fusion proteins by immunoblot analysis. As PSCFP2 is derived 
from a variant of GFP, the amino acid sequences of EGFP and PSCFP2 have 89% consensus. We 
therefore tested α-GFP in immunofluoresence assays (IFA) of PSCFP2 transfected cells and 
observed colocalisation between the two signals, indicating that α-GFP binds to and is able to 
detect PSCFP2 [data not shown]. When VACV-infected lysates were probed with α-GFP, bands 
were detected in B5R-PSCFP2 and PSCFP2-A3L lysates at approximately 65 kDa and 85 kDa, 
respectively [Figure 3.6C]. This is consistent with successful fusions between PSCPF2 (27 kDa), 
and B5 (~42 kDa) [272] and A3 (~74 kDa, processed into a ~62 kDa protein) [371]. Reprobing the 
blot with α-B5 validated the B5R-PSCFP2 fusion, with the same 65 kDa band also being α-B5 
immunoreactive. 
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Figure 3.6:  Construction and verification of PSCFP-2 tagged viruses 
BSC-1 cells were infected with WR, B5R-PSCFP2 (A) and PSCFP2-A3L (B) and cell lysates collected at 
24 hpi. PCR was conducted on proteinase K treated samples with indicated primer pairs to confirm correct 
insertion of the PSCFP2 gene into the virus. Molecular size markers are indicated on the left. (C) BSC-1 
cells were infected with WR, B5R-YFP, B5R-PSCFP2 and PSCFP2-A3L at MOI 1 and cell lysates 
collected at 24 hpi. Cell lysates were separated with SDS-PAGE and transferred to nitrocellulose 
membranes for immunoblotting with α-GFP (able to detect YFP and PSCFP2) and α-B5R as an infection 
control. Molecular size markers are indicated on the left.  
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Upon verifying the construction of PSCFP2 fusion viruses, we proceeded to analyse replication 
dynamics and subcellular localisation to assess the impact of PSCFP2 fusions. Both B5 and A3 
fusions with GFP and close GFP derivatives (such as YFP) have been widely utilised in analysis 
of VACV subcellular trafficking, with minimal to no reported impacts on protein localisation or 
viral replication [317, 374, 381]. As previously mentioned, PSCFP2 is also derived from GFP and 
maintains many of the same beneficial physical and chemical attributes of GFP including those 
that are most likely to affect virus structure and function when fused to dense virus proteins such 
as B5 and A3, such as size (they are both the same size at 27kDa) [382]). We therefore predicted 
that PSCFP2 fusions would have a similarly minimal impact on viral function.  
We first performed plaque assays and unexpectedly observed that both viruses produced 
significantly smaller plaques than parental WR. B5R-PSCFP2 showed a substantial effect on 
plaque size, with PSCPF2-A3L displaying a relatively minor reduction in size [Figure 3.7A, B]. 
Both however produced significantly larger plaques than the widely utilised and published B5R-
YFP. Due to this, we proceeded to perform immunofluoresence assays (IFA) to examine 
subcellular localisation of tagged proteins and to confirm functional microtubule-based egress of 
virus particles. While both viruses displayed effective egress to the cell periphery and the ability to 
produce actin tails, we were unable to image the PSCFP2 signal, as excitation with the appropriate 
wide field led to the rapid photoconversion of PSCFP2 and subsequent abrogation of the blue 
signal [Figure 3.7C, D]. 
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Figure 3.7:  Plaque phenotypes of PSCFP2 tagged viruses 
(A) BSC-1 cell monolayers were infected with WR, B5R-YFP, B5R-PSCFP2 and PSCFP2-A3L and 
overlayed with 1.5% CMC/DMEM. Four days post infection cell monolayers were washed and stained 
with crystal violet to observe plaques before being scanned with a Typhoon FLA9000 4 laser scanner. 
(B) The diameter of plaques was measured in ImageJ as the widest horizontal zone of clearing 
observed (n = 30). All viruses produced statistically different plaque sizes (p<0.0001, Unpaired t-test). 
For immunofluoesence assays, HeLa cells were infected with (C) B5R-PSCFP2 and (D) PSCFP2-A3L, 
then fixed and stained for immunofluorescence assays with α-B5R (green) and phalloidin (red). Scale 
bar represents 10 µm. 
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3.2.2 B5R-PSCFP2 has a low signal-to-noise ratio and does not undergo efficient 
photoconversion 
Having validated the construction of both fusion viruses, we went on to image B5R-PSCFP2 in a 
live cell system. HeLa seeded onto fibronectin coated No. 1.5 glass µ-Dishes (Ibidi, Martinsried, 
Germany) were infected with the B5R-PSCFP2 for a minimum of 7h and then imaged on an 
Olympus FV1000 confocal microscope (Olympus, Notting Hill, VIC, Aus) at 600x to 1200x 
magnification (600x optical magnification and up to 2x digital magnification).  
Infected cells were located and imaged with a 405 nm laser at 1% power (corresponding to 0.5 
mW) and 488 nm laser at 0.1% power (corresponding to <0.03 mW) to obtain “pre-activation” 
images [Figure 3.8A]. One of the main concerns with imaging of any fluorescent fluorophore is 
bleaching, which occurs when fluorophores are exposed to excitation light [383, 384]. There is an 
additional concern with photoconvertible fluorophores such as PSCFP2; that excitation light can 
also lead to inadvertent photoconversion of the fluorophore before the intended timeframe of 
imaging [312]. As such, the power of the excitation lasers is optimally set to as low a setting as 
possible while still generating a clear signal. For B5R-PSCFP2, while 1% 405 nm laser excitation 
allowed for a signal bright enough to distinguish the subcellular localisation of B5R-PSCFP2, the 
signal is faint with significant noise (produced by the emission signal sensor in low light 
conditions [384]) and distinct virus particles are not readily resolved [Figure 3.7A]. Higher levels 
led to rapid photoconversion [data not shown] and 1% was selected as a compromise between 
resolving virus particles and inadvertent photoconversion. 
Images were acquired with a 4.0 pixel/sec scan speed, this is the pixel dwell speed and indicates 
the amount of time the laser excites each pixel of the imaging field of view. Short pixel dwell 
times lead to less bleaching and unintended photoconversion, but as fluorophores are being excited 
for a shorter duration, the emission signal will not be as bright as a longer pixel dwell times, 
leading to noisier images with reduced resolution. So again, like laser power, a 4.0 pixel/sec dwell 
was selected as an optimal compromise between these factors. 
The 488 nm excitation channel is required “pre-activation” to indicate what baseline green signal 
is present in the cell, possibly owing to photoconversion that has occurred in the process of 
locating infected cells. The two channels (405 nm and 488 nm) were collected sequentially, rather 
than simultaneously. Simultaneous acquisition involves the excitation of the same pixel of the 
imaging field of view with both lasers simultaneously. Collection of the emission signal of the 
excited fluorophores by two separate photo multiplier tubes (PMTs) of the microscope also occurs 
simultaneously. Simultaneous acquisition allows for faster imaging of the field of view (if using 
two lasers, simultaneous acquisition requires half the time of the same sequential acquisition). 
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However, if two fluorophores have overlapping emission spectra, as is the case with the pre-
activation blue state and post-activation green state of PSCFP2 that both have a substantial 500-
600 nm emission tail [Figure 3.4], the emission of the shorter wavelength fluorophore (blue) will 
also be detected by the PMT assigned to detect the emission of the longer wavelength fluorophore 
(green). It is therefore necessary to image the two channels sequentially for optimal signal 
separation. 
A 40 x 40 pixel region of interest (ROI), the region of the cell with the brightest 405 nm emission 
(the trans-Golgi Network), was selected for photoconversion. For all imaging experiments, 
activation was optimised and conducted with a 40 x 40 pixel region of interest. This size was 
chosen as it was large enough to encompass both of the subcellular compartments of interest (the 
trans-Golgi network and the virus factory) 1200x magnification. The consistency of size was 
important as activation can be controlled mainly by altering three separate variables; laser power, 
time and scan speed. The same combination of these three variables will lead to different 
photoactivation efficiencies with different size ROIs as the number of iterations of the laser over 
each fluorophore will change.  
The ROI was activated with 3% of the same 405 nm laser (1.5 mW) used for obtaining “pre-
activation” images (the visible [VIS] laser, the microscope is also equipped with a second 405nm 
laser, called the SIM laser, which is described below [Section 3.2.3]), for 100 ms at a scan speed 
of 100 µs/pixel (the slowest scan speed). 1%, 2%, 4% and 5% laser were also attempted, with 
lower powers leading to a lack of visible photoconversion and higher powers leading to 
photobleaching [data not shown].  
In the representative cell, at optimised activation settings, photoactivation led to an approximately 
67% decrease in the blue signal with a concurrent approximately 39% increase in the 
photoactivated green signal [Figure 3.8B]. While this is consistent with photoconversion, the 
green signal is low both relative to the loss of the blue signal and also low in absolute terms. 
Experimentally useful photoconversion requires a high contrast between pre-activated and post-
activated states, which was not achieved [356]. For our experimental requirements to determine 
the turnover of virus particles in compartments and track their trajectories, we require the ability to 
clearly resolve and distinguish photoactivated virus particles. This was not attainable with the 
achieved level of photoconversion using this experimental set-up. 
It is important to note that the depicted cell [Figure 3.8] was selected as it effectively represents 
the pattern of conversion achieved in many other cells photoactivated with the described settings. 
However, the exact efficiency of the photoactivation differs between cells due to a combination of 
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factors, including but not limited to; the infection level, cell morphology, density of fluorescent 
signal and any background fluorescence. This way of representing data was selected because the 
averaging of photoconversion data over multiple cells artificially obscured the efficiency of 
photoconversion. As such, although percentage increase/decrease is given to easily compare tags, 
these readings are informative as qualitative indications of the effectiveness of photoactivation, 
rather than as absolute quantitative measurements. This is similarly the case for cells in following 
photoconversion images [Figure 3.9-3.10, 3.14-3.16]. 
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Figure 3.8:  B5R-PSCFP2 does not undergo efficient photoconversion 
(A) HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with B5R-PSCFP2. The trans-Golgi 
network, the brightest signal in the cell, was located by the visualisation of the PSCFP2 signal with 1% intensity 
405 nm laser excitation on an Olympus FV1000 confocal microscope and activated at the indicated region of 
interest (circle) with 3% intensity 405 nm laser. Excitation with 488 nm was also collected during imaging to 
monitor photoconversion of PSCFP2’s pre-activation blue signal to post-activation green signal. Scale bar is 10 
µm. (B) The average intensity of signal emitted by 405 nm and 488 nm laser lines in the activation region of 
interest was plotted over the course of imaging, with the point of photoactivation indicated with an arrow. 
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3.2.3 PSCFP2-A3L undergoes efficient photoconversion 
Non-photoactivatable blue and cyan fluorescent derivatives of GFP often have poor relative 
brightness to EGFP. Enhanced Blue Fluorescent Protein (EBFP) for instance is 27% of EGFP, 
while Enhanced Cyan Fluorescent Protein (ECFP) is 39% of EGFP [349, 385, 386]. Similarly, the 
blue state of PSCFP2 has a brightness of 8.6 (a product of quantum yield of 0.2 multiplied by 
extinction coefficient of 43000 M-1cm-1) and the green state has a brightness of 10.8 (quantum 
yield 0.23, extinction coefficient 47000 M-1cm-1), compared to EGFP which has a brightness of 
34, meaning the blue and green state are 25% and 31% as bright as EGFP respectively [312, 354].  
The relative low brightness of CFP can be compensated for by creating fusions with highly 
abundant viral proteins, creating viruses with denser (and therefore brighter) fluorescent signals. 
A3 is one of the most abundant proteins in the IMV, making up over 5% of total IMV weight [268, 
371]. Our previous experiences with imaging B5R-CFP and CFP-A3L virus infections have 
demonstrated that while B5R-CFP infections prove difficult to image, the high abundance and 
density of A3 in virus particles leads to bright fluorescent signals enabling good resolution of virus 
particles. We predicted a similar consequence with PSCFP2-A3L and therefore proceeded with 
imaging PSCFP2-A3L to determine if we could achieve more effective photoactivation. 
HeLa seeded onto fibronectin coated No. 1.5 glass µ-Dishes (Ibidi) were infected with the 
PSCFP2-A3L and then imaged on an Olympus FV1000 confocal microscope. Infected cells were 
imaged with the same optimised acquisition settings as used for B5R-PSCFP2; sequentially with a 
405 nm and 488 nm laser with 4.0 pixel/sec scan speed to obtain pre-activation images [Figure 
3.9A]. As predicted, the PSCFP2-A3L signal is much brighter than B5R-PSCFP2 [Figure 3.8A], 
with no distinguishable background noise and clear resolution of virus particles. 
Activation was performed with the optimised settings described above, with the exception of the 
activating laser line used; a 40 x 40 pixel region of interest (ROI), the region of the cell with the 
brightest 405 nm emission (this time the virus factory), was selected for photoconversion. The 
ROI was activated with 3% of the 405 nm laser SIM (simultaneous) scanner (instead of the 405 
nm laser VIS scanner) under “Tornado” setting for 100 ms at a scan speed of 100 µs/pixel. As can 
be seen in post-activation images [Figure 3.9A], the blue signal is completely abrogated in the 
ROI after activation, with a dramatic increase in the brightness of the green signal.  
The 405 nm SIM scanner used for activation does not, contrary to its name, allow the simultaneous 
collection of the 405 nm PSCFP2 emission. The course of activation can therefore only be 
monitored with 488 nm emission [Figure 3.9B]. The initial photoactivation led to an 
approximately 3-foldincrease in the green signal (from an emission average intensity of 550 to 
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1800 when stabilised). As the activation series was performed without a concurrent imaging in 405 
nm, the activation was repeated a second time in the same series to ensure that maximal 
photoconversion had occurred. Although the second activation led to a slight increase in the green 
signal (from an emission average intensity of 1800 to 1900 when stabilised), the large bulk of 
photoconversion occurred with the initial photoactivation. 
The SIM (simultaneous) laser scanner is a unit separate from the main laser scanning unit of the 
FV1000 confocal microscope specifically for stimulation (photoactivation or photobleaching) of 
the sample while simultaneously acquiring images, to allow for the monitoring of the ROI during 
the moment of stimulation [387]. The SIM scanner however is equipped with a 405 nm laser and 
the set up of the FV1000 microscope (at the Australian Centre of Microscopy and Microanalysis, 
ACMM) does not allow simultaneous stimulation and acquisition using a 405 nm laser, as use of 
the 405 nm SIM laser scanner blocks the light path of the 405 nm visualising laser (the visualising 
laser is the 405 nm laser of the main laser scanning unit, which I shall refer to as the abbreviation 
VIS to differentiate it from the SIM scanning unit).  
An advantage the SIM scanner does have for our purposes is that the “Tornado” scanning function, 
which instead of using raster scanning in parallel lines over the ROI, spirals the laser from edge of 
the ROI into the centre and then back. This minimises superfluous scanning, leading to more 
efficient activation or bleaching and is therefore suitable for our purposes [387]. 
The technical difficulty resulting from the aforementioned inability to use both 405 VIS and 405 
SIM lasers concurrently is that when working with the SIM laser for stimulation of a fluorophore 
that is also imaged with a 405 nm laser, pre-activation images need to be collected before the 405 
nm laser is switched off for the activation series and then switched on again for post-activation 
images. These technical difficulties also make quantitative measurements of the effectiveness of 
the activation difficult, as we cannot observe the concurrent relative decrease of the blue signal 
and increase of the green signal at the moment of activation. Nevertheless, as PSCFP2 is activated 
by the same laser used to image it, minimising the amount of time the sample is exposed to 405 
nm light to prevent off-target non-ROI activation is preferable, and together with the other 
advantages of the 405 nm SIM scanning unit, we decided to switch activation systems.  
Even with the absolute minimum exposure to 405 nm light over the course of imaging and 
photoactivation, there is substantial off-target photoconversion as can be seen by the green 
fluorescence outside the ROI. The extent of off-target photoconversion can be measured by 
comparing two cells that have been transfected with constitutively expressed PSCFP2 [Figure 
3.10]. While the cell selected for photoactivation by higher intensity excitation with the 405 nm 
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VIS laser has a 22% increase in green signal immediately post activation, the second cell has a 
29% increase in the green signal by the end of the time course (25 frames) without any intended 
high intensity photoactivation. This off-target photoconversion effectively makes the clear 
distinguishing of a specific subset of virus particles (such as IMV in the VF) over time highly 
problematic. Thus while PSCFP2-A3L produced bright, easily resolved particles that 
photoconverted effectively, PSCFP2 was unsuitable to monitor virus transport of a cohort of virus 
particles. 
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Figure 3.9:  PSCFP2-A3L undergoes efficient photoconversion 
(A) HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with PSCFP2-A3L. The virus factory, 
the brightest signal in the cell, was located by the visualisation of the region of brightest PSCFP2 signal with 1% 
intensity 405 nm laser excitation on an Olympus FV1000 confocal microscope and activated at the indicated 
region of interest (circle) with 3% intensity 405 nm SIM laser. To ensure that complete conversion was achieved, 
the region of interest was activated a second time. Post-activation images were collected 120 s after the initial 
activation. Scale bar is 10 µm. (B) Excitation with 488 nm was collected during imaging to monitor 
photoconversion of the  pre-activation blue signal to post-activation green signal. The average intensity of signal 
emitted by 488 nm laser lines in the activation region of interest was plotted over the course of imaging, with the 
two points of photoactivation indicated with an arrow. 
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Figure 3.10:  PSCFP2 photoactivates with low intensity 405 nm laser imaging 
(A) HeLa cells seeded onto fibronectin coated Ibidi dishes were transfected with CB6 PSCFP2. Two cells with 
robust PSCPF2 expression were imaged with 1% intensity 405 nm laser excitation on an Olympus FV1000 
confocal microscope and one of the cells indicated by a circle (bold line), was activated with 3% intensity 405 nm 
laser. Excitation with 488 nm was also collected during imaging to monitor photoconversion of PSCFP2’s pre-
activation blue signal to post-activation green signal. Scale bar is 20 µm. (B) The average intensity of signal 
emitted by 405 nm and 488 nm laser lines in the photoactivated cell and in the “unactivated” cell was plotted 
over the course of imaging, with the point of photoactivation indicated with an arrow.  
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3.2.4 Dendra2 fusion viruses display unperturbed subcellular localisation and microtubule-
based egress dynamics 
Following the challenges encountered with utilising PSCFP2, we moved on to another 
photoconvertible fluorescent tag, the monomeric green-to-red switcher Dendra2. The preactivation 
and postactivation forms were 2.6 and 1.8 times brighter than PSCFP2, respectively, and we 
predicted this improved brightness would enable effective imaging of lower density IEV-
membrane protein fusions like B5 [312]. Furthermore, the preactivation excitation maximum of 
Dendra2 is 490 nm, while photoconversion is achieved with high intensity 405 nm light, enabling 
visualisation of cells without inadvertent photoactivation. Although 488 nm light can also cause 
photoconversion of the fluorophore, this requires longer periods of irradiation and can be avoided 
with low pixel dwell times [312].  
B5R-Dendra2 and Dendra2-A3L were generated with the same strategies as outlined for B5R-
PSCFP2 and PSCFP2-A3L above. As we observed a significant but mild attenuation of B5R-
PSCFP2 plaque sizes, we also investigated F13L-Dendra2 as a fusion virus for IEV, as F13L-GFP 
has been reported to produce plaques very similar in size to WR [377]. To generate F13L-
Dendra2, 150 bp long flanking regions of homology, at the end of F13L (LA) and downstream of 
F13L (RA), were synthesised into a plasmid with restriction sites between them to allow for the 
insertion of Dendra2 as a C-terminal fusion [Section 2.1.2.1]. Once the fluorescent protein gene 
was inserted, restriction sites flanking the entire stretch (LA-fluorescent protein gene-RA) were 
used to clone it into a TDS vector (containing pE/L gpt and pE/L mCherry). We recombined this 
construct with WR and using TDS [Methods 2.4.1.3], selected for recombinant virus able to 
replicate in the presence of GPT selection media with visible red fluorescent plaques [313]. After 
three rounds of purification, we removed selection to allow the intragenomic recombination and 
removal of gpt and mCherry. We screened for successful recombinants by identifying plaques with 
green fluorescence following three additional rounds of plaque purification.  
We tested the integrity of all three recombinant viruses with PCR analysis from extracted genomic 
DNA. For B5R-Dendra2, a primer pair consisting of a forward and reverse primer complementary 
to the end of the B5R ORF and 300 bp downstream of the stop codon of the ORF respectively was 
used (B5R(end).for/B5R.RA.rev). While an amplicon of approximately 300 bp was produced from 
the WR control, the B5R-Dendra2 amplicon was 1000 bp; encompassing to Dendra2 (693 bp) and 
the 300 bp RA of B5R [Figure 3.11A]. When a second PCR was carried out with the same 
forward primer and a reverse primer complementary to the last 20 bp of Dendra2 
(B5R(end).for/Dendra2), the WR virus genomic DNA did not produce a visible band, while B5R-
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Dendra2 produced an amplicon of approximately 700 bp [Figure 3.11A], further validating the 
successful insertion of a B5R-Dendra2 genomic fusion. 
For F13L-Dendra2, primers complementary the start and end of the F13L ORF were used 
(F13L.for/F13L.rev). Both the WR control and the F13L-Dendra2 amplicon was approximately 
1400 bp, encompassing the F13L ORF [Figure 3.11A]. When a second PCR was carried out with 
the same forward primer and a reverse primer complementary to the last 20 bp of Dendra2 
(F13L.for/Dendra2), the WR virus genomic DNA did not produce a visible band, while F13L-
Dendra2 produced an amplicon of approximately 2100 bp [Figure 3.11A], confirming the 
successful insertion of a F13L-Dendra2 genomic fusion. 
To validate Dendra2-A3L, a primer pair consisting of a forward primer complementary to a region 
approximately 500 bp upstream of the start codon and a reverse primer complementary to a region 
500 bp into the A3L ORF was used (A3L.LA.CFPsew1/A3L2). A product of approximately 1700 
bp, encompassing the left arm (500 bp) and Dendra2 (693 bp) fused to the beginning of A3L (500 
bp) was amplified from the Dendra2-A3L genome, compared to a 1000 bp amplicon from WR 
[Figure 3.11A]. When a second PCR was carried out with a forward primer complementary to the 
first 20 bp of Dendra2 with the same reverse primer (Dendra1/A3L2), the WR genomic DNA did 
not produce a visible band compared to the 1200 bp amplicon from Dendra2-A3L [Figure 3.11A]. 
We next carried out immunoblots to confirm the expression of fusion proteins. When VACV-
infected lysates were probed with α-Dendra2, bands were detected in B5R-Dendra2, F13L-
Dendra2 and Dendra2-A3L lysates at approximately 70 kDa, 60 kDa and 85 kDa, respectively 
[Figure 3.11B]. This is consistent with successful fusions between Dendra2 (26 kDa), and B5 
(~42 kDa) [272], F13 (~42 kDa, with a 37 kDa mobility on SDS-PAGE) [377] and A3 (~74 kDa, 
processed into a ~62 kDa protein) [371]. Reprobing the blot with α-B5 validated the B5R-Dendra2 
fusion, with the same 70kDa band also being α-B5 immunoreactive. Although comparable levels 
of viral replication have occurred in each of the recombinant viruses as seen through similar levels 
of B5 expression, the relative abundance of B5, F13 and A3 can be seen by the varying strength of 
bands in the α-Dendra2 blot. 
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Figure 3.11:  Construction and verification of Dendra2 tagged viruses 
BSC-1 cells were infected with WR, B5R-Dendra2 (A) F13L-Dendra2 (B) and PSCFP2-A3L (C) and cell 
lysates were collected at 24 hpi. PCR was conducted on proteinase K treated samples with indicated 
primer pairs to confirm correct insertion of the Dendra2 gene into the virus. Molecular size markers are 
indicated on the left. (D) BSC-1 cells were infected with WR, B5R-YFP, B5R-Dendra2, F13L-GFP, F13L-
Dendra2, YFP-A3L and Dendra2-A3L at MOI 1 and cell lysates collected at 24 hpi. Cell lysates were 
separated with SDS-PAGE and transferred to nitrocellulose membranes for immunoblotting with α-
Dendra2, α-B5R and α-ß-tubulin as a loading control. Molecular size markers are indicated on the left. 
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We next performed plaque assays and determined that, like PSCFP2 fusion viruses, both B5R-
Dendra2 and Dendra2-A3L viruses produced significantly smaller plaques than parental WR. 
B5R-Dendra2 displayed a substantial effect on plaque size, while Dendra2-A3L displayed a 
relatively minor reduction [Figure 3.12A, B]. Both however produced significantly larger plaques 
than the widely utilised and published B5R-YFP. F13L-Dendra2 produced plaques not 
significantly different in size to WR, confirming that F13L is a superior tag for labelling 
enveloped from of VACV [284, 377]. Interestingly, F13L-GFP plaques were significantly smaller 
than both WR plaques and F13L-Dendra2 plaques, possibly indicating that Dendra2 fusions have 
less effect on viral morphogenesis and/or egress than GFP.  
 
Figure 3.12:  Plaque phenotypes of Dendra-2 tagged viruses 
(A) BSC-1 cell monolayers were infected with WR, B5R-YFP, B5R-Dendra2, F13L-GFP, F13L-Dendra2 
and Dendra2-A3L and overlayed with 1.5% CMC/DMEM. Four days post infection cell monolayers were 
washed and stained with crystal violet to observe plaques before being scanned with a Typhoon FLA9000 
4 laser scanner. (B) The diameter of plaques was measured in ImageJ as the widest horizontal zone of 
clearing observed (n = 30). Unless otherwise indicated, all viruses produced statistically different plaque 
sizes (p<0.0001, Unpaired t-test). 
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To further validate construction of B5R-Dendra2, F13L-Dendra2 and Dendra2-A3L, we 
performed IFA on infected cells. Unlike PSCFP2 fusion viruses, excitation with the appropriate 
wide-field filter did not lead to the rapid photoconversion of the Dendra2 and we were able to 
examine subcellular localisation of tagged proteins [Figure 3.13]. We observed a cyan signal 
throughout the cell indicating complete colocalisation between the Dendra2 signal in B5R-
Dendra2 infected cells in green with a monoclonal antibody raised against B5 in blue, verifying 
the tagging of B5 with Dendra2 [Figure 3.13A]. Performing the same B5 antibody label on F13L-
Dendra2-infected cells showed colocalisation between the two signals, verifying the construction 
of F13L-Dendra2 [Figure 3.13B]. Unlike B5R-Dendra2, F13L-Dendra2 infected cells showed 
regions where the green Dendra2 signal is stronger and other regions where the blue B5 antibody 
signal is stronger. This is consistent with the fact that although B5 and F13 are both IEV proteins 
that localise to the TGN, they differ in relative abundance. Both B5R-Dendra2 and F13L-Dendra2 
displayed effective egress to the cell periphery and efficiently induced virus-associated F-actin 
comets [Figure 3.13A-B].  
Performing the a B5 antibody label on Dendra2-A3L infected cells showed some areas of 
colocalisation between the two signals (individual virus particles disseminated through the 
cytoplasm and in a region of the cell with a strong B5 signal, the TGN), and other regions of the 
cell that were positive for Dendra2 with no B5 signal [Figure 3.13C]. This is consistent with the 
successful tagging of A3, which localises to the virus factory where IMV are generated before 
addition of B5/IEV membranes, with Dendra2. 
While generation of Dendra2-A3L was successful, fusions with A3 label all morphological forms 
of the virus (both IMV and all enveloped forms) and do not allow easy differentiation between the 
virus factory/IMV and the TGN/IEV in Dendra2-A3L infected cells without antibody labels (as 
demonstrated in Figure 3.13C). To enable the differentiation of these two compartments/different 
morphological forms with live cell microscopy that does not allow for antibody labelling, we 
introduced a second fluorescent tag, CFP, fused to B5. This was accomplished through 
coinfections of cells with Dendra2-A3L and B5R-CFP, allowing for intergenomic recombination 
and selection and purification of plaques displaying both Dendra2 and CFP fluorescent signals 
yielding a Dendra2-A3L/B5R-CFP virus [Section 2.4.1.4].  
Successful construction of this virus was confirmed by imaging fixed cells under the Olympus 
BX51 wide-field microscope and demonstrated the clear differentiation between the VF with a 
strong green fluorescence and the TGN with a strong blue fluorescence with green particles 
[Figure 3.13D]. It was not necessary to confirm construction of this virus with PCR as the 
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integration of the two fluorescent proteins into the correct viral locus through plasmid-based 
recombination cassettes had previously been verified. In the process of homologous recombination 
between two viruses, it is unlikely that a recombination event would occur that affected the locus 
of the fluorescent protein without also severly disrupting viral replication. 
 
Figure 3.13:  IFA images of viruses 
HeLa cells on coverslips were infected, fixed and stained for immunofluorescence assays. (A) B5R-
Dendra2 (green) was stained with α-B5R (blue) and phalloidin (red). (B) F13L-Dendra2 was stained with 
α-B5R (blue) and phalloidin (red). (C) Dendra2-A3L was stained with α-B5R (red). (D) Cells infected with 
Dendra2-A3L/B5R-CFP (green/blue) were imaged without staining. Scale bar represents 10 µm. 
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3.2.5 Dendra2 fusion viruses display bright fluorescence and photoconvert efficiently 
Having validated the construction of our fusion viruses, we went on to image B5R-Dendra2, 
F13L-Dendra2 and Dendra2-A3L in our live cell system. HeLa seeded onto fibronectin coated No. 
1.5 glass µ-Dishes were infected with the B5R-Dendra2 for a minimum of 7h (B5R-Dendra2 and 
F13L-Dendra2) or 5h (Dendra2-A3L) and then imaged on an Olympus FV1000 confocal 
microscope at 600x to 1200x magnification (600x optical magnification and up to 2x digital 
magnification). Infection times were chosen based on the approximate appearance of the mature 
Dendra2 fluorophore of expressed fusion proteins. The time chosen for IEV tags (B5 and F13) is 
later than the IMV tag (A3) due to their differing temporal expression profiles. 
Infected cells were located and imaged with a 488 nm laser at 0.1% power (<0.03 mW) and 559 
nm laser at 0.2% power (0.03 mW) to obtain “pre-activation” images [Figure 3.14-3.16]. Images 
were acquired with a 4.0 pixel/sec scan speed, the longest pixel dwell possible without unintended 
photoactivation [312]. The two channels (488 nm and 559 nm) were collected sequentially, as the 
pre- and post-activation fluorophores have overlapping excitation/emission spectra, with the 488 
nm laser capable of exciting the post-activation fluorophore and the PMT assigned to detect the 
emission of the post-activation fluorophore detecting the tail of the pre-activation emission spectra 
from 565 nm onwards [Figure 3.4]. 
A 40 x 40 pixel region of interest (ROI), the region of the cell with the brightest 488 nm emission 
(the TGN in B5R-Dendra2 and F13L-Dendra2 and the virus factory in Dendra2-A3L), was 
selected for photoconversion. The ROI was activated with 3% 405 nm laser (1.5 mW), for 100 ms 
at a scan speed of 100 µs/pixel (the slowest scan speed). All three viruses photoactivated 
efficiently. In B5R-Dendra2, photoactivation led to an approximately 82% decrease in the green 
signal (a 5.5-fold change) with a concurrent 338% increase in the photoactivated red signal (a 4.4-
fold change) [Figure 3.14]. This indicates a high contrast photoconversion with a 24-fold total 
change (the product of the fold changes in the green and red channels) in the fluorescent signal 
between non-photoactivated and photoactivated forms of the fusion protein. This is a substantial 
improvement on the experimentally achieved fold change of 4.3-fold for B5R-PSCFP2 [Figure 
3.8]. 
While lower fold changes were achieved for F13L-Dendra2 and Dendra2-A3L at 13.9-fold and 
11.4-fold respectively, these were not indicative of less efficient photoconversion than B5R-
Dendra2, but are rather the result of lower initial green fluorescent signals due to compartments 
with less densely packed fluorophores [Figure 3.15-3.16]. While complete conversion of 
fluorescent signal did not lead to high fold changes in the green channel, the achieved change in 
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the red channel was 4.2-fold for F13L-Dendra2 and 6.1-fold for Dendra2-A3L. These fold changes 
allow clear imaging and resolution of photoactivated red virus particles, allowing us to effectively 
track the trajectory of a selected cohort of virus particles in all three viruses. 
 112 
 
Figure 3.14:  B5R-Dendra2 undergoes efficient photoconversion 
(A) HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with B5R-Dendra2. The trans-
Golgi network, the brightest region in the cell, was located by the visualisation of Dendra2 signal with 
0.1% intensity 488 nm laser excitation on an Olympus FV1000 confocal microscope and activated at 
the indicated region of interest (circle) with 3% 405 nm SIM laser. Excitation with 0.2% 559 nm was also 
collected during imaging to monitor photoconversion of the pre-activation green signal to post-activation 
red signal. Scale bar is 10 µm. (B) The average intensity of signal emitted by 488 nm and 559 nm laser 
lines in the activation region of interest was plotted over the course of imaging, with the point of 
photoactivation indicated with an arrow. 
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Figure 3.15:  F13L-Dendra2 undergoes efficient photoconversion 
(A) HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with F13L-Dendra2. The virus 
factory, the brightest region in the cell, was located by the visualisation of Dendra2 signal with 0.1% 
intensity 488 nm laser excitation on an Olympus FV1000 confocal microscope and activated at the 
indicated region of interest (circle) with 3% intensity 405 nm SIM laser. Excitation with 0.2% 559 nm 
was also collected during imaging to monitor photoconversion of the pre-activation green signal to post-
activation red signal. Scale bar is 10 µm. (B) The average intensity of signal emitted by 488 nm and 559 
nm laser lines in the activation region of interest was plotted over the course of imaging, with the point 
of photoactivation indicated with an arrow. 
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Figure 3.16:  Dendra2-A3L undergoes efficient photoconversion 
(A) HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with Dendra2-A3L. The virus 
factory, the brightest region in the cell, was located by the visualisation of Dendra2 signal with 0.1% 
intensity 488 nm laser excitation on an Olympus FV1000 confocal microscope and activated at the 
indicated region of interest (circle) with 3% intensity 405 nm SIM laser. Excitation with 0.2% 559 nm 
laser was also collected during imaging to monitor photoconversion of the pre-activation green signal to 
post-activation red signal. Scale bar is 10 µm. (B) The average intensity of signal emitted by 488 nm 
and 559 nm laser lines in the activation region of interest was plotted over the course of imaging, with 
the point of photoactivation indicated with an arrow. 
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3.2.6 Photoconversion of Dendra2 tagged virus allows trajectory tracking of single virus 
particles 
Single virus tracking in a complex system such as VACV infection is difficult for a number of 
reasons. Microtubule-based motility is very rapid and particles move at up to 3 µm/sec. There are 
also large numbers of particles within an infected cell, often in the hundreds. To be able to track a 
single particle over extended time periods, due to the speed and quantity of other particles, 
imaging would require a very high frame rate. As previously mentioned, higher frame rates result 
in a large amount of exposure of the fluorophore to exciting light, which potentially rapidly 
bleaches particles. These issues can be large overcome with a photoactivatable fluorescent protein 
tagged virus that allows us to highlight a single virus particle and distinguish it from other virus 
particles when the infected cell is imaged at a later time point. 
To be able to identify single activated particles, efficient photoconversion is required so that there 
is high contrast between unactivated and activated particles and Dendra2-A3L satisfies these 
requirements. Having demonstrated that particles are extremely bright and the virus factory 
undergoes efficient photoconversion with optimised photoactivation settings, we went on to 
activate single virus particles to attempt longer time frame virus trajectory mapping. 
HeLa seeded onto fibronectin coated No. 1.5 glass µ-Dishes (Ibidi) were infected with the Dendra-
A3L and then imaged on an Olympus FV1000 confocal microscope. Infected cells were imaged 
sequentially with a 488 nm laser and 559 nm laser with 4.0 pixel/sec scan speed to obtain pre-
activation images [Figure 3.17]. A 40 x 40 pixel region of interest (ROI), over an isolated virus 
particle separated from the virus factory, was selected for photoconversion. The ROI was activated 
with 3% of the 405 nm SIM laser under “Tornado” setting for 100 ms at a scan speed of 100 
µs/pixel. 15 min after activation, a Z-stack from the basal to apical surface was collected (step size 
was determined by automated optimisation).  
Photoactivation was successful, inducing a bright red photoconverted particle with concurrent 
decrease in the green signal [Figure 3.17]. Another virus particle outside but at the edge of the 
selected 40 x 40 pixel region of interest was also activated, but to a lower degree than the targeted 
particle, with only slight effects on the decrease of the green signal. Due to the differences in the 
green/red contrast between the two particles, the targeted particle can still be clearly differentiated. 
All the slices from the 15 min postactivation Z-stack was condensed into a projection (all slices 
through the volume of the cell overlayed into a singular image) and the photoactivated particle can 
be located as particle with the brightest 559 nm emission and lowest 488 nm emission ratio. 
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We have demonstrated that recombinant viruses with highly abundant viral proteins such as A3 
fused to bright photoactivatable fluorescent proteins such as Dendra2, are able to be located over 
relatively long timeframes and imaged without substantial bleaching of fluorophores. Given the 
potential speed of microtubule movement of virus particles (3 µm/s), tracking of non-
photoactivatible fluorescent protein-tagged viruses would have limited tracking timeframes to a 
maximum of a few minutes (one frame every 5 s would be able to be imaged for approximately 30 
frames before fluorophores were substantially bleached). Single virus tracking has the potential to 
reveal detailed information about IMV and IEV trajectories over the course of infection.  
 
Figure 3.17:  Dendra2-A3L is an effective tag for monitoring single virus trajectory 
HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with Dendra2-A3L. Well-isolated 
single virus particles (indicated with an arrow) were located by the visualisation of Dendra2 signal with 
0.1% 488 nm laser excitation. 0.2% 559 nm laser excitation was collected preactivation to confirm the lack 
of photoconversion prior to the intended activation. The particle was activated with 3% intensity 405 nm 
SIM laser for 100 µs/pixel for 100 ms. 15 min post activation, the emission with 488 nm and 559 nm laser 
lines was collected to track post-activation trajectory. The 15 min timepoint is a projection of all the slices 
from a Z-stack taken from the apical to basal surface of the cell. Scale bar is 5 µm. 
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3.3 DISCUSSION 
Originally, our intention in using PSCFP2 as a photoactivatable tag for VACV intracellular 
transport was that utilisation of blue and green channels would allow multichannel imaging with 
another complementary viral tag in red (mRFP or mCherry). A PSCFP2-A3L virus recombined 
with B5R-mRFP for instance would allow us to highlight a specific subset of virus particles, while 
differentiating between IMV (that would be positive for PSCFP2) and enveloped forms of the 
virus (positive for both PSCFP2 and mRFP). We have substantial experience imaging mRFP 
fusions of both B5 and A3, and envisaged that imaging a photoconverted population of PSCFP2 
viruses in green simultaneously with a reference red fluorescence tag would allow the greatest 
flexibility and optical resolution for imaging virus dynamics. 
Unfortunately we encountered various difficulties imaging PSCFP2 fusion viruses. Firstly, B5R-
PSCFP2 did not generate sufficiently bright virus particles to resolve with a usable signal-to-noise 
ratio. To maximise the brightness of imaging, the pinhole of the confocal microscope was opened 
to the largest setting that did not allow laser reflection on the glass surface to enter the PMT, 
generally 400 µm. The pinhole functions to remove out of focus light from the image, which 
enables the imaging of thick samples with large amount of fluorescent signal on other focal planes 
[388]. As our samples are relatively thin at 10 µm, a relatively large pinhole allows us to capture 
the entirety of the signal in a single frame without compromising image quality with substantial 
out of focus light. Although dramatically improving the brightness of virus particles and 
compartments, we could still not achieve a usable signal-to-noise ratio. 
Other groups have reported functional difficulties in utilising PSCFP2. In direct comparisons of 
photoconvertible proteins (PA-GFP, PSCFP2, Kaede and KikGR) for utility in cell labelling for 
mouse embryonic development analysis, PSCFP2 is reported as having dim pre-activation, 
inefficient photoconversion and considerable overlap between pre- and post-activation spectral 
profiles requiring spectral unmixing [389]. This group, however, imaged preactivation PSCFP2 
using a 458 nm laser at 45% power [389]. This is the laser typically used to excite eCFP and 
Cerulean which have excitation maxima at 425 nm and 433 nm, respectively [390]. PSCFP2 on 
the other hand, is significantly short wavelength shifted, with only the slightest tail of its emission 
spectra at 458 nm [312]. The imaging settings used were therefore not reflective of the ideal 
achievable brightness of PSCFP2. 
The low brightness and interrelated inefficient photoactivation we encountered with B5R-PSCFP2 
were overcome with use of PSCFP2 fused to A3. As A3 is one of the most abundant proteins in 
the virus particle [371], PSCFP2-A3L produced substantially brighter particles that could be 
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readily resolved. Nonetheless, the spectral properties of PSCFP2 presented further technical 
difficulties we were unable to overcome. With an excitation maximum of 400 nm, “pre-activation” 
imaging with the lowest 405 nm laser power that clearly resolved virus particles (1%/0.5 mW) led 
to unintended photoactivation of the fluorophore [312]. Attempts to minimise inadvertant 
photoactivation, including use of the fastest scan speed to locate appropriate cells (infected and 
also displaying a distinct virus factory) and monitoring the photoactivation series with the 488 nm 
laser only, did not completely eliminate inadvertant photoactivation. We therefore could not 
achieve experimental “highlighting” of a subset of virus particles with targeted photoactivation. 
PSCFP2 has been effectively used in embryonic development studies utilising 3D imaging of 
organogenesis [391]. PSCFP2-labelled H2B was expressed from an electroporated plasmid 
construct in early embryos. Targeted nuclei expressing H2B-PSCFP2 were efficiently 
photoactivated with a 405 nm laser at 10% power and the photoactivated signal remained stable 
over the course of imaging, allowing cells to be tracked over time [391]. The authors did not report 
that imaging with 2% 405 nm laser caused any unintended photoactivation, perhaps due to the 
impeded penetration of light through the early embryos that are hundreds of cells thick, leading to 
lower intensities of light below the photoactivation threshold [392, 393].  
However, in an earlier study by the same group comparing different photoactivatable proteins in a 
neural tube model, with the same imaging and activation settings, there is evidence of unintended 
photoactivation due to imaging with the 405 nm laser [394]. While photoactivation led to an 
inversion of the fluorescence intensity ratio of blue signal to green signal, “pre-activation” images 
indicated that there is a non-trivial amount of green fluorescence, with the ratio of blue-to-green 
approximately 1.5:1 prior to the photoactivation [394].  
PSCPF2 can also be imaged by arc lamp excitation in widefield systems with select filters 
designed to image blue fluorophores such as DAPI [312]. As the intensity of excitation light 
cannot be controlled to the same degree as lasers in confocal systems, photoactivation upon 
imaging is likely inevitable. Surprisingly, it has been reported that long-term exposure (300 sec) of 
PSCFP2 to unfiltered 175W xenon light or 50W mercury lamp illumination led to no 
photoactivation [395]. In these photostability assays, a decrease in brightness of the non-
photoconverted PSCFP2 signal (Semrock DAPI 5060B, excitation; 350-405 nm, emission; 415-
480 nm) occurred with no detectable increase in the channel used to detect photoconverted 
PSCFP2 [395]. The authors attribute this change to photobleaching, and while a portion of the 
signal decrease is likely due to photobleaching, the filter cube used to detect photoconverted 
PSCFP2 (Semrock CFP-2432A, excitation; 425-455 nm, emission; 460-505 nm) misses both the 
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excitation and emission maxima at 490 nm and 511 nm respectively, suggesting that 
photoactivation may have been occurring without detection in the assay. 
An earlier form of PSCFP2, PSCFP, has been utilised successfully in the monitoring of diffusible 
gluocokinase translocation in response to glucose and mannoheptulose stimulation [364, 396]. 
Regions of PSCFP-tagged gluocokinase were photoactivated and the diffusion of photoconverted 
PSCFP out of the region of interest was tracked with a 488 nm laser. The monitoring of the return 
of activated signal in the ROI to baseline levels can be assessed independently of the rest of the 
cytoplasmic pool of glucokinase. Provided that complete photoactivation of all PSCFP in the ROI 
occurs, the apparent unintended photoactivation of PSCFP outside the ROI caused by imaging 
scans prior to the intended photoactivation does not affect the assay. A similar analysis approach 
does not have full utility in our VACV system, as we aimed to address hypotheses involving 
trajectory and destination of activated particles as well as rate of turnover through the 
ROI/compartment.  
As well as having less of an effect on plaque size (and therefore viral replication and transport), 
compared to PSCFP2-fusion viruses, Dendra2-fusion viruses were also bright and easily imaged. 
Photoactivated Dendra2-fusion viruses were bright enough to clearly resolve and track in all three 
recombinant viruses generated. We did not always achieve full photoconversion of the fluorophore 
as the density of signal at the compartment changed based on the fusion virus used as well as the 
shape/organisation of the compartments in individual cells. However, even in instances with 
incomplete photoconversion, a high contrast between photoactivated virus particles and the 
background red channel signal was sufficient to clearly resolve virus particles. An extremely low 
power of laser was used to image both pre- and post-activation forms of Dendra2 (0.1% of 488 nm 
laser for the preactivation green form and 0.2% of the 559 nm laser for the post-activation red 
form, corresponding to approximately 0.03 mW of energy in both cases) which is indicative of the 
density of fluorescent protein packing in virus particles as well as the 2.6-fold improvement of 
relative brightness of Dendra2 compared to PSCFP2 [312].  
Like PSCFP2, Dendra2 can be photoactivated by the same wavelength of light used to visualise 
the fluorophore at the excitation maximum (488 nm), as well as with the 405 nm laser line [312]. 
Photoactivation of Dendra2 with 488 nm light however requires that each fluorophore is exposed 
to a relatively long continuous beam of light [397]. The continuity of light can be controlled by the 
selected pixel dwell time, which determines the amount of time the laser line irradiates each point. 
Using a 4.0 pixel/sec dwell time (with 0.1% laser power) allowed us to clearly resolve Dendra2-
fusion virus particles without eliciting discernible photoactivation, as can be seen by the stable 
fluorescence signal of both pre- and post-activation forms of the protein prior to the moment of 
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photoactivation [Figure 3.14-3.16]. This lack of inadvertant photoconversion of the fluorophore 
by visualisation scans allowed us to successfully achieve targeted photoactivation at a defined ROI 
with the 405 nm laser that was not possible with PSCFP2-fusions.  
Furthermore, as we were able to use the 405 nm SIM laser line for more efficient photoconversion 
of the ROI without blocking the visualising 488 nm light path, we could acquire images in both 
488 nm and 559 nm channels simultaneously to photoactivation. The ability to image both pre- 
and post-activation channels at the moment of photoactivation allows us to assess the efficiency of 
photoconversion with brightness fold changes, measured as the fold decrease in one channel 
multiplied by fold increase in the other. We achieved fold changes between 10- and 25-fold 
compared to the reported theoretical achievable fold-change for Dendra2 of 4000 [312]. Other 
studies have demonstrated experimental fold-changes with Dendra2 similar to ours, including a 
study tracking the movement of Dendra2-tagged transcription factors through the Arabidopsis root 
(10-fold, [398]) and the original study describing the improved Dendra2 mutant (10-fold, [397]). 
While observed experimental fold-changes are much lower than the theoretical capabilities of 
Dendra2, it is important to note that fold-changes in arbitrary fluorescent units are not solely 
indicative of the effectiveness of the photoconversion, but are also highly dependent on the 
concentration of fluorescent signal in ROI, as well as the baseline/background signal (which can 
be altered by changing the sensitivity of the photon detection system of a confocal microscope, 
called the gain). As an example, in a ROI with a pre-activation reading of 101 arbitrary 
fluorescence units and a post-activation reading of 501, photoactivation would have achieved a 5-
fold change in fluorescence. A lower gain that reduced the arbitary fluorescence units by 100 
would have resulted in pre- and post-activation readings of 1 and 401, respectively, leading to a 
400-fold change, even though the effectiveness of the photoactivation is the same in both 
instances. Ultimately, although fold-changes give an indication of the contrast of pre- and post-
activation forms of a photoactivatable protein, it is fairly arbitrary and optimising settings for 
maximal fold-change ratios have minimal utility experimentally when there is a clear, assayable 
differentiation of the chosen population, as was observed for all three Dendra2-fusion viruses. 
The overall brightness and high achievable contrast of pre- and post-activated forms, combined 
with the fact that it is monomeric with a low tendency to aggregate, has meant that Dendra2 has 
been widely utilised since the original characterisation of Dendra [365] and subsequent 
optimisation [397]. It has been used to successfully differentiate the generation of newly formed 
centrioles from older photoconverted centrioles to elucidate the role of DNA damage-induced 
centrosome amplification in tumorigenesis [399]. While Dendra2 can be utilised to mark and 
differentiate subsets of fairly static structures such as centrioles, it is also ideal for tracking 
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experiments of fast moving molecules and is regularly used in such studies, including the 
investigation of the intracellular transport of molecules via the plasmodesmata of moss [400], the 
aforementioned analysis of transcription factor transport through the Arabidopsis root [398] and 
the dynamic movement of protein transport machinery in the mitochondrial membrane [401]. It is 
in this second context that we aimed to answer questions of VACV intracellular transport 
[Chapter 4]. 
A substantial limitation to live cell imaging of fluorescent fusion proteins is the rate of maturation 
of the chromophore. The maturation of the chromophore occurs after protein folding and involves 
the cyclisation of three adjacent amino acid side chains [see Section 3.1.2.2 for more details]; it is 
the chromophore maturation and not the protein folding of fluorescent protein that is the slow, 
rate-limiting step of fluorescent protein maturation [402]. As the fluorescent protein will not 
produce a fluorescent signal until chromophore maturation [340], biological events close to protein 
translation cannot be monitored with fluorescence microscopy and slower chromophore 
maturation times extend the window where viral transport dynamics cannot be monitored. While 
one of the improvements in Dendra2 over Dendra was the chromophore maturation, the maturation 
half-time of Dendra2 is still 90 min at 37oC [312, 365, 403], compared to 65 min for EGFP [404]. 
A3 is an IMV protein and is expressed earlier than IEV proteins B5 and F13, with substantial 
expression of the 74kDa precusor protein (4b) at 4 hpi [368]. We were able to detect a fluorescent 
signal with live cell microscopy of Dendra2-A3L at 5 hpi, with a strong signal at 6 hpi. Although 
B5 can be detected earlier in infection at 4 hpi, it is expressed at highest levels in infected cells at 
6-7 hpi [372]. F13 has a similar temporal expression pattern to B5, with detectable expression 
from 4-6 hpi [376]. We were able to detect bright, imageable fluorescent signals in both B5R-
Dendra2 and F13L-Dendra2 at 7 hpi. Although we had concerns that the slower Dendra2 
maturation rate (compared to EGFP) would limit our analysis of IEV egress, active wrapping is 
occurring after 6 hpi [405, 406] and 7-9 hpi is therefore an appropriate time frame to monitor IEV 
wrapping and egress. Consistent with this, studies reporting on movements of IEV utilising F13L-
GFP and B5R-GFP fusion viruses have also performed imaging at 7-8 hpi, although imaging has 
also been performed much later in infection (~24h) [263, 282, 284, 374]. 
Other uses of photoactivatable fluorescent proteins in viral contexts have included tracking HIV-1 
Pr55-Gag, the precusor for all structural determinants for HIV-1 particle formation, tagged with 
PA-GFP [407] and tracking NS5A, a key protein in the replication of Hepatitis C RNA replication, 
also tagged with PA-GFP [408]. These studies have aimed to monitor the motility of proteins over 
the course of viral assembly/replication, rather than using the photoactivatable fluorescent protein 
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fusions as markers of individual virus particles, to analyse the subcellular transport 
mechanisms/egress of particles as we have done. 
Lastly, as a combination of viral infection and imaging places a large amount of strain on cells, it 
is important to mention that a large amount of optimisation of the photoactivation protocol 
detailed in this thesis was to create optimal conditions where cells could be imaged for substantial 
periods of time without cell death.  
Phototoxicity is a significant concern in live cell confocal imaging and is largely due to light-
induced generation of reactive oxygen species (ROS) leading to oxidative damage of DNA, lipids 
and proteins [409-411]. While UV light (290-380 nm) is the most lethal, exposure of cultured cells 
to visible light in the violet range (400-450 nm), such as the wavelength of light used to 
photoactivate both PSCFP2 and Dendra2, has also been shown to induce mutations and cause cell 
death [410, 412, 413]. The damage of high intensity 405 nm light would be exponentially higher if 
utilised for visualisation of the fluorescent signal in addition to photoactivation (where only a 
small portion of the cell is exposed for 405 nm light for 100 ms). The lower amount of 
phototoxicity-related damage generated in the cells being imaged is therefore another advantage of 
tracking Dendra2 fusion viruses over PSCFP2 fusion viruses. 
VACV infections, even of non-fluorescent viruses, induces an apoptotic response in cells [414-
416], and combined with exposure to high intensity 405 nm light during photoactivation, the 
infected cells can exhibit rounding-up and detachment from the surface, obfuscating imaging 
analysis. To prevent this, cells must be well maintained (with regular passaging and discarding 
after reaching high passage numbers) and allowed to settle on the glass of the Ibidi µ-dish for 24 h 
before they are infected. Fibronectin coating of Ibidi dishes also proved critical to the successful 
imaging of Dendra2 tagged viruses. Fibronectin is a ~440 kDa glycoprotein of the extracellular 
matrix that binds to integral membrane proteins called integrins as well as extracellular matrix 
components such as collagen, fibrin, and heparan sulfate proteoglycans [417, 418]. In cell culture 
contexts, it aids in the adherence of cells to non-biological surfaces such as glass [417, 418]. 
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CHAPTER 4: Characterising the 
Transport Dynamics of Various 
Morphological Forms of Vaccinia 
Virus 
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4.1 INTRODUCTION 
All of the data represented in this chapter was generated and analysed by H. Lynn. 
4.1.1 Key viral mediators of intracellular transport 
VACV replication is a complex process involving two intracellular compartments, the VF where 
IMV are generated and the TGN where a subset of IMVs are wrapped by two lipid membranes to 
become IEV. The transport of particles from the VF to the IMV is microtubule-based transport 
step and is believed to be regulated by viral protein A27 [163], although this has been disputed 
[280].  
A second microtubule-based egress step occurs to transport IEV to the cell periphery, where the 
outer most membrane fuses with the plasma membrane to CEV. These may stimulate actin-based 
motility that generates a propulsive force to push CEV into the extracellular space, where they 
become extracellular (EEV). Two mechanisms, one involving the viral protein A36 [282-286], and 
another involving a complex of the viral proteins F12 and E2 [283, 303] have been demonstrated 
to play critical roles in the egress and/or release of membrane wrapped forms of VACV [Section 
1.3.1.3-1.3.1.4]. 
We use the novel viral imaging system optimised in Chapter 3 to analyse the transport dynamics of 
Dendra2-fusion viruses in different mutant backgrounds to dissect the relative contribution of A36 
and F12 to the process of IEV egress.  
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4.2 RESULTS 
4.2.1 B5R-Dendra2/∆F12L and F13L-Dendra2/∆A36R display small plaque phenotypes 
consistent with transport defects 
Having validated the correct expression and photoconversion of IEV-protein tagged viruses B5R-
Dendra2 and F13L-Dendra2, we introduced deletions of virus transport proteins F12 and A36 to 
analyse the contribution of these proteins to the dynamics of IEV wrapping and egress. Co-
infections with B5R-Dendra2 and ∆F12L [303], and F13L-Dendra2 and ∆A36R [215] were 
performed [Section 2.3.1.4]. As recombinant viruses with A36R and F12L deletions have 
described defects in subcellular transport and a parallel reduction in plaque size [215, 316], 
resulting double recombinants were expected to produce small plaques with Dendra2 fluorescence. 
Appropriate plaques with expected fluorescence properties were selected from doubly infected cell 
lysates and purified by three rounds of plaque purification.  
To confirm that the small plaque phenotype was due to the incorporation of the deletion mutant 
allele rather than another mutation, we examined B5R-Dendra2/∆F12L and F13L-
Dendra2/ΔA36R by immunofluorescence for the hallmarks of microtubule- and actin-based 
transport [Figure 4.1]. Both B5R-Dendra2/∆F12L and F13L-Dendra2/ΔA36R viruses had a 
reduction in the appearance of EEV, and those that reached the cell surface were confined to 
central regions of the cell where the trans-Golgi network lies in close proximity to the plasma 
membrane [Figure 4.1]. Furthermore, we observed that while virus particles that did reach the cell 
surface in B5R-Dendra2/∆F12L were able to produce actin tails, this was not the case for F13L-
Dendra2/ΔA36R [Figure 4.1]. These results are consistent with ∆F12L and ∆A36R, indicating 
that the B5R-Dendra2/∆F12L and F13L-Dendra2/ΔA36R plaque phenotypes during purification 
were due to the successful recombination of these deletions.  
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Figure 4.1:  Subcellular localisation of mutant viruses 
HeLa cells were infected with B5R-Dendra2/∆F12L and F13L-Dendra2/∆A36R before being fixed and 
stained for immunofluorescence assays. Non-permeablised cells (NP) were stained with α-B5 (blue) 
(which will indicate CEV that have reached the surface of the cell) before being permeablised and stained 
with AlexaPhalloidin (red); Dendra2 fusions are seen in green. Insets are of a CEV with colocalisation of 
Dendra2 signal and the α-B5 antibody. B5R-Dendra2/∆F12L retains actin-based motility and an actin tail 
can be seen associated with the CEV. Scale bar represents 10µm. 
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4.2.2 B5R-Dendra2/∆F12L and F13L-Dendra2/∆A36R disperse from the TGN at a reduced 
rate and are not transported as far as parental strains 
To characterise the dynamics of IEV transport out of the TGN, a series of live cell imaging 
experiments were carried out with B5R-Dendra2, B5R-Dendra2/∆F12L, F13L-Dendra2 and F13L-
Dendra2/∆A36R. HeLa seeded onto fibronectin coated No. 1.5 glass µ-Dishes (Ibidi) were 
infected with the appropriate virus and then imaged on an Olympus FV1000 confocal microscope 
at 7 to 9.5 hours post infection. Infected cells were imaged sequentially with a 488 nm laser and 
559 nm laser with 4.0 pixel/sec scan speed to obtain pre-activation images. A 40 x 40 pixel ROI 
over the region of the cell with the brightest 488 nm (Dendra2) emission was selected for 
photoconversion. The ROI was activated with 3% of the 405 nm SIM laser under “Tornado” 
setting for 100 ms at a scan speed of 100 µs/pixel.  
At 15 min and 30 min post activation, a Z-stack of the photoactivated cell (with step size 
determined by automated optimisation) from the basal to apical surface was collected with 488 nm 
and 559 nm lasers to image both non-photoconverted and photoconverted signal. Z-stacks had 
between 7-14 slices, depending on the thickness of the cell being imaged. A digital projection of 
all Z-slices was created to allow the visualisation of the entirety of the fluorescent signal in an 
infected cell with a single 2D image [Figure 4.2].  
Individual virus particles clearly resolved in the Z-projection as dispersed from the TGN were 
marked in ImageJ and counted manually. As each frame of the Z-stack took approximately 2 
seconds to image, it is possible that particles were being transported on microtubules or actin tails 
between different z slices over the course of imaging. Therefore, particles that were present in <2 
µm distance from each other in a linear trajectory over 3 slices were determined to be particles 
being transported or drifting across the z-axis (through movement of the cell etc.) and were only 
marked/counted once. Data from 17 to 26 cells per virus from three replicates (using the same 
viral stock to infect a new well of cells) carried out over three separate days were pooled and 
analysed [Figure 4.3A].  
A mean of 31.1 ± 3.92 particles were transported out of the TGN at 15 min post-activation for 
cells infected with B5R-Dendra2, 15.1 ± 1.47 for B5R-Dendra2/∆F12L, 33.0 ± 2.70 for F13L-
Dendra2 and 13.0 ± 1.44 for F13L-Dendra2/∆A36R [Figure 4.3A]. For all viruses, the large bulk 
of virus dispersal from the TGN occurs in the first 15 min post photoactivation, although there is a 
slight increase in the mean number of virus particles dispersed from the TGN at the 30 min time 
point compared to the 15 min timepoint. This increase was 8.17 particles for B5R-Dendra2, 0.612 
for B5R-Dendra2/∆F12L, 0.810 for F13L-Dendra2 and 3.73 for F13L-Dendra2/∆A36R. This 
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indicates that more transport out of the TGN is occurring between 15-30 min post-activation and 
while this increase is apparently substantial for B5R-Dendra2 and F13L-Dendra2/∆A36R, none of 
the increases were statistically significant.  
Comparisons in the number of particles dispersed in different virus infections showed that as 
expected, both mutations led to dramatic reductions relative to their parental strains. B5R-
Dendra2/∆F12L showed a mean reduction of 16.0 virus particles from B5R-Dendra2 at 15 min 
post-activation (p < 0.0001) and 23.6 at 30 min post-activation (p < 0.0001). A similar reduction 
was seen between F13L-Dendra2/∆A36R and F13L-Dendra2, with a 20.0 difference at 15 min (p 
< 0.0001) and 17.0 difference at 30 min post-activation (p < 0.0001).  
A qualitative indication of the longer-term effects of this restricted dispersal can be seen in the 
density of Dendra2 signal in the TGN even prior to photoactivation [Figure 4.4]. Both mutants 
have a higher density signal in the TGN than their parental strain, although the difference is 
particularly apparent between F13L-Dendra2 and F13L-Dendra2/∆A36R. This higher density of 
signal is likely due to the accumulation of virus particles unable to be transported out of the 
compartment. It is important to note that although these trends in signal density were generally 
observed and imaging settings were consistent between viruses and cells, we were unable to 
quantify this observation from our collected data. Our imaging settings were determined by clear 
resolution of individual virus particles and due to the extremely high relative intensity of signal at 
the TGN, the dynamic range of pixels of the image was saturated at the TGN. 
To further elucidate differences between our parental and mutant strains, we performed a second 
set of analyses on these same image series measuring the distance travelled by virus particles. The 
distance between the virus particle and the TGN was measured in ImageJ as the linear distance in 
the X-Y axis from the closest edge of the TGN. We did not account for distance travelled in the Z-
axis for two reasons; firstly, the Z-axis stretching/distortion typical of imaging on confocal 
systems makes accurate measurements along the Z-axis extremely difficult, secondly, the HeLa 
cells used in these experiments are thin, with cells approximately 10 µm deep while they span 
between 50 – 100 µm at their widest point, restricting dispersal predominantly to the X-Y axis. 
The distance travelled by all virus particles (between 5 – 48 particles per cell) in six cells of each 
virus infection (two cells chosen randomly from each of the three replicates) were pooled [Figure 
4.3B]. 
B5R-Dendra2 particles were transported a mean distance of 15.3 ± 0.775 µm from the TGN at 
15min post-activation, B5R-Dendra2/∆F12L were transported 4.68 ± 0.378 µm, F13L-Dendra2 
were transported 11.7 ± 0.647 µm and F13L-Dendra2/∆A36R were transported 6.02 ± 0.412 µm 
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[Figure 4.3B]. Similarly to the result observed for number of particles dispersed out of the TGN, 
the majority of the assayed measurement had already occurred by the 15 min post-activation time 
point, although there is a slight increase in the mean of distance dispersed at the 30 min time point 
compared to the 15 min timepoint. This increase was 1.44 µm for B5R-Dendra2, 0.561 µm for 
B5R-Dendra2/∆F12L, 1.07 µm for F13L-Dendra2 and 0.747 µm for F13L-Dendra2/∆A36R. This 
indicates that particles were transported further in the cytoplasm during the 15-30 min post-
activation timeframe than had occured in the first 15 min. While this increase is consistent over all 
viruses, none of the increases were statistically significant.  
Comparisons in the distances particles were transported in different virus infections showed that as 
expected, both mutations led to dramatic reductions relative to their parental strains, mirroring the 
trends observed in the number of particles dispersed [Figure 4.3A]. B5R-Dendra2/∆F12L was 
transported a mean distance of 10.7 µm less than B5R-Dendra2 at 15 min post-activation (p < 
0.0001) and 11.5 µm less at 30 min post-activation (p < 0.0001). A similar result is seen when 
comparing F13L-Dendra2/∆A36R and F13L-Dendra2, with F13L-Dendra2/∆A36R being 
transported a mean distance of 5.68 µm less than F13L-Dendra2 at 15 min post-activation (p < 
0.0001) and 5.99 µm less at 30 min post-activation (p < 0.0001) [Figure 4.3B].  
Comparisons between number of particles dispersed in different virus infections showed no 
significant difference between B5R-Dendra2 and F13L-Dendra2 at either time point (p = 0.6865 
and p = 0.2897) [Figure 4.3A], indicating that defects as seen in the plaque size attenuation of the 
B5R-Dendra2 fusion [Figure 3.12] may not be clearly apparent in the first round of replication as 
measured at this timeframe (7-9.5h post-infection). However, there was a significant difference 
between the distance travelled by B5R-Dendra2 and F13L-Dendra2 particles at both 15 min (p = 
0.0004) and 30 min (p = 0.0001), with B5R-Dendra2 particles being transported further from the 
edge of the TGN than F13L-Dendra2 particles [Figure 4.3B]. 
This difference also allows us to contextualise a comparison between the distance travelled by 
particles of B5R-Dendra2/∆F12L and F13L-Dendra2/∆A36R even though they have different 
parental backgrounds. While the parental strain F13L-Dendra particles were transported less far 
than B5R-Dendra, F13L-Dendra2/∆A36R particles are transported further than B5R-
Dendra2/∆F12L, with a mean difference of 1.34 µm at 15 min post-activation (p = 0.0195) and 
1.53 µm at 30 min post-activation (p = 0.0163) [Figure 4.3B]. This indicates that the deletions are 
having an affect on transport beyond the transport impacts of the Dendra2 fusions. 
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Figure 4.2:  Transport of IEV out of the trans-Golgi network 
HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with (A) B5R-Dendra2 and B5R-
Dendra2/∆F12L, (B) F13L-Dendra2 and F13L-Dendra2/∆A36R. The trans-Golgi network was located by 
the visualisation of the Dendra2 signal with 488 nm laser excitation on an Olympus FV1000 confocal 
microscope and activated at the indicated region of interest (circle). At 30min post activation, a z-stack 
was collected with 488 nm and 559 nm laser lines and the projection of all slices generated. Examples of 
particles migrated out of the region of interest are indicated with arrows.  
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Figure 4.3:  Dynamics and characteristics of IEV transport 
HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with B5R-Dendra2, B5R-
Dendra2/∆F12L, F13L-Dendra2 and F13L-Dendra2/∆A36R. The trans-Golgi network was activated and a 
z-stack was collected with 488 nm and 559 nm laser lines at 15 and 30 min post activation. (A) Particles 
migrated out of the TGN were counted (n=18 cells, pooled from at least 3 replicates performed with the 
same stock in different wells) or (B) the distance migrated from the edge of photoactivated region was 
measured for all virus particles in cells analysed in (A) (6 cells for each condition, two randomly selected 
in each of the three replicates). Virus particles per cell ranged from n=5 to n=48, depending on the virus. 
ns: P > 0.05, *: P ≤ 0.05, **: P ≤ 0.01, ***: P ≤ 0.001, ****: P ≤ 0.0001. 
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Figure 4.4:  Density of Dendra2 signal at trans-Golgi Network 
HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with B5R-Dendra2, B5R-
Dendra2/∆F12L, F13L-Dendra2 and F13L-Dendra2/∆A36R. Cells were imaged with a 488 nm laser line. 
Three replicate cells are depicted horizontally. Scale bar is 10 µm. 
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4.2.3 IEV do not undergo substantial intracompartment transport in the TGN 
Having addressed questions of the wrapping and dispersal of IEV from the TGN, we went on to 
investigate the internal organisation of the compartment. HeLa seeded onto fibronectin coated No. 
1.5 glass µ-Dishes (Ibidi) were infected with F13L-Dendra2 and then imaged on an Olympus 
FV1000 confocal microscope at 7 to 9.5 hours post infection. Infected cells were imaged 
sequentially with a 488 nm laser and 559 nm laser with 4.0 pixel/sec scan speed to obtain pre-
activation images. A 40 x 40 pixel region of interest (ROI) over approximately half of the TGN 
was selected for photoconversion. The ROI was activated with 3% of the 405 nm SIM laser under 
“Tornado” setting for 100 ms at a scan speed of 100 µs/pixel.  
At 15 min and 30 min post activation, a Z-stack of the photoactivated cell (with step size 
determined by automated optimisation) from the basal to apical surface was collected with 488 nm 
and 559 nm lasers to image both non-photoconverted and photoconverted signal. A digital 
projection of all Z-slices was created to allow the visualisation of the entirety of the fluorescent 
signal in an infected cell with a single 2D image [Figure 4.5A].  
In 32% of cells, attempted activation of half of the TGN was unsuccessful and resulted in 
activation of more than two thirds of the compartment [data not shown]. We believed this was due 
to the orientation of the TGN in the 3D space of the cell. Half-compartment ROI selection and 
photoactivation was performed with XY scanning, as Z-stacks are too time consuming to allow 
effective monitoring of the moment of photoconversion. The TGN however spans multiple 
depths/Z-slices of the cell and photoactivation occurs in a tube of light through all depths of the 
sample and photoactivation performed in XY scanning only can therefore potentially activate 
substantially more of the TGN than intended.  
Of the cells where close to 50% of the compartment was successfully activated, we measured the 
angle of dispersed particles relative to the center of the TGN. Particles that dispersed to the 
cytoplasm on the same side of the cell as the activated half of the TGN had readings from 0o to 
180o and particles dispersed to the opposite side had readings from 0o to -180o. A schematic of 7 
randomly chosen particles in 3 cells is depicted in Figure 4.5B. The angle of dispersal was 
measured for all photoactivated virus particles in 12 cells (4 cells each from 3 replicates) and 
revealed that 78% of virus particles disperse to the same side of the cell as the photoactivated half 
of the TGN [Figure 4.5C]. This indicates that the relative position to MTOC strongly affects the 
directionality of trafficking of IEV. We also observed that there was no substantial intra-
compartmental movement of photoactivated signal between the two halves of the TGN at either 
the 15min or 30min time frames. 
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Figure 4.5:  Directionality of photoactivated virus particles from half of the TGN 
HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with F13L-Dendra2. (A) The trans-
Golgi network was located by the visualisation of the Dendra2 signal with 488 nm laser excitation on an 
Olympus FV1000 confocal microscope and then approximately half of the compartment was activated at 
the indicated region of interest (circle). At 30 min post activation, a z-stack was collected with 488 nm and 
559 nm laser lines and the projection of all slices generated. Examples of particles migrated out of the 
region of interest are indicated with arrows. (B) A schematic representation of the resultant egress of 
particles from the activated half of the trans-Golgi network (represented in dark grey) from three cells (n=7 
particles per cell) at 30min post activation with particles from each individual cell coloured green, blue and 
red. (C) The directionality of egressed particles from the region of interest was measured (n=12 cells with 
n=10 particles pooled from at least 3 replicates). Scale bar is 10 µm. 
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4.2.4 Dendra2-A3L/B5R-CFP allows differentiation between the VF and TGN 
As previously mentioned, as a core protein, Dendra2-A3L fusions will label all morphological 
forms of the virus and both the VF and TGN will have a strong fluorescent signal. To differentiate 
between the VF and TGN, a second fluorescent tag (ECFP) was introduced to recombinant viruses 
as a fusion with IEV protein B5 [Figure 3.12D]. This would lead to VF exhibiting Dendra2 
fluorescence, while the TGN would be positive for both Dendra2 and ECFP fluorescence. To 
confirm that the two compartments could be clearly differentiated, we performed live-cell imaging 
of the virus. HeLa seeded onto fibronectin coated No. 1.5 glass µ-Dishes (Ibidi) were infected with 
Dendra2-A3L/B5R-CFP and then imaged on an Olympus FV1000 confocal microscope at 7-9 hpi. 
Infected cells were imaged with a 458 nm laser to detect ECFP fluorescence and a 488 nm laser to 
detect Dendra2 fluorescence [Figure 4.6]. 
In most cells observed, both compartments were visible in both the 458 and 488 nm channels, 
although the ratio of fluorescent signal of the two channels enabled us to differentiate the VF 
indicated with the asterisk (lower 458 nm signal to a higher 488 nm signal) from the TGN 
indicated with the hash (higher 458 nm signal to lower 488 nm signal) [Figure 4.6]. The detection 
of both compartments in the 488 nm channel is a result of the replicative cycle of VACV; A3-
positive IMV are transported from the VF to the TGN for wrapping where they accumulate to a 
degree before disseminating into the cytoplasm. The detection of both compartments in the 458 
nm channel on the other hand is due to the substantial spectral overlap of ECFP and Dendra2. The 
excitation range for ECFP is approximately 350 to 500 nm, with a 430 nm peak that drops to a 
negligible excitation at 480 nm [419]. Dendra2 has a pre-activation excitation spectrum that 
extends from approximately 400 to 530 nm with a peak at 488 nm [Figure 3.4C]. Excitation of 
ECFP at 458 nm will therefore excite both fluorophores, leading to the detection of both 
compartments in the 458 nm channel (although Dendra2 is excited suboptimally and appears 
relatively less bright than ECFP). There is no similar cross stimulation with the 488 nm laser, as 
this is beyond the functional excitation spectrum of ECFP. 
To confirm that we were able to clearly differentiate the two compartments even with the 
complicating factors, we performed imaging on the same infected cells with the 405 nm laser that 
excites ECFP with no excitation of Dendra2 [Figure 4.6]. As expected, a single compartment was 
detected with and verified our identification of the TGN as the compartment with a ratio of higher 
458 nm fluorescence relative to 488 nm fluorescence (marked with an asterisk). It was impractical 
to differentiate the VF from the TGN by utilising the 405 nm laser in our tracking experiments as 
405 nm excitation will lead to photoactivation of the Dendra2. 
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Figure 4.6:  Virus factory and trans-Golgi Network are easily distinguishable 
HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with Dendra2-A3L/B5R-CFP. Z-
stacks were collected with 405 nm, 458 nm and 488 nm laser excitation on an Olympus FV1000 confocal 
microscope from which projections were generated. Two representative cells are depicted vertically. The 
VF is marked with an adjacent asterisk and the TGN is marked with an adjacent hash. Scale bar is 10 µm. 
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Having verified our ability to differentiate the VF and TGN with 458 and 488 nm laser lines, we 
attempted to fate track IMV from the VF (either to the TGN for wrapping or directly into the 
cytoplasm). HeLa seeded onto fibronectin coated No. 1.5 glass µ-Dishes (Ibidi) were infected with 
Dendra2-A3L/B5R-CFP and then imaged on an Olympus FV1000 confocal microscope at 7-9 hpi. 
Infected cells were imaged with a 458 nm laser to detect ECFP fluorescence and then sequentially 
with a 488 nm laser and 559 nm laser with 4.0pixel/sec scan speed to obtain pre-activation images. 
A 40 x 40 pixel region of interest (ROI) over the VF was selected for photoconversion. The ROI 
was activated with 3% of the 405 nm SIM laser under “Tornado” setting for 100 ms at a scan 
speed of 100 µs/pixel.  
At 60 min post activation, a Z-stack of the photoactivated cell (with step size determined by 
automated optimisation) from the basal to apical surface was collected with 458nm, 488 nm and 
559 nm lasers to image the ECFP signal and both non-photoconverted and photoconverted 
Dendra2 signal. A digital projection of all Z-slices was created to allow the visualisation of the 
entirety of the fluorescent signal in an infected cell with a single 2D image [Figure 4.7]. Imaging 
at earlier time points (15 min and 30 min) post activation were also attempted, but did not reveal 
significant egress out of the VF, indicating that IMV morphogenesis occurs at a slower rate than 
wrapping to form IEV. We were able to track the transport of IMV to the TGN, with 
approximately 11 photoactivated particles present in the region of the representative cell with the 
TGN in the 60 min projection [Figure 4.7].  
Quantifying this process in a statistically significant way in the imaging window of 7 to 9 hpi 
proved difficult due to the close juxtaposition of the two compartments (with the VF often 
wrapping around the TGN to a certain degree in three dimensional space), which led to the off-
target photoactivation of particles in the TGN. Rare cells had distinctly isolated compartments, so 
while we did not achieve quantification in the scope of this thesis, it is possible with our 
photoactivation system. Similarly, it would also be possible to differentiate between the rate of 
transport into the TGN compared to the cytoplasm by scanning the 60 min postactivation 
projection with the 405 nm laser to differentiate which of the dispersed particles were IMV or 
IEV. 
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Figure 4.7:  Egress of particles from virus factory 
HeLa cells seeded onto fibronectin coated Ibidi dishes were infected with Dendra2-A3L/B5R-CFP. The 
virus factory was located by the visualisation of the Dendra2-A3L signal with 488 nm laser excitation and 
exclusion of the TGN-localised Dendra2 signal by concurrently visualising the B5R-CFP signal with 458 
nm laser excitation. The virus factory was activated at the indicated region of interest (circle). The TGN is 
indicated with the asterisk. At 60 min post activation, a z-stack was collected with 458 nm, 488 nm and 
559 nm laser lines and the projection of all slices generated. Scale bar is 10 µm.  
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4.3 DISCUSSION 
B5R-Dendra2 and F13L-Dendra2 produced significantly different plaque sizes, with B5R-Dendra 
appearing to have some degree of attenuation compared to F13L-Dendra2 and WR [Figure 3.11], 
confirming previous reports that indicated F13L fusions are a more ideal IEV/WV tag than B5R 
fusions [284]. We made multiple attempts to generate a ∆F12L mutant in the parental F13L-
Dendra2 strain. However, due to the attenuation of the ∆F12L strain combined with the fact that 
the two genes F12L and F13L are adjacent, relatively rapid methods of generating double 
recombinants through coinfections [Section 2.4.1.3] were not possible. Creation of this virus was 
therefore not achieved in the timeframe of this study. This being said, the differences between 
B5R-Dendra2 and F13L-Dendra2 were variable in our imaging experiments; there was no 
significant difference observed between the number of virus particles dispersed from the TGN in 
the course of imaging (at both 15min and 30min timepoints) [Figure 4.3A]. B5R-Dendra2 did 
display further dispersal from the TGN than F13L-Dendra2, 15.3 ± 0.775 µm and 11.7 ± 0.647 
µm, respectively at 15 min (p = 0.0088) and 16.8 ± 0.733 µm and 12.8 ± 0.671 µm respectively at 
30 min (p = 0.0047) [Figure 4.3B]. 
Altering the functioning of many diverse infection processes will affect the ability of the virus to 
undergo efficient cell-to-cell spread and therefore the plaque size of VACV. Deletion and mutation 
studies of proteins that play key roles in IMV production, wrapping [272, 280, 325, 379], 
microtubule-based egress [215, 289], actin-based propulsion into neighboring cells [292], and the 
repulsion of super infecting virions [215, 299] all cause small plaque phenotypes.  
In many cases, a single viral protein may have multiple functions in the replicative cycle and 
determining the cause of plaque size defects is difficult. B5 for instance plays roles in the 
wrapping of IEV, their subsequent egress and formation of EEV [272, 325], EEV release [420, 
421] and in the repulsion of super infecting virions [422]. Immunogold labeling electron 
microscopy of B5R-GFP fusion viruses indicate that C-terminal fusions of fluorescent proteins do 
not cause aberrant wrapping [374]. Although not a direct assay on wrapping, our observed egress 
of a similar number of IEV into the cytoplasm in both B5R-Dendra2 and F13L-Dendra2 suggest 
that potentially aberrant wrapping is not the most likely cause of the plaque defect in B5R-
Dendra2 [Figure 4.3A]. Furthermore, the longer average distance B5R-Dendra2 was transported 
through the cytoplasm indicates that the fusion does not cause deleterious effects to microtubule-
based egress of IEV particles. 
It is possible that B5R-Dendra2 fusions are causing defects in cell-to-cell spread due to effects 
later in the replicative cycle such as in EEV release. Formation of CEV in VACV involves the 
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fusion of the outer of two IEV membranes to the plasma membrane. B5 is believed to play roles in 
the tethering of CEV to the cell surface through protein interactions in its substantial luminal 
domain, as a P189S mutation has been shown to lead to dramatic increases in EEV release [420, 
421]. Although the mechanisms behind release of attachment of CEV to produce free EEV is 
incompletely understood, it has been hypothesised that the B5P189S mutation leads to weak luminal 
interactions that lead to decreased tethering of CEV to the cell [302]. Perhaps counterintuitively, 
increased EEV release in some cases led to smaller plaque sizes [421]. However, as Dendra2 is 
fused to the C-terminus of B5 rather than in the N-terminal luminal region, it is unlikely that there 
would be altered luminal interactions that would lead to plaque size defects. 
Repulsion of super infecting virions involves the blocking of viral entry into already infected cells 
through cell signalling pathways which enables super infecting virions to be directed toward 
neighboring uninfected cells and allows viral spread to occur beyond the rate of replication [299]. 
Similarly to the involvement of B5 in EEV release, the demonstrated role of B5 in the repulsion of 
superinfecting virions has also been shown to involve the luminal domain of B5, relying on the 
presence of the short consensus repeat (SCR) 4 [422]. Therefore, again, it is unclear that a C-
terminal fusion would affect this process, although the mechanism for repulsion of superinfecting 
virions is as of yet incompletely characterised. 
As mentioned, we did detect a significant difference in the distance virus particles were 
transported out of the IEV, however B5R-Dendra2 dispersed further than F13L-Dendra2, a 
transport phenotype that is inconsistent with the demonstrated smaller plaque size. Ultimately, the 
cause of the attenuation of cell-to-cell spread of the B5R-Dendra2 fusion virus remains unclear, 
although it is possible that the defect occurs later in the replication cycle or it is relatively mild and 
requires multiple cycles of replication and spread to present clearly.  
For all viruses, the large bulk of virus dispersal from the TGN occurs in the first 15min post 
photoactivation, with a slight increase in the mean of virus particle number dispersed from the 
TGN at the 30 min time point compared to the 15 min timepoint. While it may seem that this 
could be due to the rate of wrapping slowing over the course of infection, this is not what is 
represented in our data, which is a pooled aggregate from cells between 7 and 9 hpi. A potential 
explanation is that at any one point there is a pool of completely enveloped IEV ready to be 
transported out of the TGN into the cytoplasm, while a more gradual rate of wrapping of IEV 
occurs in the background. The movement out of the TGN captured in the 15 min series would 
therefore encompass the rate of transport of IEV out of the TGN with the slight increase of 
particles seen between 15 and 30 min time points indicating the more gradual rate caused by 
wrapping of IEV additional to the transport into the cytoplasm. It must also be considered that 
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while IEV are transported out of the TGN, EEV will also be lost to the extracellular space and no 
longer be detected in our post-activation Z-stacks, causing reductions in assayed number of 
particles transported out of the TGN. Imaging more time points sooner after postactivation, at 1, 5, 
10min would allow us to clarify and quantify these various contributing factors. 
For all viruses, there is still a strong photoconverted signal in the TGN at the end of imaging 
[Figure 4.4], indicating that there is a pool of matured Dendra2 fusion protein either in the 
membranes of the TGN in the process of wrapping the viruses or on wrapped viruses yet to be 
transported out. Although it is possible that there would never be complete turnover of the 
photoconverted signal out of the compartment, carrying the experiment at longer time frames 
would also provide us with important information on the virus life cycle. For instance, it might 
allow us to monitor the rate of complete wrapping and transport out of the compartment, and more 
clearly distinguish the effect of mutations on these processes. Such measurements would not be 
possible in FRAP experiments, which are clouded by the translation of new fusion protein and 
maturation of the already present fluorophore. 
As previously outlined [Section 1.3.1.3-1.3.1.4] both A36 and F12 (and E2, which complexes with 
F12) have been implicated it microtubule based transport, with deletion mutants displaying 
defective egress of IEV [282, 283, 285]. This deficiency in ∆A36 has been mapped to WD/WE 
motifs in A36 that bind to the TPR domains in the N-terminus of KLC2 and mediate interactions 
between IEV and kinesin-1 [286]. Unlike A36, F12/E2 are not intergral membrane proteins and 
have been shown to associate with A36, which may mediate their association with the virus [291, 
303, 304]. If however F12/E2 is acting through A36, perhaps in a regulatory role that stabilises the 
interaction between kinesin-1 and A36, that loss of F12/E2 leads to a stronger phenotype than loss 
of A36 cannot be explained.  
In an attempt to resolve this paradox, we quantified the number of virus particles egressing from 
the TGN, as well as the distance egressed particles travelled. Due to the mild attenuation of B5R-
Dendra2, comparisons between B5R-Dendra2/∆F12L and F13L-Dendra2/∆A36R must be 
analysed in the context of the slight differences between their parental strains. We demonstrated 
that the number of particles transported out of the TGN over a 15 or 30 min time point is not 
significantly different between the two parental strains B5R-Dendra2 and F13L-Dendra2 (p = 
0.6865 and p = 0.2897, respectively) and likewise that there were not significant differences 
between the two mutant viruses at either time point (p = 0.3264 and p = 0.6441) [Figure 4.3A].  
On the other hand, the distance IEV particles egressed into the cytoplasm was significantly 
different, with average distance dispersed 4.68 µm for B5R-Dendra2/∆F12L and 6.02 µm for 
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F13L-Dendra2/∆A36R at 15 min (p = 0.0195) [Figure 4.3B]. As a direct comparison between 
their two parental strains shows that B5R-Dendra2 particles disperse a significantly further 
distance from the edge of the TGN than F13L-Dendra2 particles, that B5R-Dendra2/∆F12L 
particles do not disperse as far as F13L-Dendra2/∆A36R virus particles appears to indicate that the 
two proteins have a different strength of effect in the run length of microtubule-based transport.  
It has been previously demonstrated that fewer CEV are formed in a ∆F12L background than a 
∆A36R background [283]. Our data reveals that this is due to IEV particles in a ∆F12L 
background having shorter run lengths in the cytoplasm than ∆A36, as opposed to having less IEV 
particles egressing from the TGN. This disparity is suggestive of a differential affinity/recruitment 
of ∆F12L and ∆A36R viral cargoes to microtubule motors. Many viruses, including PRV [124, 
423], HSV [180, 424] and HIV-1 [144] have been visualised undergoing saltatory bidirectional 
movement, even in an overall anterograde egress out of the cells. This bidirectionality may play 
roles in important processes such as navigating around physical blockades along particular 
microtubule paths [131, 182]. In HSV, this process involves the simultaneous binding of motors 
with opposing directionalities (kinesin-1 and dynein) that are regulated to achieve effective 
transport [134]. While it is possible that there is a similar process occurring in VACV egress, 
kinesin-1 at least appears to play a dominant role in the egress of VACV IEV and subsequent 
attenuation of ∆F12L and ∆A36R deletion mutants. 
It has been reported that ∆F12L and ∆E2 do not recruit kinesin-1 even in the presence of A36 
[290], but also that a A36WEWD/AAAA mutant (a microtubule-based transport defective mutant of 
A36 that does not effect actin-based motility) does not recruit kinesin-1 in the presence of F12 
[286]. These results were determined with cryoimmuno-electron microscopy (cryo-EM) and 
immunofluorescence microscopy (IFA) respectively, with antibodies raised against KLC2. The 
apparently contradictory results can be explained by the limitations of the techniques used; cryo-
EM gold labelling only sparsely labels epitopes on the viral surface and immunofluorescence-
based assays rely on targeted fluorescent signals exceeding baseline fluorescent noise. In either 
instance, it is possible that the respective deletions/mutation led to reductions of KLC recruitment 
and subsequently to the KLC signal falling below an assayable threshold, without total abrogation 
of viral interaction with kinesin-1.  
That both ∆F12L and ∆A36R mutants are able to egress into the cytoplasm indicates that both 
have the ability to undergo some degree of microtubule-based motility, indicating some functional 
redundancy between the two proteins. That either deletion mutant is able to undergo some 
microtubule-based motility is a finding that has been reported individually by other groups [283, 
285]; with a focus on defining a single viral protein (either F12 or A36) as being the critical 
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mediator of microtubule-based egress without significant acknowledgement of the complexity of 
viral interaction with kinesin-1. Until recently, A36 was the only viral protein demonstrated to 
directly interact with kinesin-1, as assayed by multiple means including Y2H, FRET and GST-
pulldowns [181, 286, 288]. However, it has now been established that there is also a direct 
interaction between the F12/E2 complex and kinesin-1, with HA-tagged F12 co-precipitating with 
KLC2 only in the presence of E2 [425]. 
As both viral proteins are able to interact with kinesin-1, the variable run length of deletion viruses 
may be due to the differential recruitment of KLC isoforms to the virus. While A36 displayed no 
preferential association with KLC1 or KLC2 [286], F12/E2 prefentially co-precipitated with KLC2 
over KLC1 [425]. Furthermore, it has been reported that siRNA mediated knockdown of KLC1 
led to slight increases in the efficiency of IEV transport and the resultant plaque size, with no such 
effect observed with KLC2 knockdown [425]. This implies that the specific KLC isoform that 
mediates the association of viral cargo to kinesin-1 has impacts on the dynamics of viral transport. 
In infections with a ∆F12L virus, A36 is still present to interact with both KLC1 and KLC2 
isoforms. In the reverse situation with a ∆A36R infection, only F12 is available to interact with 
kinesin-1 through KLC2; the lack of viral recruitment of KLC1 may increase the speed of 
transport dynamics and lead to longer run lengths [Figure 4.3B].  
The N-terminal domain of KLC associates with KHC, while the C-terminal domain contains a six 
tetratricopeptide repeat (TPR) motifs to mediate cargo binding [426]. The association of cargos 
through WD/WE motifs can induce conformational changes in the KLC TPR domain [60, 427]. 
Cargo-induced conformational changes may subsequently influence kinesin-1 motor activation, 
through relief of motor autoinhibition [62, 428].  
The current model of IEV egress is as follows: A36 associates with KLC with the TPR groove 
located at the N-terminal half of the TPR domain of KLC [286]. F12 has been demonstrated to 
bind to both A36 [429] and E2 [285], with E2 itself able to associate with the C-terminal TPR tail 
of KLC [425]. Deletion of either A36 or F12 (thereby preventing viral association of E2 bound 
KLC) limits viral association with the kinesin-1 motor, leading to strong attenuation, although IEV 
egress is not totally abrogated. The differential preferences for KLC isoforms might explain the 
changed dynamics and subsequent run lengths of the limited microtubule-based transport of 
∆A36R and ∆F12L.   
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CHAPTER 5: Subcellular Transport of 
Ectromelia Virus 
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5.1 INTRODUCTION 
The work detailed in this chapter has been published: H Lynn, J Horsington, LK 
Ter, S Han, YL Chew, RJ Diefenbach, M Way, G Chaudhri, G Karupiah, TP 
Newsome [2012]. Loss of Cytoskeletal Transport during Egress Critically Attenuates 
Ectromelia Virus Infection In Vivo. Journal of Virology. 86(13), 7427-7443. The 
deletion virus was generated by S. Han. Figure 5.6 panels A and B were generated by 
J. Horsington. H. Lynn carried out all other data generation and analysis.  
5.1.1 Ectromelia virus 
Ectromelia virus (ECTV), a member of the orthopoxvirus genus of Poxviridae, is the causative 
agent of mousepox. It was first isolated from infected laboratory mice in 1930 and this strain 
subsequently named the Hampstead strain [430]. Although the virus is predominantly identified in 
laboratory mouse populations, ECTV is also able to infect wild mice [431]. While some 
poxviruses such as VACV and monkeypox have a broad host range and can cause disease in many 
animal species, others including VARV and ECTV are very host specific [432]. ECTV is only able 
to cause disease in mice, with very large doses of virus required to cause subclinical infections in 
other animals including rats and rabbits [433]. 
After the initial isolation of the Hampstead strain, a variety of others were isolated and 
characterised, including Moscow (Mos), Naval, Ishibashi and NIH-79. Of these, Mos is the most 
commonly used laboratory strain, being both highly virulent and infectious [433, 434]. Depending 
on the route of inoculation and the mouse strain inoculated [Section 6.1.2.2], an extremely small 
amount of virus, between 0.3 – 4 plaque forming units (pfu) per ml are required to cause mortality 
in 50% of the infected population (referred to as the median lethal dose, LD50) within 
approximately 10 days [433, 435]. This high infectivity and virulence (as well as making mouse 
infection with ECTV Mos a pertinent disease model for smallpox [435] [Section 6.1.3]) has many 
experimental benefits, including the ease of inoculations and the ability to monitor disease 
progression to mortality within relatively short time frames. 
The ECTV Mos genome has been sequenced and collated at The Viral Bioinformatics Resource 
Centre (http://athena.bioc.uvic.ca/). It is approximately 208 kb and encodes for 177 genes ([436], 
http://www.poxvirus.org/). There is very little genetic variance between different strains of ECTV, 
with ECTV Mos and ECTV Nav sharing 99.5% sequence identity [436]. Broadly, species across 
the orthopoxvirus genus share a large degree of genetic similarity, with the highly conserved 
central 100 kb of orthopoxvirus genomes displaying 90% sequence identity between all species 
[230]. At the more variable terminal regions of the genome, 12 out of 100 genes (including 
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previously mentioned IEV proteins A56R and B5R) are present in all species. Phylogenetic 
analyses of these genes show low genetic distances of 0.0150–0.0354, with readings closer to 0 
indicating more genetic similarity [230]. 
There is a wealth of knowledge on the pathogenesis of ECTV and the murine immune response to 
infection [Section 6.1.2.3]. Despite this, there is surprisingly little known regarding the cell 
biology of infection, with research until now focusing primarily on viral subversion of the immune 
system [437-439], the ubiquitin proteosome system [440, 441] and viral mediated syncytia 
formation [442]. 
While the replication cycle of ECTV has not yet been characterised, as with other orthopoxviruses, 
it has been presumed to follow that of the prototypal poxvirus VACV, due to aforementioned 
genomic similarity, as well as structural similarities between members of the genus. Structurally, 
ECTV virions are indistinguishable from other poxviruses by electron microscopy [433].  
Preliminary studies on ECTV interaction with the actin cytoskeleton have been carried out [443, 
444] [442] primarily in an attempt to identify actin-based motility as seen in other poxviruses 
VACV, MPXV and VARV [192, 264]. While it appears that actin-based motility is occurring, this 
has not been demonstrated definitively, nor has the mechanism and responsible ORF(s) been 
identified. Microtubule-based transport on the other hand has not been investigated, even 
phenotypically. We therefore aimed to elucidate mechanisms of viral mediation of subcellular 
transport, including interactions with the microtubule and actin cytoskeleton. This knowledge also 
provides us with a foundational framework to dissect the role of subcellular transport in animal 
model, which is investigated and discussed in Chapter 6.  
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5.2 RESULTS 
5.2.1 Virus particles undergo microtubule-based transport during ECTV infection 
Orthopoxvirus infection results in the formation of highly compartmentalised replication centres 
during productive infection. These replication centres can be identified using a combination of 
histological markers and stains. For example, the virus factory is positive for DNA stains such as 
DAPI and viral markers including p14 (A27) [163] but negative for IEV/EEV/CEV markers A36, 
A33, A34 and B5, which localise to the trans-Golgi network where IMV are wrapped to form IEV 
[191, 281].  
Using a combination of stains and antibodies specific to VACV proteins found to cross-react with 
their ECTV homologues, we analysed BSC-1 cells infected with ECTV Mos at various time points 
post-infection. We looked for early hallmarks of viral replication, specifically the generation of the 
virus factory. The virus factory in poxviruses initially appears as a series of punctate sites in the 
perinuclear region that exclude host proteins and are surrounded by rough endoplasmic reticulum 
(RER). As viral crescents begin to form, the RER dissociates and a large compartment of low 
electron density (by electron microscopy) forms with the concurrent accumulation of viral DNA 
[249, 250, 445]. 
Using DAPI staining, we identified DNA positive virus replication sites with a characteristic 
punctate appearance and distribution through the cytoplasm early in infection that coalesced into a 
singular, more diffusely stained structure identified approximately 4-8 hours post infection (hpi). 
This was delayed comparatively to cells infected with VACV WR, where virus factories had 
formed in 20% of cells at 2 hpi [Figure 5.1A]. B5 expression was initiated at approximately the 
same time and was generally concentrated to a structure localised adjacent to the nucleus that may 
be a collapsed trans-Golgi network or early endosome [data not shown and Figure 5.3B]. 
Overall, ECTV infection closely resembles VACV infection, albeit slower by approximately 1.5-
fold. 
The perinuclear localisation of B5 expression indicates that ECTV IEV face a similar transport 
step for their delivery to the cell periphery. In VACV, this transport step is dependent on 
microtubule-based transport and we therefore tested whether the appearance of CEV/EEV required 
an intact microtubule cytoskeleton. With the exception of a few key proteins A33, A34 and A56 
[Figure 1.10], CEV/EEV have identical viral markers as IEV, including B5. As previously 
mentioned, CEV/EEV are differentiated from IEV in immunofluorescence assays by applying α-
B5 antibodies to cells that have not been permeabilised. As antibodies are too large to diffuse 
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through intact cell membranes, only IEV that have reached the cell periphery and fused with the 
cell membrane to become CEV/EEV will be detected. 
HeLa cells infected with ECTV produce large numbers of CEV/EEV 24 hpi [Figure 5.1B]. 
Treatment of cells with nocodazole, an agent that interferes with microtubule polymerisation and 
therefore disrupts microtubule-based transport, drastically reduced the appearance of CEV/EEV at 
the cell surface [Figure 5.1B]. Nocodazole was applied to infected cells at 8 hpi, chosen to 
correlate to our approximate observed IEV formation time frame. This nocodazole treatment 
therefore would not disrupt post-entry transport of incoming virus particles and formation of the 
virus factory that in VACV is also microtubule dependent [248], while preceding transport of IEV 
to the cell periphery. Washout of nocodazole allows microtubules to repolymerise thus restoring 
microtubule-based transport. Following washout of nocodazole, the appearance of CEV/EEV was 
restored [Figure 5.1B]. This confirms that similar to VACV replication, ECTV requires 
microtubule transport [263, 284, 287, 374]. 
In VACV, the molecular motor that mediates this microtubule-dependant transport is kinesin-1 
[Section 1.1.3.2, 1.3.1] [181, 282, 286]. We therefore conducted immunofluorescence assays with 
a α-KHC antibody and colocalised the kinesin-1 heavy chain of the kinesin-1 motor complex to α-
B5 labelled IEV particles [Figure 5.1C]. These B5-positive particles are IEV rather than non-virus 
vesicular B5 expression as they colocalise with a DAPI signal. IMV that stain positive for the 
DNA genome with DAPI while lacking a B5-positive membrane do not colocalise with the α-
KHC signal, suggesting that it is an IEV specific protein or proteins recruiting kinesin-1. This 
suggests that the mechanism of microtubule transport is also conserved between ECTV and 
VACV [181, 282, 286, 290].  
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Figure 5.1:  ECTV utilises microtubules for egress 
(A) BSC-1 cells were infected with ECTV or VACV at MOI 1 and fixed at the indicated time points. Cells were 
stained with DAPI and assessed for the presence of a virus factory (n=50 per timepoint, in duplicate). The 
percentage of virus factory containing cells was calculated. Error bars indicate standard error. (B) HeLa cells 
were infected with ECTV and at 8 hpi 33 µM nocodazole was added to wells and either fixed 16 h later or 
washed three times in cell growth medium as a nocodazole wash-out control. Wash-out controls were allowed 
to incubate for an additional 24 h post wash-out before being fixed. Non-permeabilised cells (NPC) were 
stained for immunofluorescence assays with α-B5 (green) and DAPI (blue). The dotted line indicates the cell 
periphery, as determined by phase contrast microscopy. (C) HeLa cells infected ECTV, fixed and probed with 
α-B5 (red), KHC antisera (green) and DAPI (blue). Arrowheads indicate CEV. Asterisk indicates a B5-
positive, DNA-negative particle, likely to be non-viral localisation of B5. Scale bars represent 10 µm. 
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5.2.2 Actin-based transport is active during ECTV infection 
Having determined that an intact microtubule network is required during ECTV infection, we next 
investigated actin-based motility. Although it has been previously reported that ECTV stimulates 
actin polymerisation under virus particles [443], the mechanism involved in this process has not 
been well characterised.  
Our first step towards this goal was to carry out immunofluorescence assays (IFA) of ECTV-
infected cells of a variety of cell lines, including two murine lines; NIH3T3 and Mouse Embryonic 
Fibroblasts (MEFs). Virus-induced actin tails can be visualised by simultaneously labelling the 
virus particle and F-actin; they can be distinguished from other cellular F-actin structures as virus 
particles colocalise with the top of the actin tail and the tails characteristically taper at their tail end 
as F-actin depolymerises.  
CEV were labelled with α-B5 in non-permeablised cells, followed by permeablisation and staining 
with either phalloidin, a phallotoxin that binds to F-actin, or an antibody targeted against cortactin 
a cellular protein that has weak actin nucleating activity in vitro but is best described as an actin 
bundling protein [446, 447]. No requirement for cortactin has been identified in VACV, but it has 
established roles in many processes including cell migration, invasion and endocytosis [448]. It is 
present in the cortical actin cytoskeleton but also localises to regions of active Arp2/3 complex F-
actin nucleation. 
We observed robust induction of typical orthopoxvirus-induced actin-based motility in all cell 
types examined with multiple visualisation techniques [Figure 5.2]. While we noticed distinct 
morphological differences between ECTV and VACV tails, we initially analysed the onset of actin 
tail formation in ECTV compared to VACV. A time course of actin tail formation revealed that 
tails were present in approximately 65% of ECTV-infected BSC-1 cells at 16 hpi and 100% at 24 
hpi [Figure 5.3A]. In comparison, 50% of cells infected with VACV showed actin tails at 8 hpi, 
with 100% at 16 hpi. This approximately 1.5-fold delay in actin tail formation is consistent with 
the slower ECTV replication cycle as previously observed [Section 5.3.1].  
Actin-based motility of VACV is dependent on recruitment of N-WASP to phosphorylated 
tyrosines on A36 (via the adaptor proteins Nck, Grb2 and WIP), which then locally stimulates 
activity of the Arp2/3 complex [292-298]. We first observed through immunofluorescence analysis 
of ECTV-infected cells that phosphorylated tyrosine localised to virus particles (as visualised by 
dsDNA stain DAPI) and the tip of actin tails [Figure 5.3C].  
Based on the VACV actin nucleation cascade, we tested whether N-WASP was also required for 
ECTV induced actin-based motility. Infection of N-WASP knockout MEFs resulted in cells bereft 
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of virus-associated actin tails, a phenotype that was rescued by transient expression of GFP-tagged 
N-WASP [Figure 5.3D]. Taken together, these results demonstrate that in addition to a high 
conservation at the genomic level, the replication of ECTV is highly conserved to that of VACV at 
the cellular level, although consistently slower. Like VACV, replication of ECTV includes 
transport of IEV that appears to be dependent on kinesin-1-mediated microtubule transport and N-
WASP-Arp2/3 complex-dependent actin-based motility. 
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Figure 5.2:  Actin-based motility of ECTV and VACV in various cell types. 
(A) HeLa, NIH3T3 or MEFs were infected with ECTV or VACV, fixed and stained for immunofluorescence 
assays with α-B5 (NPC) (red), phalloidin (green) or (B) α-B5 (NPC) (red) and α-cortactin (green). Arrowheads 
indicate a CEV associated with an actin tail. Scale bars represent 10 µm. 
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Figure 5.3:  Actin-based motility of ECTV is via a N-WASP dependent pathway 
(A) BSC-1 cells were infected with ECTV or VACV at MOI 1 and fixed at the indicated time points. Cells were 
stained with phalloidin and assessed for the presence of actin tails (n=50 per timepoint, in duplicate). The 
percentage of actin tail containing cells was calculated. Error bars indicate standard error. (B) ECTV-infected 
cells were also probed with α-A36-Y112 (green), α-B5R (red) and DAPI (blue) or (C) phalloidin (red), an anti-
phosphotyrosine antibody (4G10, green) and DAPI (blue). (D) N-WASP(-/-) MEFs were mock-transfected or 
transfected with a N-WASP-GFP expression vector (green). Twenty-four h post-transfection, cells were infected 
with ECTV and fixed. For immunofluorescence assays, fixed cells were stained with phalloidin (red) and DAPI 
(blue). Arrowheads indicate IEV (B) or IEV associated with an actin tail (C, D). Scale bars represent 10 µm. 
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5.2.3 ECTV encodes a homologue of VACV protein A36 
The IEV-specific viral transmembrane protein A36 is a critical mediator of both actin- [301] and 
microtubule-based transport of VACV [181, 282, 286] [Section 1.3.1.3]. We searched the ECTV 
(Moscow) genome for a homologue of A36 that might be responsible for subcellular transport of 
IEV during ECTV replication. We identified the ECTV open reading frame 137.5f as a candidate 
A36R homologue (which shall be referred to as ECTV A36R henceforth), consistent with previous 
findings [436]  
ECTV A36R resides at a conserved genomic locus and encodes a hypothetical protein of 160 
residues with 92% amino acid identity with the first 157 residues of VACV A36 [Figure 5.4A]. A 
1 bp deletion in the nucleotide sequence leads to the formation of a premature stop codon and 
subsequent loss of homology from position 155 of ECTV A36 onwards and truncation of the C-
terminus. Despite this predicted C-terminal truncation, the regions critical for actin-based motility 
(Tyr 112) [301] and the dominant interaction with kinesin-1 (WD 97-98) were conserved [181, 
286]. While the ancillary interaction for kinesin-1 at residues 64-65 is WE motif in VACV A36, an 
amino acid substitution has resulted in a second WD motif in ECTV A36 that is unlikely to have 
an effect on kinesin-1 binding capabilities [286]. The ancillary site for actin-based motility (Tyr 
132) was missing from ECTV A36. 
Using antiserum raised against a peptide corresponding to residues 105-119 of VACV A36 (α-
A36-Y112) we tested expression of ECTV A36 during ECTV infection in BSC-1 cells. Expression 
begins between 4-8 hpi, compared to 2-4 hpi for VACV A36, which displayed a faint band in the 4 
hpi lysate. Migration on an SDS-PAGE gel indicated that ECTV A36 had an approximate size of 
32 kDa, smaller than VACV A36, which migrates indicating a 43-50 kDa size [215] [Figure 
5.4B]. Although both proteins migrated considerably above their predicted molecular weight, the 
discrepancy is consistent with the deletion in the 3’ of ECTV A36R ORF.  
In DNA viruses, early and late gene expression refers to the expression of genes from the parental 
genome or expression that requires de novo mRNA synthesis, respectively [Section 1.3.1]. 
Poxviruses have further regulation resulting in an additional post-replicative phase preceding late 
gene expression called the intermediate phase [256]. Among other functions, early gene expression 
is essential for the establishment of replicative machinery responsible for DNA replication in the 
cell [257]. VACV A36 has an early component to its expression; it contains an early RNA start 
and termination sequence surrounding the ORF, and northern blotting of RNA extracted early in 
infection confirmed early transcription [215].  
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To test if the expression profile of ECTV A36 also had an early component, we performed VACV 
and ECTV infections in the presence of cytosine arabinoside (AraC), an inhibitor of DNA 
replication and late gene expression. A visible band was produced in both time points assayed; 
indicating that expression of ECTV was also under regulation by an early promoter [Figure 5.4B]. 
Using the same antibody as the immunoblot, immunofluorescence analysis of ECTV-infected cells 
was carried out. We observed that A36 localised to a perinuclear structure presumed to be the 
trans-Golgi network, due to the colocalisation of a strong, compartmental B5 signal. A36 also 
colocalised with B5 and DAPI at single virus particles, consistent with IMV-labelling [Figure 
5.3B]. 
 
Figure 5.4:  ECTV encodes a highly conserved homolgue of A36R 
(A) Translations of open reading frames A36R in ECTV Mos (NCBI Genome Accession: AF012825) and 
A36R in VACV WR (NCBI Genome Accession: AY243312) obtained from www.poxvirus.org and aligned 
in Geneious 5.4.4 (Biomatters Ltd). Bars represent bipartite tryptophan domains for binding of kinesin-1 
and microtubule-based motility. Chevrons represent tyrosine phosphorylation sites for actin-based motility. 
(B) BSC-1 cells were infected with ECTV or VACV at MOI 1 in the absence or presence of 40µg/ml AraC 
(Sigma) at the time points indicated. Cell lysates were separated with SDS-PAGE and transferred to 
nitrocellulose membranes for immunoblotting with α-A36-Y112, detecting ECTV or VACV A36. 
Immunoblots were also probed with α-β-actin as a loading control. Molecular size markers are indicated 
on the left.  
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5.2.4 Deletion of A36R results in defective subcellular transport 
As ECTV A36R appeared to be a homologue of VACV A36 based on sequence conservation, 
expression and localisation, we sought to demonstrate that ECTV A36R was also required for 
actin- and microtubule-based motility. We generated a vector construct designed to replace the 
A36R ORF with selectable marker gpt, an E. coli gene that encodes xanthine-guanine 
phosphoribosyltransferase to allow growth on GPT selection media, and screenable marker 
monomeric red fluorescent protein (mRFP) from an artificial synthetic early/late promoter [308] 
[Section 2.1.2.2]. We recombined this construct with ECTV and selected for recombinant virus 
able to replicate in the presence of GPT selection media with visible red fluorescent plaques 
[Section 2.4.2]. 
After three rounds of purification, we tested the integrity of the ΔA36R recombinant virus with 
PCR analysis from extracted genomic DNA [Figure 5.5A]. A primer pair consisting of a forward 
and reverse primer complementary to a region approximately 900 bp upstream of the start codon 
and 900 bp downstream of the stop codon of the ORF respectively amplified a product of 
approximately 2300 bp, encompassing the ORF (486 bp) in the ECTV genome 
(a36r.rafor/a36r.larev, Table 2.1). In the ΔA36R recombinant virus, this product was 
approximately 3000 bp, consistent with the deletion of the ORF and insertion of the recombination 
cassette including gpt (152 bp) and mRFP (678 bp). When a second PCR was carried out with a 
forward primer complementary to the first 24 bp of the ORF with the same reverse primer (a36r. 
for/a36r.larev, Table 2.1), the ΔA36R virus genomic DNA did not produce a visible band, 
consistent with the predicted deletion of the ORF. 
We next carried out immunoblots to confirm that A36 protein expression was abrogated in the 
ECTV ΔA36R virus. While a band was detectable in the ECTV-infected lysates probed with α-
A36-Y112, no equivalent band was visible in ECTV ΔA36R-infected lysates [Figure 5.5B]. 
Reprobing this immunoblot with α-mRFP demonstrated robust expression of the screenable 
marker in ECTV ΔA36R-infected lysates, further validating the construction of the deletion virus. 
Of interest, when lysates were probed with antisera raised against the C terminus of VACV A36 
(α-A36), the lack of a detectable band in ECTV-infected lysates is consistent with the absence of 
this region in the ECTV A36R ORF. This A36 protein abrogation was also reflected in 
immunofluorescence assays of ECTV ΔA36R-infected cells, where a A36 signal could no longer 
be detected [Figure 5.5C]. This is further confirmation that the predicted C-terminal truncation is 
present in the ECTV Moscow stock used in this study. 
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With the construction of ECTV ΔA36R verified, we went on to analyse replication dynamics and 
spread. We performed an EEV release assay in which we measured virus particles released by 
infected cells into supernatant at 32 hpi. Compared to the 3.93 x 103 infectious EEV produced by 
ECTV, ECTV ∆A36R demonstrated an approximately 50-fold reduction in release, with 8.53 x 
101 infectious EEV produced [Figure 5.6A]. This was despite the total production of infectious 
virus (in both cells and supernatant) being unaffected by the A36R deletion [Figure 5.6B]. These 
results indicated that although normal levels of virus were being produced, IEV in ECTV ∆A36R 
were not reaching the surface of the cell to become EEV. 
When we carried out plaque assays, ECTV ΔA36R were observed to produce small plaques with 
mRFP fluorescence [Figure 5.6C]. When measured, their average size was approximately half the 
diameter of those produced by the parental strain [Figure 5.6D]. Reduction in plaque size is 
consistent with compromised subcellular transport, as deficient viral transport to the cell periphery 
leads to retarded infection of neighbouring cells in the monolayer and subsequent inhibition of 
plaque formation. For example, in a VACV, recombinant viruses with A36R, A34L, B5R and 
F12L deletions have described defects in subcellular transport and a parallel reduction in plaque 
size [215, 303, 325, 449]. 
We next examined ECTV ΔA36R-infected cells by immunofluorescence for the hallmarks of 
microtubule- and actin-based transport. Loss of A36R resulted in a reduction in the appearance of 
EEV, and those that reached the cell surface were confined to central regions of the cell where the 
trans-Golgi network lies in close proximity to the plasma membrane [Figure 5.7A]. This 
phenotype was reminiscent of the defects seen in nocodazole-treated cells, consistent with 
disrupted microtubule-based transport [Figure 5.1B]. This was further confirmed by the lack of 
ECTV ∆A36R virus particle colocalisation with KHC compared to ECTV [Figure 5.7B]. 
Furthermore, we found that any virus particles that did reach the cell surface were unable to 
produce actin tails, demonstrating that actin-based motility was also abrogated [Figure 5.7C].  
To confirm that these phenotypes were due specifically to the loss of A36 expression, we tested if 
transient expression of GFP-tagged ECTV A36R and A36R-Y112F could rescue any aspects of 
virus transport. While both constructs were able to rescue transport of IEV to the cell surface 
[Figure 5.8A], only A36R-GFP and not A36R-Y112F-GFP was able to rescue actin-based 
motility [Figure 5.8B]. This is consistent with previous findings made with VACV, where 
mutation of the critical Tyr 112 to Phe abrogates actin-based motility [292]. In summary, ECTV 
A36 is a functional homologue of VACV A36 and is required for efficient IEV intracellular 
transport and actin-based motility during ECTV infection. 
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Figure 5.5:  Construction and verification of ECTV ∆A36R. 
(A) BSC-1 cells were infected with ECTV or recombinant ECTV ∆A36R and cell lysates collected at 48 hpi 
Genomic DNA was extracted and PCR was conducted with two primer pairs a36r.lafor/a36r.rarev and 
a36r.for/a36r.rev to confirm deletion of A36R and insertion of selection cassette. Uninfected cell lysate 
genomic DNA and no template control were run simultaneously as negative controls. Molecular size 
markers are indicated on the left. Schematic of the PCRs performed is represented on the right. (B) BSC-1 
cells were infected with VACV, VACV ∆A36R, ECTV or ECTV ∆A36R at MOI 1 and cell lysates collected 
at 16 hpi (VACV) or 48 hpi (ECTV). Cell lysates were separated with SDS-PAGE and transferred to 
nitrocellulose membranes for immunoblotting with α-A36 (raised against the C terminus of VACV A36 that 
is absent in ECTV A36), α-A36-Y112, α-mRFP and α-ß-actin as a loading control. Molecular size markers 
are indicated on the left. (C) HeLa cells were infected with ECTV ∆A36R, fixed and stained for 
immunofluorescence assays with α-A36-Y112 (green), α-B5 (red) and DAPI (blue). mRFP expressed by 
ECTV ΔA36R was bleached by the addition of a high concentration of P-phenylenediamine [1% (w/v)] into 
mounting solution. Arrowheads indicate IEV. Scale bar represents 10 µm. 
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Figure 5.6:  ECTV ΔA36R results in reduced EEV release and virus spread. 
BSC-1 cells were infected with ECTV or ECTV ∆A36R at MOI 0.1 and (A) supernatants were collected at 
32 hpi and centrifuged at 3350 rcf for 10 min to remove cells and cellular debris or (B) all cells were 
scraped into supernatants at 16 hpi before undergoing three freeze/thaw cycles to release viruses. Plaque 
assays were performed with BSC-1 monolayers overlayed with 1.5% CMC/DMEM and stained 5 dpi with 
crystal violet to quantify plaques. Differences between ECTV and ECTV ∆A36R were statistically different 
(p=0.0018, Unpaired t-test) for infectious EEV released, but not for total infectious virus. (C) BSC-1 cell 
monolayers were infected with ECTV or ECTV ∆A36R and overlayed with 1.5% CMC/DMEM. Four dpi, 
plaques were visualised with phase contrast microscopy (top panels) and fluorescent microscopy (bottom 
right panel). Scale bar represents 100µm. The diameter of plaques was determined in ImageJ as the 
widest point at which cytopathic effects were observed (circle). (D) Data from three replicates was pooled 
for n = 30. ECTV and ECTV ∆A36R were statistically different (p<0.0001, Unpaired t-test). 
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Figure 5.7:  Deficient actin- and microtubule-based motility of ECTV ΔA36R. 
(A) HeLa cells were infected with ECTV or ECTV ∆A36R, fixed and probed for immunofluorescence 
assays with α-B5 (NPC) (green) and DAPI (blue). The dotted line is the cell periphery, as determined by 
phase contrast microscopy. (B) Infected cells were also probed with α-B5 (red), KHC antisera (green) and 
DAPI (blue) or (C) α-B5 (NPC) (red), phalloidin (green) and DAPI (blue). mRFP expressed by ECTV 
ΔA36R was bleached by the addition of a high concentration of P-phenylenediamine [1% (w/v)] into 
mounting solution. Arrowheads indicate IEV. Scale bars represent 10 µm. The localisation in the cells 
depicted are representative of the large majority (99%) of infected cells. 
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Figure 5.8:  Transport defects of ECTV ΔA36R are restored by transient A36 
expression. 
(A) HeLa were infected with ECTV ∆A36R and transfected with vector constructs of A36R-GFP and 
A36Y112F-GFP (green) for transient expression under pE/L, fixed then stained for immunofluorescence 
assays with α-B5 (NPC) (red) and DAPI (blue). The dotted line indicates the cell periphery, as 
determined by phase contrast microscopy. (B) Infected and transfected cells were also probed with 
phalloidin (red) and DAPI (blue). Scale bars represent 10 µm. 
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5.2.5 ECTV actin tails display different morphology to VACV actin tails 
As previously mentioned, we observed that actin tails that localised to EEV during ECTV 
infection had a divergent morphology to VACV tails being, on average, shorter in length (1.59 µm 
for ECTV and 2.88 µm for VACV, Figure 5.10A) and this difference was found to be statistically 
significant (p<0.0001, Unpaired t-test). The difference in actin tail morphology could be due to 
differences between the viral initiators (ECTV A36 and VACV A36) of actin polymerisation, in 
particular the C-terminal truncation, differences in other viral proteins or the time point at which 
actin-based motility was visualised due to the delayed ECTV replication cycle.  
As VACV infected cells at 24 hpi retained the ‘VACV-like’ morphology [Figure 5.2A], we 
determined that the distinct morphologies of ECTV- and VACV-induced actin tails was not due to 
delayed replication dynamics. We therefore focused on testing the former hypotheses. We 
examined CEV-associated actin tails in VACV ΔA36R and ECTV ΔA36R infected cells 
transiently rescued with GFP-tagged VACV A36 and ECTV A36. Actin-based motility was 
rescued in all infection/transient expression combinations, with transiently expressed A36R-GFP 
colocalising to B5-positive CEV particles that formed actin tails [Figure 5.9B-C]. 
We went on to quantify the length of tails [Section 2.5.5.1] and found that VACV ΔA36R rescued 
with both GFP-tagged VACV A36 or ECTV A36 produced tails were not statistically different to 
VACV. This was not the case with ECTV ΔA36R; both construct rescues produced tails longer 
than ECTV, a difference that was statistically significant. While this was potentially due to 
overexpression of transient constructs, ECTV ΔA36R produced statistically shorter tails than 
VACV ΔA36R when rescued with either GFP-tagged VACV A36 or ECTV A36 (unpaired t-test, 
p=0.0006 and p=0.0041 respectively) [Figure 5.10A]. This verified that the difference in CEV-
associated actin tail morphology is inherent to the background of the virus and not the identity of 
the viral initiator.  
To further elucidate the phenotypic differences between VACV and ECTV actin-based motility, 
we carried out live cell imaging of infected cells and examined the speed and persistence of actin 
tails. This analysis revealed that differences in CEV-associated actin tail morphology did not lead 
to changes in the average speed of actin-based motility [Figure 5.10B-C, Video. S1-2]. We did 
however observe that there was more speed variation between individual actin tails produced by 
ECTV than VACV, with standard deviations of 0.050 µm/s and 0.018 µm/s, respectively. 
Furthermore, we found that ECTV-induced actin tails were visible for shorter periods of time 
compared to VACV; while 100% of VACV-induced actin tails visible at the start of imaging 
persisted for the duration of imaging (1 min 13 s), only 28% persisted over this time frame for 
ECTV [Figure 5.10D].  
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Figure 5.9:  Actin-based motility rescued with transient VACV or ECTV A36R expression  
Representative cells of BSC-1 cells infected with VACV WR, VACV ∆A36R, ECTV Mos, ECTV ∆A36R 
and transfected with vector constructs containing VACV A36R-GFP (B) or ECTV A36R-GFP (C) for 
transient expression under pE/L. Cells were fixed and stained for immunofluorescence assays with α-B5 
(NPC) (green) and phalloidin (red) to visualise actin tails. VACV A36R-GFP and ECTV A36R-GFP were 
visualised in the green channel, but have been represented in blue. Scale bars represent 10 µm. 
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Figure 5.10:  Characteristics of ECTV actin-based motility 
(A) Tail lengths of 6 actin tails from at least 6 different cells (as shown in Figure 5.9) in three replicates 
(n=118) were measured in ImageJ and pooled. There were significant differences in tail lengths (n/s 
means not significant, **p<0.005, ***p<0.001 and ****p<0.0001, Unpaired t-test). (B) HeLa cells were 
infected with VACV or ECTV, transfected with pE/L Lifeact-GFP and imaged 8-10 hpi (VACV) or 24-26 hpi 
(ECTV). Arrowhead indicates tip of actin tail, asterisk indicates a stationary object. (C) Average speeds of 
actin tails in 5 different cells (n=25) calculated over 6 consecutive frames (3.7 s apart), with the Manual 
Tracker Plugin in ImageJ. (D) Percentage of actin tails in 5 different cells (n=25) that visibly persisted over 
60 consecutive frames (1.2 s apart) of image acquistion, VACV and ECTV were statistically different 
(p<0.0001, Log-rank [Mantel-Cox] Test). 
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DISCUSSION 
The ECTV Mos genome is highly conserved between related members of the orthopox genus, 
with approximately 90-99% identity at the amino acid level for IEV-specific proteins [436]. Our 
analysis of ECTV replication suggests the morphogenesis pathway that gives rise to IEV is also 
conserved. A subset of IMV generated at the virus factory acquires B5 and A36 immuno-reactivity 
and are transported to the cell periphery in a microtubule-dependent manner. We observed a delay 
in the replication of ECTV in vitro compared to VACV WR that was independent of cell type and 
origin of host cells. Although it might be expected that a virus of murine origin would replicate 
more efficiently, we were unable to find evidence to support this. At the minimum, other factors 
play a more significant role in the cells we analysed. The difference in replication dynamics may 
reflect adaptation by VACV to replication in cultured cells, as this delay is not apparent in vivo 
where infection of mice with either VACV or ECTV is lethal 6-8 days post-infection [215]. This 
interpretation is complicated by the absence of a known endemic host for VACV and differences 
in virus titer used to achieve a lethal dose. 
Through immunoblot analyses, we observed that like VACV A36, ECTV A36 has an early 
component to its expression profile and alignments of the promoter region up to 100 nucleotides 
upstream of the open reading frames of the two genes showed 98% identity. The early expression 
of VACV A36 is believed to be important in repulsion of super infecting virions, a process which 
allows viral spread to occur at a rate beyond the speed of its replicative cycle [299]. Through cell 
surface signalling, viral entry into already infected cells is blocked and super infecting virions are 
directed toward uninfected cells [299]. Our results show that, as ECTV A36 is expressed early, it 
is possible that repulsion of super infecting virions also occurs in ECTV.  
We have shown that the viral protein ECTV A36 plays a key role in mediating subcellular 
transport of ECTV, as has been shown previously for VACV A36 during VACV replication [181, 
215, 263, 282, 286, 292, 300]. Divergent orthopoxviruses appear to encode functional homologues 
of A36 at conserved genomic loci and while these are highly conserved at the N-terminus they 
lack significant sequence conservation (8-15% amino acid identity) at the C-terminus [450]. 
ECTV A36 is consistent in displaying greater diversity at the C-terminus, in fact possessing the 
greatest extent of divergence amongst all available orthopoxvirus genomes with its predicted 63 
residue C-terminus truncation. 
Immunoblot analysis confirmed that ECTV A36R encoded a truncated protein. Nonetheless, it 
retains the essential transport functions of VACV A36 and possesses microtubule-based motility 
[Figure 5.6-5.7]. These observations are in agreement with a previous study in which microtubule 
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transport of CEV is rescued in a VACV ΔA36R strain by the expression of the transmembrane 
domain of A36 fused to A3671-100 suggesting that a KLC-binding site lies within this region [282]. 
This was further supported with yeast 2-hybrid assays demonstrating A3681-100 was sufficient to 
mediate binding to KLC [181].  
As previously mentioned, kinesin-1 recruitment (both KHC and KLC1 and KLC2) has been 
narrowed down to a bipartite tryptophan motif at residues 64/65 (WE) and 97/98 (WD) of VACV 
A36 [286], the second WD site which is within the A3681-100 minimum binding domain 
established by Ward and Moss (2004). While ECTV A36 is conserved at the WD site, it has an 
amino acid substitution of another acidic residue at the WE site, creating a second WD site. Even 
though the sites are not absolutely conserved, a bipartite tryptophan domain is retained. In their 
study, Dodding and colleagues demonstrate that substitution of the WE/WD bipartite tryptophan 
motif with a WD/WD motif from Calsytenin retains kinesin-1 recruitment, and this substitution is 
unlikely to have any deleterious effects on microtubule-based motility. ECTV IEV particles were 
still found to partially colocalise with both components of the kinesin-1 motor complex, KHC and 
KLC [Figure 5.7B and data not shown] suggesting that microtubule transport of IEV is likely to 
operate via a conserved mechanism during ECTV replication [286].  
Furthermore, although the exact role of the F12/E2 complex in microtubule motility of VACV 
remains to be clarified, as previously discussed, evidence suggests that it can interact directly with 
KLC2 and may have roles in modulating kinesin-1 motor activity [Section 4.3]. ECTV Mos 
possesses a highly conserved homolog to both VACV WR F12 (EVM035, Genbank accession: 
AAM92339.1) and E2 (EVM042, Genbank accession: AAM92346.1) that have 96.69% and 
97.69% identity with their VACV WR homolog respectively, which may further suggest a 
conserved mechanism of microtubule-based motility. 
Actin-based motility has been observed across the orthopox genus in VACV [264], ECTV (this 
study and [442-444]), VARV and monkeypox [192], as well as in more distantly related 
poxviruses such as myxoma virus [451] and yabalike disease virus [451-453]. In the closely 
related orthopoxviruses the nucleation of actin filaments is likely to be mediated by homologues 
of VACV A36, as we have demonstrated is the case in ECTV. Significantly, ECTV A36 is also 
the only orthopoxvirus homologue to lack the second tyrosine (Tyr 132) [450], nonetheless, 
ECTV A36 is sufficient to promote actin-based motility in ECTV and VACV [Figure 5.9C].  
Interestingly, although the more divergent poxviruses do not encode A36 orthologues, the 
genomic locus where functional actin nucleators are encoded is conserved [452]. This study is 
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only the third report defining the loss of actin-based motility in a recombinant virus deleted for the 
viral nucleator, along with VACV and baculovirus [193, 454].  
We observed that ECTV-induced actin tails were morphologically distinct from those present 
during VACV infection, being shorter in length, a difference that was independent of the time 
point examined. The obvious explanation for these findings was the absence of the Grb2 binding 
site (Tyr 132), which when mutated to Phe blocks phosphorylation and Grb2 recruitment and 
results in shorter actin tails, increased virus motility and higher N-WASP turnover [293, 295].  
However, although shorter, ECTV-induced actin tails were not faster than VACV-induced actin 
tails. This inconsistency was clarified through cross-rescue experiments with GFP tagged VACV 
A36 and ECTV A36. Although ECTV ∆A36R rescued with either construct led to tails 
statistically longer than ECTV, this was likely an artefact of transient expression and still resulted 
in tails shorter than those produced by VACV ∆A36R rescued with the same constructs. This 
indicated that the identity of the infecting virus and not the nucleator is likely responsible for the 
distinct actin tail morphology.  
Following tyrosine phosphorylation of A36, actin tail formation in VACV infection is largely 
dependent on host cell machinery. The core cellular cascade involves Nck (recruited by A36Y112), 
Grb2 (recruited A36Y132), WIP, N-WASP and the Arp2/3 complex [292-298]. Infection with 
orthopoxviruses leads to disruption of many host-signaling pathways that impact on actin 
dynamics within the cell. Beyond the core cascade, other host proteins are recruited to virus-
induced actin tails including cortactin, lamellipodin, profilin and VASP [455-459]. While the 
effects of many of these host-factors has yet to be determined, some have demonstrated roles in 
enhancing actin-based motility; depletion of the formin FHOD1 and the GTPase Rac1 (part of the 
same cell-signalling cascade) for instance leads to a decrease in the number and length of actin 
tails formed [460]. It is possible that host factors that impact actin dynamics are differentially 
stimulated by VACV and ECTV infection, but elucidation of the mechanism that defines the 
different rates of actin nucleation between VACV and ECTV must await future studies. 
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CHAPTER 6: Disrupting Subcellular 
Transport in an Endemic Animal 
Model 
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6.1 INTRODUCTION 
The work detailed in this chapter has been published: H. Lynn, J. Horsington, 
L.K. Ter, S. Han, Y.L. Chew, R.J. Diefenbach, M. Way, G. Chaudhri, G. Karupiah, 
T.P. Newsome [2012]. Loss of Cytoskeletal Transport during Egress Critically 
Attenuates Ectromelia Virus Infection In Vivo. Journal of Virology. 86(13), 7427-
7443. Mouse work and associated data analysis was carried out by our collaborators 
L.K. Ter, G. Chaudhri and G. Karupiah. H. Lynn was involved in design, planning 
and interpretation of experiments and provision of viral stocks. 
6.1.1 The immune response  
Even the most simple of animals possess some form of an immune system, which has evolved as 
as a defence against the challenge of pathogens. The immune response is divided into two arms, 
the innate immune system and adaptive immune system, although much interplay exists between 
both [461]. The innate immune system encompasses the immune responses that are immediate and 
non-specific and includes physical barriers, the inflammatory response, phagocytotic leukocytes 
and natural killer (NK) cells [461]. The adaptive immune system, which is exclusive to 
vertebrates, is antigen specific and acquired during the lifetime of the animal. It is composed of 
antibody-mediated humoral immunity generated by B-lymphocytes and cell mediated processes 
involving T-lymphocytes [462]. Due to the fact that the lymphocytes of the adaptive immune 
system must expand and mature following exposure to novel antigens, upon first 
exposure/primary infection, the response is not as immediate as the innate immune response [462]. 
6.1.2 ECTV Disease Progression 
The natural route of infection of susceptible mice with ECTV is through skin abrasions; with virus 
able to enter the lower layers of the epidermis or dermis from external sources such as other 
infected animals or the environment [431, 434] [Figure 6.1]. Infection at the primary site of 
inoculation will then spread to the draining lymph nodes where viruses can be detected as early as 
8 hpi. Replication occurs at the draining lymph node before entering the bloodstream to cause 
primary viremia that leads to the spread to organs, with high viral loads in the spleen and liver at 
3-4 days post infection (dpi) [434]. Replication will again occur here and death of infected cells 
near sinusoidal vasculature releases large amounts of virus into the blood stream [237]. This 
secondary viremia leads to infection of distal sites in the body and ultimately, the formation of 
papules on the skin characteristic of poxviral diseases. At 5-13 dpi, virus is detected in most 
tissues and susceptible animals will succumb to the tissue necrosis of major organs [463]. 
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Multiple factors contribute to the disease progression and severity of ECTV-caused disease, with 
mild, self-limiting disease in some animals and severe ulceration and death in others. These 
factors include the viral strain, the dose of the virus, the route of infection and the genetic 
background of the mouse being inoculated. As previously mentioned, the ECTV Mos strain is a 
commonly used due to its high virulence and infectiousness [433-435]. However, only some mice 
strains, including BALB/c, A/J and DBA/2, are susceptible to infection. Wild mice populations 
have variable susceptibility [464] and other common laboratory strains such as C57BL/6 are 
resistant to infection. These differences in susceptibility are due to well-characterised differences 
in the immune functions of these various strains, a fact that has been utilised to dissect immune 
factors that contribute to the control of ECTV infection.  
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Figure 6.1:  ECTV disease progression 
ECTV disease progression in susceptible mice begins with viral entry through abrasions in the skin, viral 
dissemination then occurs through the lymph nodes, blood stream and major organs such as the liver 
and spleen. Secondary vireamia then leads to small pox like ulceration in its final stages, which is often 
fatal. Image from [434]. 
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6.1.3 Immune response to ECTV infection 
As ECTV infection occurs through abrasions in the skin, the initial immune response against 
ECTV involves specialised cell types present in the skin for responding to invading pathogens that 
include keratinocytes, melanocytes, Langerhans cells (LC) and dendritic epidermal T-Cells 
(DETCs) [434]. Keratinocytes will be activated by the inflammatory response generated in 
response to skin trauma and are then able to recognise viral components through Toll-like 
receptors (TLRs) and other pathogen-assocated molecular pattern recognition receptors. TLR 
signalling leads to the stimulation of the antiviral response including production of interferon 
(IFN) [465]. The production of these first waves of cytokines leads to signalling cascades that 
activate downstream effectors of both the innate and adaptive immune system that contribute to 
control of ECTV infection. For instance, cytokine activated LCs containing viral antigens migrate 
through the dermal layers to reach the lymph node where they can then present antigens to naïve T 
and B-lymphocytes [434]. 
While the B-lymphocyte generated humoral response to ECTV infection may contribute to 
complete recovery or protection upon reexposure, control of primary infection requires cell-
mediated immunity, including a polarised type 1 response [329, 331]. Type 1 responses are 
defined by strong cellular immune responses, specifically helper type 1 (Th1) lympocytes 
secreting cytokines such as interleukin-2 (IL-2), IFN-α and IFN-γ that amplify phagocytic activity 
[466]. Type 2 responses on the other hand involve Th2 lymphocytes secreting a different suite of 
cytokines including IL-4, IL-5, IL-10 and IL-13 to stimulate the humoral response with an 
associated high antibody production [466]. A polarised type 1 response with associated cytotoxic 
T lymphocyte (CTL) response was observed in resistant C57BL/6 mice, while susceptible 
BALB/c and A/J mice displayed a type 2 response with limited CTL activation [329]. NK cells 
have also been demonstrated play important roles in the recovery from infection [467, 468]. As a 
part of cell-mediated immunity in the innate immune system, they are involved in the early control 
of ECTV and are activated rapidly following ECTV infection [329, 468, 469].  
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6.1.4 ECTV an effective model of infection processes in an endemic host 
Due to the hazards and limited host range of working with VARV and the unknown host and 
origin of VACV, ECTV infection in mice has been used extensively as a model for smallpox 
infection [434, 435]. There are many similarities between infection and disease progression in 
both systems. Like VARV in humans, ECTV causes a characteristic exanthematous rash in the final 
stages of disease progression and although the progression of this stage to death occurs approximately 
2-3 times faster in ECTV infection of mice, the high virulence of ECTV causes mortality rates that 
mimic the 40-90% seen in smallpox outbreaks [237, 470, 471].  
Secondly, while ECTV is naturally transmitted by abrasions in the skin, intranasal models of 
infection can be used to model large droplet transmission of VARV in humans [435, 472, 473]. 
Like VARV, the lung is not involved in early infection and prior to the exanthematous rash in the 
pre-exanthem period, virus is detectable in respiratory gases [471, 474]. Futhermore, relatively 
small inoculums, often less than 1 pfu will cause an LD50 in susceptible animals, although it is 
unknown the exact inoculum of VARV required to cause similar disease in humans, it is believed 
to be low [433, 435, 470]. In comparison, intranasal infection of mice with CPXV requires 
inoculums of over 106 pfu to cause disease with an LD50 [475].  
Beyond its effectiveness in modelling smallpox, the use of a model in mice provides many 
advantages. Conducting experiments with a small animal presents relative technical ease, and the 
restricted host range of ECTV limits biosafety concerns. Moreover, the mouse immune system has 
been extensively characterised, and the similarities and differences between the mouse and human 
immune system are well understood (reviewed in [476] and [477]. The various advantages of the 
mouse infection model therefore afford us the opportunity to address the contribution of 
subcellular transport pathways to virulence in an endemic host. 
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6.2 RESULTS 
6.2.1 ECTV ΔA36R is attenuated in vivo 
Having demonstrated that A36R plays a conserved role in directing the subcellular transport of 
ECTV, we examined the effects of disabling this motility on infection of the ECTV-susceptible 
BALB/c mouse strain using three different doses of virus. In the group that received the lowest 
dose of 102 pfu ECTV, 10 of 15 mice (66%) succumbed to mousepox and died by 18 days dpi 
[Figure 6.2A]. Mice that had survived past day 18 developed pox lesions on their tails that 
ulcerated with time and were therefore euthanised at 28 dpi for ethical reasons. Animals in the 
groups infected with 103 (n=7) or 104 pfu (n=6) of ECTV succumbed to mousepox with 100% 
mortality, with a mean time to death of 11.1 and 8.8 days, respectively. All mice infected with 
ECTV had unkempt hair coat and hunched posture from about day 6 pi and generally became 
moribund before they died. In contrast, mice infected with the 3 different doses of ECTV ΔA36R 
survived until at least 33 dpi with no overt clinical signs of disease [Figure 6.2A].  
Organism-wide dissemination of virus was clearly affected by deletion of A36R. The viral load in 
the draining lymph nodes, spleen and liver at 5 dpi was 3 to 4 log10 pfu higher in mice infected 
with 102 pfu ECTV than in those infected with ECTV ΔA36R [Figure 6.2B]. This difference 
further increased to 5 log10 pfu at 8 dpi due to the increasing viral load in all organs of ECTV 
infected mice and decreasing viral load in all organs of ECTV ΔA36R infected mice [Figure 
6.2C]. While ECTV infection is lethal in BALB/c mice, ECTV ΔA36R infection is readily 
controlled, showing strong attenuation in vivo. This attenuation was also evident in C57BL/6 wild 
type [data not shown] and C57BL/6 Rag-1-/- mice, which lack B or T cells, and therefore do not 
possess adaptive immunity [Figure 6.2D]. Titers of ECTV ΔA36R were between 1 to 4 log10 PFU 
lower than those of ECTV at 5 dpi.  We were unable to determine viral load in organs of Rag1-/- 
mice at 8 dpi as all mice infected with ECTV had died by this time whereas those infected with 
ECTV ΔA36R were still alive with no clinical signs of disease.  
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Figure 6.2:  Virulence of ECTV ΔA36R in mouse infections. 
Groups of 6-15 female BALB/c mice were infected subcutaneously in the left hind leg with 102, 103 or 104 
pfu ECTV or ECTV ∆A36R. Mice were monitored for (A) survival over 33 days. Survival for 102 and 103 
pfu ECTV ∆A36R were 100%. There were significant differences in survival of mice infected with ECTV or 
ECTV ∆A36R (p<0.0001 at 102 and 103 pfu and p<0.001 at 104 pfu, Log-rank [Mantel-Cox] Test). Data 
shown for the 102 dose of virus has been combined from 2 different experiments. Separate groups of mice 
were infected with 102 pfu virus and euthanised at (B) 5 or (C) 8 dpi and the viral load in lymph nodes, 
spleens and livers was quantified by viral plaque assays. Groups of 5 C57BL/6 Rag-1-/- female mice were 
infected with 103 pfu ECTV or ECTV ∆A36R and euthanized at (D) 5 dpi and the viral load in lymph nodes, 
spleens and livers was quantified by plaque assays. Titers of ECTV and ECTV ∆A36R in lymph nodes, 
livers and spleens were significantly different (*p<0.05, **p<0.01, Mann-Whitney test). Data shown in B, C 
and D are viral load ± SEM. The horizontal dotted lines indicate the limit of detection of the viral plaque 
assay, which is 1 log10 pfu.  
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6.2.2 NK response 
The finding that ECTV ΔA36R titers were significantly lower compared to those of ECTV even in 
C57BL/6 Rag-1-/- mice early during the course of infection suggested that either the virus 
replicated poorly in vivo or that the innate immune system effectively controlled virus replication. 
As mentioned, since NK cells play a key role in controlling ECTV, we assessed the cytolytic 
activity of NK cells in virus-infected BALB/c and C57BL/6 wild type mice at 5 dpi, the peak of 
the NK cell response. The NK cell activity induced by ECTV ΔA36R was more than 3-fold lower 
in BALB/c mice and at least 27-fold lower in C57BL/6 mice than the activity that was generated 
by ECTV infection in both strains of mice [Figure 6.3A-B]. The data suggested that it is unlikely 
that NK cells contributed to the early control of mutant virus replication.  
 
 
Figure 6.3:  NK responses to ECTV and ECTV ∆A36R infection 
Splenic NK cell responses were measured by the 51chromium release assay. Groups of 3 (A) BALB/c and 
(B) C57BL/6 mice were infected with 103 pfu of ECTV or ECTV ∆A36R virus. Spleen cells were extracted 
and cultured with 51Cr-labelled YAC-1 target cells for 4 h and the radioactivity in the supernatant 
measured in a TopCount NXT™ scintillation counter to give a measure of lysis.  
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6.2.3 ECTV ΔA36R infection induces protective immunity 
We determined whether ECTV ΔA36R, which replicated poorly in mice, induced any protective 
immunity to ECTV.  All mice that had survived infection with either 102, 103 or 104 pfu ECTV 
ΔA36R were challenged with a lethal dose (104 pfu) of ECTV at 33 dpi.  Eight days later, mice 
were sacrificed, their spleen, liver and lymph nodes collected for determination of viral load 
whereas the serum was used to measure anti-ECTV antibody titers. Splenocytes were used to 
measure the recall anti-ECTV-specific CTL response. 
Virus was below the level of detection in spleen, liver and lymph nodes in mice challenged with a 
lethal dose of ECTV [data not shown], indicating that a primary infection with all 3 doses of 
ECTV ΔA36R induced protective immunity against a subsequent lethal virus challenge. Recall 
anti-ECTV CTL responses were generated in all groups at near comparable levels in magnitude 
[Figure 6.4A].  
Since antibody plays a critical role in recovery and virus control during both primary and 
secondary ECTV infection [330, 478], we measured virus-specific antibodies in sera obtained 
from mice infected with ECTV ΔA36R during primary infection and subsequent secondary 
challenge. ECTV-specific IgG was clearly induced during primary (14 and 28 dpi) infection with 
ECTV ΔA36R and 8 days post-challenge with ECTV [Figure 6.4B]. Antibody titers were 
augmented as the virus inoculum dose was increased.  It was also evident that as the antibody 
response matured over time (i.e. between 14 and 28 dpi), the anti-ECTV IgG titers also increased. 
In addition, IgG titers were boosted further in all groups following secondary virus challenge. 
ECTV ΔA36R generated neutralizing antibodies during a primary infection, and neutralising titers 
increased substantially after the secondary virus challenge [Figure 6.4C]. 
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Figure 6.4:  ECTV ΔA36R infection induces protective immunity 
At 33 dpi, all BALB/c mice inoculated with 102, 103 or 104 pfu ECTV ∆A36R mice that survived were 
challenged with a lethal dose of ECTV by the subcutaneous route. Mice were sacrificed at day 8 post-
challenge and sera, spleen, liver and lymph nodes were collected. The recall CTL response (A) in the 
spleen was similar in all groups.  ECTV-specific IgG was measured by ELISA in sera (B) during primary 
(0, 14 and 28 dpi) and 8 days after secondary challenge. ECTV-specific IgG titers increased with 
increased doses of virus innoculum, over time post-infection and after secondary challenge (* p<0.05, ** 
p< 0.01, Mann Whitney test) Serial dilutions of sera, starting at a 1:50 dilution, obtained from mice during 
primary infection with varying doses of ECTV ∆A36R (broken lines) and after secondary challenge with 
ECTV (solid lines) were used to determine neutralising activity (C). ECTV ∆A36R induced neutralising 
antibody during primary infection, albeit, levels were below the 50% neutralising titer (horizontal dotted 
line). Virus was not detected in any of the organs following a secondary virus challenge (data not shown). 
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6.3 DISCUSSION 
The reduced microtubule transport and loss of virus-associated actin tails due to disruption of 
A36R function in ECTV had a significantly attenuated phenotype in vivo in two susceptible strains 
of mice. First, the ECTV-susceptible BALB/c mouse strain did not exhibit any clinical signs of 
disease and survived doses that were otherwise fatal with ECTV. ECTV ΔA36R titers were 
several orders of magnitude lower in the draining lymph node, spleen and liver than titers of 
ECTV at 5 and 8 dpi. Second, ECTV ΔA36R was also attenuated in Rag-1-/- mice, which are 
devoid of an adaptive immune system. Viral load in organs of this strain were also orders of 
magnitude lower compared with titers of ECTV at 5 dpi. All Rag-1-/- mice infected with ECTV 
died from the infection at 8 dpi whereas those infected with ECTV ΔA36R were still alive with no 
clinical signs of disease [data not shown]. Although we envisage that Rag-1-/- mice would have 
eventually succumbed to infection with the mutant virus since adaptive immunity is essential for 
complete recovery [329, 479], this finding further attests to the importance of microtubule 
transport and actin-based motility for virus replication, spread and ability to cause disease. 
The BALB/c strain normally generates poor immune response to ECTV infection and depending 
on the virus dose, succumbs to mousepox between 7-20 dpi [Figure 6.2A] [329, 480]. However, 
when infected with mutant viruses lacking thymidine kinase activity or immune evasion molecules 
that target interferon function, they are able to generate an antiviral immune response and recover 
[478, 480, 481]. Thus, reducing the level of virus replication can tip the balance in favour of the 
BALB/c mouse, allowing it sufficient time to mount CTL and antibody responses to overcome an 
infection that is otherwise lethal.  
The NK cell response to ECTV infection generally peaks by 5 dpi and contributes to early virus 
control [329, 468, 469]. We reasoned that replication of the ECTV ΔA36R was possibly 
controlled by NK cells, as mutant virus titers were at least 1-4 log10 pfu lower than ECTV at 5 dpi.  
However, infection of the ECTV-susceptible BALB/c or ECTV-resistant C57BL/6 mice with the 
mutant virus induced very weak NK cell cytolytic activity that was several fold lower in 
magnitude than the activity generated by ECTV in both mouse strains.  
The specific requirement for individual innate cell types in controlling ECTV is currently 
unknown. Although it is possible that other innate cell types such as dendritic cells are involved in 
rapidly reducing mutant virus titers, we believe that the attenuated phenotype of this virus, in 
contrast to some other ECTV mutants discussed above, is due to its inability to replicate 
efficiently as a consequence of defective subcellular transport. 
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Although we did not measure the primary CTL response in BALB/c mice infected with ECTV 
ΔA36R, it is very likely that cell-mediated immunity contributed to the recovery from primary 
infection [329]. Anti-ECTV antibody was clearly generated during primary infection and this 
response is vital for complete recovery from a primary infection [Figure 6.4B].  
Despite the significant attenuation of ECTV ΔA36R, it nonetheless induced protective immunity. 
BALB/c mice that had recovered from infection with 3 different doses of ECTV ΔA36R were 
protected against challenge with a lethal dose of ECTV. At day 8 post-challenge, we were unable 
to demonstrate the presence of virus in all organs examined. Recall CTL and antibody responses 
were clearly generated, and are indicative of induction of T and B cell memory during primary 
infection [Figure 6.4A-C]. Although a role for cell-mediated immunity cannot be completely 
excluded, humoral immunity is known to be absolutely required for recovery from a secondary 
orthopoxvirus infection. We have previously shown that humoral immunity but not the function of 
CD4 or CD8 T lymphocyte subsets is required to control virus replication during the acute phase 
of a secondary ECTV infection [330, 478]. This requirement for antibody is not unique to ECTV 
as elimination of CD4 or CD8 T cells does not affect monkeypox virus clearance or the 
neutralising antibody response during the acute phase of a secondary infection in VACV 
vaccinated macaques [482].  
As the vaccine responsible for the irradication of smallpox, VACV has been extensively 
investigated as a vaccine vector for infectious diseases and as a vector for therapeutic 
immunisation against cancer  (reviewed in [483]). Being a large double stranded DNA virus that 
replicates entirely in the cytoplasm, VACV affords many advantages in use as a vaccine vector 
including the amenability to genetic modification and the ability to carry large genetic inserts with 
very minimal risk of intergration into the host genome [483]. However, the pathogenicity of many 
VACV strains present concerns in immunocompromised and immunonaive individuals. Highly 
attenuated, non-replicating MVA provides a substantially safer vaccine vector alternative with 
preclinical trials with animals for infectious diseases including HIV, malaria and and tuberculosis 
demonstrating efficacy [484, 485]. However, once progressed to clinical trials, in many cases, 
only moderate immunogenicity has been achieved, likely due to the extent of attenuation in MVA 
[483].  
Single gene deletions that attenuate viruses can be adequately safe while retaining higher levels of 
immunogenicity [486]. The findings in the current study suggest that orthopoxvirus vectors with 
A36 deletions may be considered as safe vaccine candidates. A36 deletions generate virions 
expressing all envelope proteins, so while they have defective transmission and are severely 
attenuated, all neutralising epitopes are present in their natural state. 
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This is the first ECTV recombinant virus with a WV-specific open reading frame deleted. The 
significant reduction in the capacity of mutant virus to replicate locally and be transmitted to other 
tissues in vivo highlights the importance of WV and the specific roles played by A36 in 
subcellular transport. Deletion of genes encoding WV-specific proteins in VACV such as A36, B5 
and A34 also led to highly attenuated infections in mice [215, 272, 487, 488]. However, intranasal 
infection of mice with VACV WR require large doses of between 104 – 106 pfu to achieve 
substantial mortality [215, 272, 487], which may not be reflective of doses of variola virus 
required to cause disease and death in humans. Using lower infectious doses (10-2 – 10-4 pfu), we 
have shown that deletion of A36R in ECTV attenuates the virus to the extent that even genetically 
susceptible mice are able to survive the infection and generate immunological memory. Our 
characterisation of the role and function of A36R with a combination of a host and its natural 
pathogen offers considerable advantages to elucidate its contribution to virulence. 
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CHAPTER 7: Conclusions 
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7.1 SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
We have utilised recent advances in fluorescent protein technology, specifically the development 
of photoactivatable fluorescent protein Dendra2, to establish an imaging system to fate track the 
different morphological forms of VACV over relatively long timeframes. We constructed 
recombinant viruses expressing core protein A3 and envelope proteins B5 and F13 fused to 
Dendra2 in both parental and deletion strains of the WR strain. All Dendra2-fusion viruses were 
bright and photoconverted efficiently. We were able to target both compartments and single virus 
particles for photoactivation and tracking, a testament to the sophistication of our imaging system. 
We examined the dynamics of envelopment at and egress from the TGN, including the effect on 
A36 and F12 on those processes. It has been previously suggested that the F12/E2 complex may 
associate with virus particles through A36 [429], but this is inconsistent with the observation that 
F12 deletions result in more severe attenuation of IEV egress resulting in the formation of less 
EEV and smaller plaque phenotypes [283, 303]. Over the time frames examined, we found that 
while a similar number of IEV egressed from the TGN, the distance virus particles of the ∆F12L 
mutant were transported from the TGN was significantly less than the ∆A36R mutant, which 
could account for the stronger attenuation observed in previous phenotypic assays. 
As both mutants appear to be able to undergo some degree of microtubule-based motility (albeit 
much reduced compared to parental viruses), these reduced run lengths may be due to the 
differential recruitment of molecular motor kinesin-1 to the virus particle rather than the complete 
inability to recruit kinesin-1. Our findings therefore suggest a path to consolidation of apparently 
contradictory findings in the field that define either A36 or F12/E2 as the sole critical mediator of 
microtubule-based motility [283, 285]. Elucidating how F12/E2 associate with the virus may shed 
further light into the role F12/E2 plays in microtubule-based motility. 
Although limited by time constraints, the viruses created and the imaging system established 
would easily allow us to extend our analyses to the transport dynamics of IMV from the VF. 
Similar to our analysis of deletion viruses of proteins important to IEV egress, we could image the 
subcellular transport of a ∆A27 mutant to clarify the role this protein plays on microtubule-based 
motility and the viral life cycle.  
We have also characterised the subcellular transport mechanisms of ECTV, which allows us to 
investigate the contribution of subcellular transport in a well-characterised endemic host. We 
found that ECTV encodes an A36 homologue (ECTV-Mos-142) that is highly conserved despite a 
large truncation at the C terminus. Deleting the ECTV A36R gene leads to a reduction in the 
number of extracellular viruses formed and to a reduced plaque size, consistent with a role in 
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microtubule transport. We also observed a complete loss of virus-associated actin tails, another 
phenotype dependent on A36 expression during VACV infection.  
Infection of ECTV-susceptible BALB/c mice with ΔA36R resulted in drastically attenuated 
pathogenesis, including a strong reduction in the spread of virus from the site of inoculation and 
lower viral load in the major target organs. Virus spread and replication was also significantly 
curtailed in Rag-1-deficient mice, which lack a functional adaptive immune system. Taken 
together, these findings demonstrate the critical role that subcellular transport pathways play not 
only in orthopoxvirus infection in an in vitro context but also during orthopoxvirus pathogenesis 
in a natural host.  
Despite the attenuation of ECTV ∆A36R, BALB/c mice that survived ΔA36R infection effectively 
generated protective antibody and cytotoxic T lymphocyte (CTL) responses and were able to 
overcome a subsequent lethal challenge with wild-type ECTV. This suggests that orthopoxvirus 
vectors with A36 deletions may be considered another safe vaccine alternative. Attentuating virus 
spread by disabling transport mechanisms maintains the integrity of virion epitopes and is an 
attractive generic approach to generate safe vaccines. 
Deletion of A36, as a mediator of both microtubule and actin-based motility, does not allow us to 
distinguish between the contributions of each type of subcellular transport to pathogenesis. 
However, the critical residues involved in both processes have been identified in VACV and are 
both conserved in ECTV, with a WD/WD motif (WE/WD in VACV) mediating microtubule-
based motility and a Y112 residue (the ancilliary Y132 site present in VACV is absent in ECTV) 
mediating actin-based motility. Future directions therefore could involve the construction of 
ECTV a A36Y112F mutant virus to be used in the mouse model to dissect the specific contribution 
of actin-based motility in a host organism. As microtubule-based motility precedes actin-based 
motility, a A36WDWD/AAAA is unlikely to reveal substantial phenotypic differences to the ∆A36R 
strain due to microtubule-based motility alone. However, the impact of superrepulsion on 
organism-wide dissemination would be able to be examined. 
Subcellular transport pathways are critical steps in the replication of many viruses, particularly 
large DNA viruses that are significantly hindered by the host cytoplasm environment [489]. 
Recruitment of cellular microtubule motors during virus egress is often complex, requiring 
multiple, redundant interactions with surface viral proteins. These surface viral proteins are often 
pleiotropic and possess key roles in other stages of morphogenesis, obfuscating straightforward 
genetic analysis of their function in transport. For example, egress of Herpes Simplex Virus-1 
(HSV-1) requires kinesin-1 function and while HSV-1 tegument proteins pUL36 (VP1/2) and 
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pUL37 are good candidate interaction partners [134], null mutants do not produce enveloped 
virions [490, 491]. The effect of these mutations on kinesin-1 recruitment therefore cannot be 
effectively analysed and in fact, no mutations in HSV-1 have been identified that mimic the loss of 
kinesin-1 function [492, 493]. Similarly, ablation of kinesin-2 function blocks Kaposi’s Sarcoma-
Associated Herpesvirus release and while viral protein ORF45 has been shown to interact with 
kinesin-2 through Y2H screens, again null mutants are morphologically defective [139, 494].  
In contrast, the microtubule-dependent egress of VACV is mediated by interactions between A36 
and F12 and the kinesin-1 complex, disruption of either producing a strong defect in virus 
transport. We have exploited this knowledge and translated it to the related ECTV to demonstrate 
movement on microtubules and polymerised actin is essential for virus propagation and 
transmission in its natural host. In an intact animal, cell-to-cell virus transmission occurs in a 
complex 3-dimensional environment of tissue. This is distinct from the predominantly 2-
dimensional surface imposed by virus cell culture techniques such as plaque assays, where virus 
spread occurs within a cell monolayer and which may overstate the importance of cytoplasmic 
transport. Our results confirm that cytoplasmic transport is a fundamental barrier to orthopoxvirus 
transmission in an intact host and therefore an attractive target for inhibiting viral pathogenesis. 
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